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Orthohantaviruses are negative sense single stranded RNA viruses that are 
capable of causing severe respiratory and haemorrhagic disease in humans. 
Currently, many aspects of the orthohantavirus lifecycle are poorly understood 
predominantly due to difficulties in detecting and quantifying orthohantavirus 
components. Here, I developed new and efficient techniques to quantify 
orthohantavirus proteins, RNA and infectious viral particles. These techniques 
were used to provide a detailed understanding of the orthohantavirus lifecycle 
kinetics.  Additionally, I examined the interactions of the orthohantavirus 
nucleocapsid protein (NP) with the host cell.  The NP has functions in viral 
transcription, translation and immune evasion as well as encapsidation of viral 
RNAs. As orthohantaviruses have been found to form persistent infections in 
vitro the molecular mechanisms behind this were of particular interest I 
examined the interaction of the Tula orthohantavirus (TULV) NP with host-cell 
components using co-localisation assays at early, peak and persistent 
infections. Furthermore, to explore the sites of viral replication within the host 
cell, RNA labelling techniques were utilised in combination with 
immunofluorescent analysis. RNA fluorescent in situ hybridisation probes 
designed against the sense and anti-sense S segment RNA were used to 
assess the localisation of viral RNA in vitro in conjunction with TULV NP and 
previously identified interacting host cell proteins.  
Here, I identified distinct localisation of TULV NP in Vero E6 cells at 36 hpi, 7 
dpi and 30 dpi notably the formation of large filamentous structures in the 
perinuclear region of infected cells in addition to establishing multinucleate 
cells during persistent infection.  These filamentous structures appear to be 
maintained through the vimentin intermediate network. Additional TULV NP 
was found to show high levels of co-localisation with the Golgi and the stress 
granule marker, TIA-1.  These markers also showed high-levels of co-
localisation with sense and anti-sense TULV S segment RNA which may 
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Chapter 1 : Introduction 
 
1.1 General Introduction   
 
1.1.1  Bunyavirales 
1.1.1.1 Bunyavirales order 
Orthohantaviruses are negative sense single-stranded RNA viruses which 
belong to the Negarnaviricota phylum, which contains nearly all the negative 
sense RNA viruses that have been classified to date. The phylum is divided 
into the subphyla Haploviricotina (haplo ‘simple’, generally non-segmented) 
and Polyploviricotina (polyplo ‘complex’, generally segmented). The 
Bunyavirales order is located within the Ellioviricetes class of the 
Polyploviricota sub-phylum. At the time of writing, the Bunyavirales order 
contains twelve viral families; Arenaviridae, Crulivirdae, Fimoviridae, 
Hantaviridae, Leishbuviridae, Mypoviridae, Nairoviridae, Peribunyaviridae, 
Phasmaviridae, Phenuiviridae, Tospoviridae and Wupedeviridae. These 
families comprise negative sense RNA viruses with between 2 and 3 genome 
segments and contain a variety of pathogens of mammals, bird, fish, reptiles 
and plants in addition to apathogenic virus species (Maes et al., 2019). Table 
1 describes different viral species within the Negarnaviricota phylum. A 
phylogenetic representation of selected members of the Negarnaviricota can 
be seen in Figure 1.  
 
1.1.1.2 The Hantaviridae family  
As of March 2019, the Hantaviridae family contains four genera; Loanvirus, 
Mobatvirus, Orthohantavirus and Thottimvirus that together comprise a total 
of 41 recognised species (Maes et al., 2019). Table 2 describes various 
characteristics of each of these species, including geographic distribution, 
host species and pathogenicity in humans. The phylogenetic relationship of 
hantaviruses based on the nucleotide sequence of the small (S) genome 
segment reveals clustering into four groups, representing each of the four 
genera (Figure 2). Within the Orthohantavirus genera, species are further 
clustered due to geographic location and virus pathogenicity in humans (Table 
 
2 
2). There is strong evidence for co-evolution of the orthohantaviruses with 
their host species over the past 90-100 million year and additionally for host-
switching events due to close geographic proximity of different potential hosts. 
These two mechanisms have shaped orthohantavirus evolution and the 
relationship between viral host and pathogenicity (Plyusnin and Sironen, 
2014). 
Recently several sub-families, genera and species have been added to the 
family. These include the Actantavirinae and Agantavirinae sub-families which 
comprise fish-borne hantaviruses and the Repantavirinae sub-family, which 
contains a Gecko-borne hantavirus. These recent additions bring the total 
number of orthohantavirus species to 46 (Abudurexiti et al., 2019). Hereafter 
members of the Hantaviridae family or Orthohantavirus genus will be referred 
to by the generic titles of “hantaviruses” or “orthohantaviruses”, respectively. 
 
1.1.2  History  
1.1.2.1 Identification  
Orthohantaviruses have likely been associated with human disease 
throughout history, with anecdotal descriptions of orthohantavirus-like disease 
described in Chinese medical records as far back as AD680 and it has been 
suggested that the epidemic of sweating sickness in medieval England may 
have been caused by a person-to-person transmitted orthohantavirus 
(Taviner et al., 1998). More recently, documentations of disease consistent 
with hantaviral infections appear in Russian hospital records in the early 
1900s, along with descriptions of field nephritis outbreaks during World Wars 
I and II (Casals et al., 1970; Johnson, 2000), as well as during the Korean 
conflict (1950-1953), when soldiers were diagnosed with a disease referred to 
at the time as Korean haemorrhagic fever (KHF) (Johnson, 2000). In 1978, 
Hantaan virus (HTNV) was identified as the etiological agent of KHF, isolated 
from Korean striped field mouse (Apodemus agrarius coreae) (Lee et al., 
1978; Lee et al., 1982). Isolated HTNV virions were described to contain a 
tripartite genome of negative sense RNA which placed them within the 
Bunyaviridae family (present: Bunyavirales order) but lack of serological cross 
reactivity with existing bunyavirus members placed HTNV within its own, 
separate genus (present: Hantaviridae family, containing four genera) 
 
3 
(Schmaljohn et al., 1983; Schmaljohn and Dalrymple, 1983). HTNV remains 
the prototypical hantavirus member, and type species of the orthohantavirus 
genus. 
The description of KHF is entirely consistent with the hantavirus-mediated 
disease now known as haemorrhagic fever with renal syndrome (HFRS). 
Other human disease outcomes caused by hantavirus infections include 
nephropathia epidemica (NE), which is considered to be a milder form of 
HFRS, and hantavirus cardiopulmonary syndrome (HCPS). 
Since 1978, many more orthohantavirus species have been isolated. In 1980, 
the causative agent of NE was found to be Puumala virus (PUUV) isolated 
from Myodes glareolus (bank vole, formerly Clethrionomys glareolus) 
(Brummer-Korvenkontio et al., 1980). The causative agent of an acute 
respiratory disease HCPS in the USA was isolated from the deer mouse, 
Peromyscus maniculatus, and named Sin Nombre virus (SNV) (Feldmann et 
al., 1993; Hallin et al., 1996). Together, HFRS, NE and HCPS are the three 
recognised clinical syndromes caused by hantavirus infection, see section 
1.1.3 for more details. It should be noted that orthohantavirus species are 
frequently identified and it is likely that this family will continue to expand, with 





Figure 1 Molecular phylogenetic analysis of selected members of the 
Negarnaviricota phylum by maximum likelihood method.  
The evolutionary history was inferred by using the maximum likelihood 
method (Whelan and Goldman, 2001). The tree with the highest log 
likelihood (-10322.31) is shown. The percentage of trees in which the 
associated taxa clustered together is shown next to the branches. Initial 
tree(s) for the heuristic search were obtained automatically by applying 
Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances 
estimated using a JTT model, and then selecting the topology with 
superior log-likelihood value. The tree is drawn to scale, with branch 
lengths measured in the number of substitutions per site. The analysis 
involved 27 amino acid sequences from Negarnaviricota phylum. All 
positions containing gaps and missing data were eliminated. There was 
a total of 176 positions in the final dataset. Evolutionary analyses were 
conducted in MEGA7 (Kumar et al., 2016). 
 
 





Lassa virus LASV K03362 
(Clegg and Oram, 
1985) 
Lymphocytic choriomeningitis virus LCMV GQ862982 (Palacios et al., n.d.) 
Junin virus AHV D10072 
(Ghiringhelli et al., 
1989) 
Hantaviridae Orthohantavirus 
Andes virus ANDV NC003466 (Gu et al., 2013) 
Puumala virus PUUV KJ994776 (Ali et al., 2015) 
Hantaan virus HTNV KT935057 (Song and Kim, n.d.) 
Seoul virus SEOV KP645198 (Wang et al., 2015) 
Sin Nombre virus SNV L37904 (Chizhikov et al., 1995) 
Tula virus TULV NC005227 (Plyusnin et al., 1995) 
Nairoviridae Orthonairovirus 
Dugbe virus DUGV NC_004157 (Bridgen et al., 2002) 
Hazara virus HAZV NC_038711 
(Lewandowski et al., 
n.d.) 
Crimean Congo haemorrhagic fever 
virus 
CCHFV AJ010649 (Chinikar et al., 2016) 
Phenuiviridae Phlebovirus Rift valley fever virus RVFV MG273460 (Ikegami et al., 2017) 
Peribunyaviridae Orthobunyavirus 
Bunyamwera virus BUNV NC_001927 (Elliott, 1989) 
Akabane virus AKAV LC217487 (Yanase et al., 2018) 
La Crosse virus LACV KP271116 (Lambert, n.d.) 
Insthoviricetes Articulavirales Orthomyxoviridae 
Alphainfluenzavirus Influenza A H1N1 virus IVA M63767 (Gorman et al., 1991) 
Betainfluenzavirus Influenza B virus IVB M20174 (DeBorde et al., 1988) 
Haploviricotina Monjiviricetes Mononegavirales 
Bornaviridae Orthobornavirus Borna disease virus BDV EU095836 (Puorger et al., 2010) 
Filoviridae 
Ebolavirus Zaire virus EBOV L11365 (Sanchez et al., 1989) 
Marburgvirus Marburg virus MARV GQ433353 (Lofts et al., 2011) 
Paramyxoviridae 
Henipavirus 
Hendra virus HeV NC_001906 (Wang et al., 2000) 
Nipah virus NIV AF376747 (Chua et al., 2002) 
Morbillivirus Measles virus MeV AJ250073 (Truong et al., 2001) 
Rubulavirus Mumps virus MuV AJ937822 (Mallya et al., n.d.) 
Pheumoviridae Orthopneumovirus Human respiratory syncytial virus HRSV DQ780568 (Sun et al., n.d.) 
Rhabdoviridae Lyssavirus Rabies virus RV L20672 
(Nadin-Davis et al., 
1993) 
Table 1 Negarnaviricota phylum virus species.  




Figure 2 Molecular phylogenetic analysis of selected members of the 
Hantaviridae family by the maximum likelihood method.  
The evolutionary history was inferred by using the maximum likelihood 
method (Whelan and Goldman, 2001). Tree with the highest log likelihood 
(-14249.66) is shown. Percentage of trees in which the associated taxa 
clustered together is shown next to the branches. Initial tree(s) for the 
heuristic search were obtained by applying Neighbor-Join and BioNJ 
algorithms to a matrix of pairwise distances estimated using a JTT model, 
and then selecting the topology with superior log-likelihood value. Tree is 
drawn to scale, with branch lengths measured in the number of 
substitutions per site. Analysis involved 41 amino acid sequences from 
Hantaviridae family with a total of 416 positions in the final dataset. All 
positions containing gaps and missing data were eliminated. Evolutionary 
analyses were conducted in MEGA7 (Kumar et al., 2016). Blue cross – 














Loanvirus Longquan LQUV JX465422 Asia Chiroptera Horseshoe bats (Rhinolophus sp.) Unknown (Guo et al., 2013) 
Mobatvirus 
Laibin LAIV KM102247 Asia Chiroptera Black-Bearded Tomb Bat (Taphozous melanopogon) Unknown (Xu et al., 2015) 
Nova NVAV KR072621 Hungary and France 
Chiroptera/Sorici
dae/Talpidae 
European Mole (Talpa europaea), bats and shrews Unknown (Gu et al., 2015) 
Quezon QZNV KU950713 Philippines Chiroptera Geoffroy's rousette bat (Rousettus amplexicaudatus) Unknown (Arai et al., 2016) 
Orthohantavirus 
Amda MGAV KF974360 Japan Muridae Laxmann's Shrew (Sorex caecutiens) Unknown 
(Bennett et al., 
2014) 
Andes ANDV NC003466 Chile, Argentina Cricetidae Long-Tailed Colilargo (Oligoryzomys longicaudatus) HCPS 
(Meissner et al., 
2002) 
Asama ASAV EU929072 Japan Talpidae Japanese Shrew Mole (Urotrichus talpoides) Unknown (Arai et al., 2008) 
Asikkala ASIV KC880341 Europe Soricidae Common Shrew (Sorex araneus) Unknown 
(Radosa et al., 
2013) 
Bayou BAYV GQ200820 North America Cricetidae Marsh Rice Rat (Oryzomys palustris) HCPS 




BCCV AB689163 North America Cricetidae Cotton Rat (Sigmodon hispidus) HCPS 
(Koma et al., 
2012) 
Bowe BOWV KC631782 Africa Soricidae Doucet's Musk Shrew (Crocidura douceti) Unknown (Gu et al., 2013) 
Bruges BRGV KX551960 Europe Talpidae European Mole (Talpa europaea) Unknown 
(Laenen et al., 
2018) 
Cano Degladito CDGV DQ285566 South America Cricetidae Alston's Cotton Rat (Sigmodon alstoni) Unknown 
(Milazzo et al., 
2006) 
Cao Bang CBNV EF543524 Asia Soricidae Common Shrew (Sorex araneus) Unknown (Song et al., 2007) 
Choclo CHOV DQ285046 
Central and South 
America 
Cricetidae Northern Pygmy Rice Rat (Oligoryzomys fulvescens) HCPS 
(Nelson et al., 
2010) 
Dabieshan DBSV JF796022 Asia Muridae Chinese White-Bellied Rat (Niviventer confucianus) Unknown (Wang et al., n.d.) 
Dobrava-
Belgrade 
DOBV GU904031 Europe Muridae Mice (Apodemus sp.) HFRS 
(Kirsanovs et al., 
2010) 
El Moro Canyon EMCV NC038423 
North and Central 
America 
Cricetidae 
Western Harvest Mouse (Reithrodontomys megalotis), 
Mexican Woodrat (Neotoma mexicana) 
HCPS (Hjelle et al., 1994) 
Fugong FUGV KT899701 Asia Cricetidae Small Oriental Vole (Eothenomys eleusis) Unknown (Ge et al., 2016) 
Fusong FUSV EF442087 Asia Cricetidae Grey Red-Backed Vole (Myodes rufocanus) Unknown 
(Zhang et al., 
2007) 
Hantaan HTNV KT935057 Asia Muridae Striped Field Mouse (Apodemus agrarius) HFRS 
(Song and Kim, 
n.d.) 
Jeju JJUV HQ834695 Asia Soricidae 
Asian Lesser White-Toothed Shrew (Crocidura 
shantungensis) 
Unknown (Arai et al., 2012) 
 
 
Kenkeme KKMV KJ857341 Asia Soricidae Flat-Skulled Shrew (Sorex roboratus) Unknown 
(Wang et al., 
2014) 
Khabarovsk KBRV KJ857345 Eurasia Cricetidae Maximowicz's Vole (Microtus maximowiczii) Unknown 
(Wang et al., 
2014) 
Laguna Negra LNV AF005727 South America Cricetidae Small Vesper Mouse (Calomys laucha) HCPS 
(Johnson et al., 
1997) 
Luxi LUXV HM756286 Asia Cricetidae Yunnan Red-Backed Vole (Eothenomys miletus) Unknown 
(Zhang et al., 
2011) 
Maporal MAPV AB689164 
Central and South 
America 
Cricetidae Pygmy Rice Rat (Oligoryzomys sp.) 
Unknown/Ap
athogenic 
(Koma et al., 
2012) 
Montano MTNV AB620100 
Central and South 
America 
Cricetidae Orizaba Deer Mouse (Peromyscus beatae) Unknown (Kariwa et al., n.d.) 
Necocli NECV KF481954 South America Cricetidae 





Oxbow OXBV FJ539166 North America Talpidae American Shrew Mole (Neurotrichus gibbsii) Unknown (Kang et al., 2009) 





Puumala PUUV KJ994776 Northern Europe Cricetidae Bank vole (Myodes glareolus) NE (Ali et al., 2015) 
Rockport RXPV HM015223 North America Talpidae Eastern mole (Scalopus aquaticus) Unknown (Kang et al., 2011) 
Sangassou SANGV JQ082300 Africa Muridae Flat-nosed wood mouse (Hylomyscus simus) 
HFRS (not 
confirmed) 
(Klempa et al., 
2012) 
Seoul SEOV KP645198 




Asian house shrew (Suncus murinus), Rat (Rattus sp.) HFRS 
(Wang et al., 
2015) 
Sin Nombre SNV L37904 North America Cricetidae North American deermouse (Peromyscus maniculatus) HCPS 
(Chizhikov et al., 
1995) 
Thailand THAIV KC490916 Asia Muridae 
Greater bandicoot rat (Bandicota indica), Black rats 
(Rattus rattus) 
HFRS 
(Reynes et al., 
2014) 
Tula TULV NC005227 Europe Cricetidae European common vole (Microtus arvalis) HFRS 
(Plyusnin et al., 
1995) 
Yakeshi YKSV JX465423 Asia Soricidae Taiga shrew (Sorex isodon) Unknown (Guo et al., 2013) 
Thottimvirus 
Imjin MJNV KJ420559 Asia Soricidae Ussuri White-Toothed Shrew (Crocidura lasiura) Unknown (Lin et al., 2014) 
Thottopalayam TMPV NC010704 India and Asia Soricidae Asian house shrew (Suncus murinus) Apathogenic (Song et al., n.d.) 
Table 2 Orthohantavirus genus and species.  
Geographical location, host family/order, host species and associated disease are shown. HFRS – Haemorrhagic fever with renal 
syndrome, NE – Nephropathia Epidemica, HCPS – orthohantavirus cardiopulmonary syndrome
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1.1.3  Transmission, Disease and Pathogenesis  
1.1.3.1 Rodent to rodent transmission  
Hantaviruses are maintained in rodent populations by indirect transmission 
through inhalation of infected excreta and horizontal transmission through 
aggressive behaviour, grooming and sexual contact (Camaioni et al., 2001; 
Botten et al., 2002; Kallio et al., 2006; Hardestam et al., 2008). There is also 
evidence that orthohantaviruses can be maintained in rodent populations 
through transmission from bites of trombiculid and gamasid mites. 
Orthohantaviruses may be maintained in the mite populations through vertical 
transovarial transmission (Yu and Tesh, 2014). Orthohantaviruses tend to cause 
asymptomatic, persistent infections in host species (Schountz et al., 2007; 
Easterbrook and Klein, 2008; Sanada et al., 2011; Perley et al., 2019). However, 
some orthohantavirus species have been shown to have a negative impact on 
host survival, such as PUUV which impairs the winter survival of bank voles 
(Kallio et al., 2007; Voutilainen et al., 2016).   
 
1.1.3.2 Rodent to human transmission  
Hantaviruses are zoonotic pathogens of humans, transmitted to humans from 
infected rodents. Infections in humans primarily arise from indirect transmission 
of the virus through the inhalation of infected rodent excreta (faeces, urine or 
saliva) (Figure 3) (Hart and Bennett, 1999). Orthohantavirus infections can be 
linked to rodent invasion into homes, workspaces or close contact with infected 
rodents (Zeitz et al., 1995; Hjelle et al., 1996; Plyusnin et al., 1997; Ahlm et al., 
1997; Van Loock et al., 1999). Rodent bites have also been implicated in the 
transmission of orthohantaviruses to humans (Schultze et al., 2002; Hirsch et al., 
2003).  
 
1.1.3.3 Human to human transmission  
Generally humans act as a dead-end host for orthohantaviruses and only ANDV 
has been documented to be transmitted person-to-person (Wells et al., 1997; 
Padula et al., 1998; Martinez et al., 2005). Other examples of human-to-human 
transmission of orthohantaviruses have occurred through organ transplantation 
and blood transfusion. Vertical transmission has also been documented (Lee, 




Figure 3 Transmission cycle of orthohantaviruses.  
Orthohantaviruses are transmitted by rodent hosts where they form 
persistent, asymptomatic infections. Increased rainfall causes an 
abundance of food leading to larger rodent populations. Rodent invasion 
into human habitats increase risk of transmission due to aerosolization of 
rodent excreta such as when cleaning. Aerosolised infective particles are 
inhaled leading to human infection.  
 
1.1.3.4 Haemorrhagic fever with renal syndrome  
There are estimated to be 150,000-200,000 hospitalisations due to HFRS per 
year with a case fatality rate of 1-10%. The majority of hospitalisations occur in 
China, Korea and Russia (Bi et al., 2008). In China, there were 1,625,002 cases 
of HFRS between 1950-2014 with a fatality rate of 2.89% (Jiang et al., 2016). In 
Europe, a milder form of HFRS is prevalent with mortality rates of 0.1-1%. This 
milder disease is named nephropathic epidemica (Mustonen et al., 2013). It is 
likely due to similarities in symptoms between HFRS/NE and other diseases such 
as leptospirosis and influenza (Clem et al., 2008) that orthohantavirus disease is 
underreported in the general population. In the UK 32.9 % pet fancy rat owners 
were seropositive for orthohantavirus antigens but very few hospitalisations have 
been reported (Duggan et al., 2014).  
HFRS has an incubation period of 10 days to 6 weeks and is characterised by 
fever, hypotension leading to circulatory collapse, haemorrhage and acute 
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kidney injury (AKI). There are typically five phases to HFRS: febrile, hypotensive, 
oliguric, polyuric and convalescent. The cause of death is typically due to renal 
insufficiency, shock or haemorrhage (Jonsson et al., 2010; Jiang et al., 2016).  
 
1.1.3.5 Hantavirus cardiopulmonary syndrome  
New World orthohantaviruses in the Americas are known to cause HCPS, a 
severe, respiratory disease which has mortality rates of up to 40% (Hjelle and 
Torres-Pérez, 2010). HCPS has an incubation period of 1-6 weeks and is 
characterised by fever, haemorrhage, hypotension, rapid onset respiratory 
failure and cardiogenic shock. There are five phases to HCPS: incubation, febrile 
prodrome, cardiopulmonary, diuretic and convalescent. Cause of death is usually 
due to pulmonary oedema and cardiogenic shock (Jonsson et al., 2010; Hjelle 
and Torres-Pérez, 2010).  
 
1.1.3.6 Pathogenesis  
Both HFRS and HCPS diseases are characterised by a loss in vascular integrity 
and capillary leakage (Hjelle and Torres-Pérez, 2010). Orthohantaviruses are 
known to replicate in capillary endothelial cells but rarely show signs of cytopathic 
effect suggesting the pathogenesis must be due to an alternate mechanism 
(Pensiero et al., 1992; Temonen et al., 1993). Orthohantavirus infection of the 
vascular endothelium induces increased permeability of the capillary monolayer. 
This may be due to the use of β3 integrins for host cell entry. β3 integrins are 
reported to interact with vascular endothelial growth factor receptor 2 (VEGFR2) 
which interacts with VE-cadherin for maintenance of the endothelial barrier. 
Orthohantavirus infection induces upregulation of vascular endothelial growth 
factor (VEGF), a cytokine which is a potent promoter of vascular permeability. 
VEGF binds to VEGFR2 and induces degradation of VE-cadherin leading to 
disruption in the adherens junctions and, in doing so, increases vascular 
permeability.  
Orthohantavirus infection leads to structural remodelling of kidney cells causing 
disruption of tight junctions and reduced vascular integrity. Vascular leakage may 
be the cause of pulmonary oedema in the lungs and acute nephritis in the 
kidneys (Geimonen et al., 2002; Shrivastava-Ranjan et al., 2010; Krautkramer et 
al., 2011; I. Gavrilovskaya et al., 2012). Pathogenic orthohantavirus interactions 
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with β3 integrins may also impact platelet function. Thrombocytopenia (low blood 
platelet count) is characteristic of most orthohantavirus infections. 
Orthohantaviruses may bind to β3 integrins on quiescent platelets and recruit 
these platelets to endothelial cell surface where they form a surface layer over 
infected cells. This recruitment of platelets may lead to the development of 
thrombocytopenia in patients (Gavrilovskaya et al., 2010; Vaheri, Henttonen, et 
al., 2013).   
An increased level of cytotoxic T lymphocytes (CTLs) has been associated with 
orthohantavirus infection. Infected cell cultures treated with CD8+ T cells 
displayed increased permeability suggesting CTLs may also be involved in 
increased endothelial cell permeability during orthohantavirus infection (Kanerva 
et al., 1998; Terajima and Ennis, 2011; Rasmuson et al., 2011). 
Orthohantaviruses have been shown to have developed escape mechanisms to 
avoid killing by CTLs. Infected endothelial cells obtained from patients show little 
to no damage by CTLs. Orthohantaviruses are able to block CTL mediated cell-
death by interfering with the action of granzyme-B and caspase-3 through 
interactions with the nucleocapsid protein (NP) (Gupta et al., 2013; Solà-Riera et 
al., 2019). Remarkably, NK cells activated by orthohantavirus infected cells were 
shown to not kill infected cells but instead targeted uninfected cells for cell-death. 
This suggests orthohantavirus induce killing of uninfected endothelial cells by 
decreasing the activation threshold of NKs so that normal expression of human 
leukocyte antigen-1 (HLA-1) triggers cell death mechanisms. Orthohantavirus 
infected cells display a higher than normal expression of HLA-1 antigens and so 
are not targeted for cell death (Gupta et al., 2013; Braun et al., 2014). The death 
of uninfected cells would reduce the integrity of the vasculature epithelium and 
contribute to capillary leakage.  
Infected individuals also display high levels of cytokines, especially tumour 
necrosis factor alpha (TNFα), interleukin-1 (IL-1), IL-2, IL-6 and IL-8. Disease 
severity can be correlated with high levels of IL-6 (pro-inflammatory) and TNFα 
but with low levels of tumour growth factor beta (TGFβ) (immunosuppressive) 
(Linderholm et al., 1996; Borges et al., 2008; Outinen et al., 2010; Sadeghi et al., 
2011). The immune response to orthohantavirus infection contributes 





Figure 4 Orthohantavirus pathogenesis.  
Orthohantavirus pathogenesis is characterised by thrombocytopenia and 
increased permeability of the vascular endothelium. A) Activation of natural 
killer cells by orthohantavirus infected cells may lead to killing of 
neighbouring uninfected cells. B) Virus binding to β3 integrins leads to 
disruption of tight and adherens junctions and viral induced upregulation of 
VEGF leads to degradation of VE-cadherin via binding to VEGFR2. Both 
these mechanisms lead to reduced vascular integrity. C) Additionally, 
release of cytokines from immune cells leads to a pro-inflammatory 




1.1.3.7 Global distribution and notable outbreaks 
Orthohantaviruses have been discovered on every continent, with the exception 
of Antarctica. The type of human disease outcome associated with 
orthohantavirus infection correlates with global location (Figure 5); HCPS is 
associated with hantaviruses from the Americas, such as SNV and Andes virus 
(ANDV) whereas Asian and Europe hantaviruses such as SEOV and HTNV 
typically cause HFRS. In contrast, NE is the most common disease outcome of 
hantaviruses isolated from European countries, with PUUV, and to a lesser 
extent, Dobrava virus (DOBV) being responsible for the majority of human 
infections (Schmaljohn and Nichol, 2012).  
No orthohantavirus-related disease has been reported in other countries. 
However in Africa, Sangassou virus (SANGV) was identified in the African wood 
mouse (Hylomyscus simus) (Klempa et al., 2006; Klempa et al., 2012) and 
rodents seropositive for orthohantavirus antigens have been identified in 
Australia (Bi et al., 2005) (Table 2, Figure 5). It is possible that either 
orthohantaviruses in these countries (Australia and Africa) are apathogenic in 
humans or that pathogenic orthohantaviruses have yet to be identified. This may 
be the more likely option due to many orthohantavirus infections causing 
subclinical presentations in humans, such is the example of PUUV where it is 
estimated that at least 80% of cases do not require medical attention (Vaheri, 
Henttonen, et al., 2013). 
The impact of industrial globalisation on the distribution of orthohantavirus 
infections is apparent, especially in the example of SEOV, which uniquely among 
orthohantaviruses, has an almost global distribution due to the world-wide 
transport of its host, Rattus norvegicus (Lin et al., 2012; Jameson et al., 2013). 
The importation of infected laboratory or pet rats and the unintentional 
importation of wild rats on ships have introduced SEOV into local rat populations 
(Kerins et al., 2018). In the USA and UK, several SEOV outbreaks have been 
linked to pet fancy rat ownership and can be traced back to imported rats or 
infected rat-breeding colonies (McElhinney et al., 2016; Kerins et al., 2018).  
Increased transmission of orthohantavirus to soldiers during wartime is likely due 
to increased exposure to rodents due to the poor living conditions and hygiene. 
During World War I, “trench nephritis” may have been caused by orthohantavirus 
infections and during World War II a leptospirosis-like disease afflicted soldiers 
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in Finnish Lapland (Clement, 1997). During the Korean War, more than 3000 
united nation soldiers were affected by a condition known as field nephritis 
characterised by acute renal failure with a mortality rate of 7% (Johnson, 2000; 
Muranyi et al., 2005).  
In the US, an acute illness characterised by adult respiratory distress syndrome 
(ARDS) was identified in the Four Corners region, the intersection of Utah, New 
Mexico, Arizona and Colorado. Throughout 1993, 24 patients were identified with 
a mortality rate of 50%, with over half belonging to Native American and Hispanic 
minority groups (Koster et al., 1993). This virus responsible for this outbreak was 
later identified and named SNV (originally Four Corners virus). Since 1993 
several other hantaviruses have been identified to cause HCPS in America such 
as Black Creek Canal virus, Bayou virus and Chocolo virus.  
Other important hantavirus outbreaks in the Americas were the 1996 Argentina 
ANDV outbreak and the 2011 Chile ANDV outbreak. Unusually, these outbreaks 
were characterised by person-to-person transmission of the virus. Generally, 
only infection in the index patient reported exposure to rodents, with the other 
patients having no rodent-interaction and with low occupational risk of rodent 
contact. Through epidemiological investigation, it was identified that transmission 
was likely through inhalation of infective saliva or aerosols due to close contact 
between individuals (Martinez et al., 2005). Often, attending physicians became 
symptomatic, followed by their spouses or other close contacts which is 
indicative of person-to-person transmission (Wells, Estani, et al., 1997). 
Phylogenetic analysis of viruses isolated from the 1996-1997 Argentina-Chile 
outbreak provided evidence for person-to-person transmission through nearly 
identical viral sequences despite geographic distance (>2200 km)  (P. J. Padula 
et al., 1998). ANDV remains the only orthohantavirus to display of person-to-
person transmission and has high case fatality rates of 15-36% which appears 
to depend on the experience of the attending physician (Wells, Estani, et al., 
1997; Wells, Young, et al., 1997; P J Padula et al., 1998; Chaparro et al., 1998; 





Figure 5 Geographical distribution of pathogenic orthohantaviruses.  
Global location of incidence of pathogenic orthohantaviruses. Orthohantavirus cardiopulmonary syndrome (HCPS) shown in red, 
haemorrhagic fever with renal syndrome (HFRS) shown in blue and Nephropathia Epidemica (NE) shown in green. The map is 




1.1.3.8 Environmental impact on orthohantavirus disease  
As orthohantaviruses are primarily transmitted to humans by exposure to 
rodents and/or rodent excreta, the environmental determinants of rodent 
populations are important for tracking outbreaks in human populations. 
Climate is a significant factor for increased outbreaks in human populations. 
Climate conditions, such as El Niño, cause increased rainfalls leading to 
increased vegetation, more food availability and consequently larger rodent 
populations. This increases the likelihood of human-to-rodent contact and 
orthohantavirus transmission (Guterres and de Lemos, 2018).  
Deforestation, agriculture and land-conversion all contribute to increased 
exposure to rodent populations. Individuals working in unsanitary conditions 
or with occupational risks (e.g. forestry, farming, sewage work, veterinarians) 
will have a greater chance of contact with rodents. In addition, reduced 
habitats or extreme weather scenarios, such as unseasonal snow, leads to 
increased rodent home invasion and a higher chance of exposure and 
transmission of orthohantaviruses to humans (Jonsson et al., 2010). It is likely 
in the current climate of deforestation and urbanisation that orthohantavirus 
outbreaks will become more common.  
 
1.1.3.9 Antivirals, vaccines and control 
Currently, there are no effective recognised antiviral therapeutics or vaccines 
available in the UK or the USA. Treatment is generally limited to supportive 
palliative care including fluid replacement, supplemental oxygen and, if 
required, mechanical ventilation (WHO, 2015). 
However, some antivirals have shown a degree of effect on orthohantaviral 
infection. Ribavirin, Favipiravir and 1-beta-d-ribofuranosyl-3-ethynyl-[1,2,4] 
triazole (ETAR) are antivirals which affect the function of the virus encoded 
RNA dependant RNA polymerase (RdRp) (Szabó, 2017). Ribavirin and ETAR 
are nucleoside analogues which have an inhibitory effect on inosine 
monophosphate dehydrogenase and limit the synthesis of GTP. Ribavirin in 
addition to showing effectiveness in in vivo models of HFRS has been 
associated with decreased morbidity and mortality in HFRS patients but has 
proved ineffective in HCPS cases (Huggins et al., 1991; Mertz et al., 2004; 




been described to show antiviral effects against HTNV (Chung et al., 2008) 
and Favipiravir has been associated with decreased viral replication in cell 
culture (Buys et al., 2011). Other antiviral drugs which may prove efficacious 
in the treatment of orthohantaviral disease include; lactoferrin which may 
interfere with viral adsorption (Murphy et al., 2001) and immunotherapies 
utilising the protective effect of neutralising antibodies or polyclonal sera 
against orthohantaviruses (Xu et al., 2002).  
In addition to antivirals, some inactivated orthohantavirus vaccines are 
currently in use in China, Korea and Russia. Hantavax™ is a formalin-
inactivated HTNV vaccine produced by amplifying HTNV in mouse brains. In 
Russia, a bivalent PUUV/Dobrava-Belgrade (DOBV) formalin-inactivated 
vaccine has been developed (Krüger et al., 2011; Song et al., 2016). However, 
it is worth noting that most antivirals and vaccines still need to pass pre-clinical 





1.2 Orthohantavirus life cycle 
 
1.2.1  Genome Organisation  
Hantaviruses are single-stranded negative-sense RNA viruses with a tripartite 
segmented genome. These segments are denoted as the small (S), medium 
(M) and large (L) segments based on their relative nucleotide lengths, and 
each has a common organisation with an ORF flanked by highly-conserved 
untranslated regions (UTRs). The S segment encodes the NP, the M segment 
encodes the glycoprotein precursor (GPC) and the L segment encodes the 
RNA dependent RNA polymerase (RdRp). The S segment, in some 
orthohantavirus species, encodes an additional non-structural (NSs) protein 
from an overlapping ORF via leaky scanning (Vera-Otarola et al., 2012; 
Muyangwa et al., 2015).   
 
1.2.2  Virus structure  
Mature hantavirus particles are pleomorphic in shape forming broadly 
spherical particles (60-160 nM diameter) in addition to tubular particles (~350 
nM long and ~80 nM diameter) (Hart and Bennett, 1999; Huiskonen et al., 
2010; Battisti et al., 2011). The viral RNA segments are wrapped into 
ribonucleoproteins (RNPs) by the NP. Orthohantavirus RNPs appear to form 
rigid helices with the virion and have been visualised by negative stain 
electron microscopy within virus particles and cells (Goldsmith et al., 1995; 
Huiskonen et al., 2010; Battisti et al., 2011; Arragain et al., 2019) (Figure 6). 
Each segment is packaged into a virus particle made up of a lipid bilayer 
studded with glycoprotein spikes that comprise heterodimer complexes of Gn 
and Gc proteins that are derived through processing of the GPC (Elliott, 1990; 
Huiskonen et al., 2010; Reguera et al., 2014; Li et al., 2016). Gn-Gc 
complexes form a lattice to encapsulate the viral bilayer envelope with Gn 
localising to outer surface (Rissanen et al., 2017). Figure 6 shows a schematic 
of a generic hantavirus particle alongside electron micrographs of purified 






Figure 6 Schematic of the orthohantavirus virus particle.  
A) Orthohantaviruses are comprised of a lipid bilayer studded with 
glycoprotein Gn and Gc tetramers. Contained within the virus particle is 
the tripartite genome making up the small, medium and large segment. 
The nucleocapsid protein encapsidates the viral genome and complexes 
with the RdRp to form the RNP. B-C) Representative images of 
orthohantavirus virions B) Cryo-electron tomogram section of TULV 
particles (Huiskonen et al., 2010) C). Thin-section transmission electron 
microscopy of SNV particles (Goldsmith et al., 1995) 
 
1.2.3  Virus entry  
Current evidence suggests multiple orthohantaviruses including HTNV, SNV, 
SEOV, PUUV and NYV (Gavrilovskaya et al., 1999; Mou et al., 2006) utilise 
the abundant cell-surface receptors αvβ3 and αIIbβ3 integrins on endothelial 
cells for cell attachment and internalization. Integrins are heterodimeric 
proteins made up of an α and β subunit. There are 8 different β subunits and 
18 different α subunits which combine to form 24 different integrins (Hynes, 
2002). The αvβ3 and αIIbβ3 are expressed on the vascular endothelium and 
platelets respectively and interaction with orthohantavirus may alter their 
normal function and induced the pathogenic effects seen in orthohantavirus 




The HTNV glycoprotein spikes bind integrin β3 via interactions at  a conserved 
CNP (Cys-Asn-Pro) motif located in the N-terminal of glycoprotein Gc (Mou et 
al., 2006). The use of β3 integrins may be linked to the pathogenicity of 
orthohantavirus due to their function in maintaining vascular integrity and 
involvement in vasodilation and vasoconstriction (Gavrilovskaya et al., 1999). 
Alternatively, it has been suggested that pathogenic orthohantaviruses (HTNV 
and PUUV) additionally require the decay-accelerating factor (DAF) for viral 
entry in polarised epithelial cells. The DAF-receptor is located on the apical 
surface of epithelial and endothelial cells, whereas β3 integrins are located on 
the basolateral surface. DAF-binding may lead to the opening of tight junction 
suggesting that the polarisation of virus entry may be another, important, 
factor in the pathogenesis of orthohantaviruses (Krautkramer and Zeier, 2008; 
Klempa et al., 2012; Dalrymple and Mackow, 2014). The correlation between 
viral pathogenesis and entry receptor is supported by the observation that the 
non-pathogenic orthohantavirus PHV utilises β1 integrins and not β3 integrins 
for cell entry, whereas pathogenic orthohantaviruses utilise β3 integrins 
(Gavrilovskaya et al., 1998; Gavrilovskaya et al., 1999). As viral pathogenesis 
is a complex process it is likely this mechanism alone may not account 
completely for orthohantavirus pathogenesis. SANGV, purported to be a 
pathogenic orthohantavirus, has been suggested to utilise β1 integrins for cell 
attachment suggesting more complex interactions than just viral entry receptor 
interactions are responsible for pathogenesis (Klempa et al., 2012). After 
attachment to the cell, internalisation may be achieved by clathrin-mediated 
endocytosis (HTNV) (Jin et al., 2002). ANDV may be internalised through 
clathrin-mediated endocytosis but may also utilise micropinocytosis in a 
clathrin-independent mechanism (Chiang et al., 2016). Additionally, it has 
been reported that pro-cadherin 1 is a critical receptor for the entry of New 
world hantaviruses such as ANDV and SNV. Orthohantavirus glycoproteins 
are thought to recognise the extracellular cadherin repeat domain of pro-
cadherin-1 leading to viral attachment and entry (Jangra et al., 2018).  
 
1.2.4  Virus RNA transcription and replication  
After orthohantaviruses are internalized within cells, virions are trafficked to 




release the viral genome segments into the cytoplasm (Cifuentes-Muñoz et 
al., 2014; Mancini et al., 2015). The low pH (~5.0-6.0) of endosomes triggers 
a conformational change in the glycoprotein structure which stimulates fusion 
of the viral and endosomal membranes (Jin et al., 2002; Vaheri, Strandin, et 
al., 2013).  
The glycoprotein Gc contains conserved histidine residues which allow 
sensing of low pH environments which induce the Gn-Gc lattice to undergo a 
dramatic conformational change where Gn dissociates from Gc (Cifuentes-
Muñoz et al., 2014; Rissanen et al., 2017). The Gc protein forms a stable 
homotrimer with an exposed fusion loop which inserts into the endosomal 
membrane (Figure 7). This extended conformation collapses which brings the 
viral and endosomal membranes into close proximity allowing membranes to 
fuse and form a viral fusion pore. Viral RNPs can then be released into the 
cytoplasm (Cifuentes-Muñoz et al., 2014; Mancini et al., 2015). The pH 
required for fusion of viral and target membranes varies between different 
orthohantavirus species with HTNV requiring pH 6.3 and ANDV requiring pH 
5.6 (Arikawa et al., 1985; Cifuentes-Munoz et al., 2011).  
 
 
Figure 7 Schematic of low-pH induced conformational change of 
orthohantavirus glycoproteins Gn and Gc.  
Left displays mature viral envelope structure with Gn as a mature 
tetramer and Gc in its pre-fusion dimeric form. Acidification (right) 
induces disassembly of the Gn-Gc heterodimeric complex and formation 
of extended Gc trimer. The fusion loop (FL) extends outward to contact 





After release, viral genomes are transported to sites of replication which have 
yet to be identified (Jin et al., 2002; Vaheri, Strandin, et al., 2013). 
Orthohantavirus replication sites are likely to be similar to other members of 
the Bunyavirales order such as Bunyamwera virus (BUNV) where viral 
replication factories are located around the Golgi complex (Fontana et al., 
2008). Transcription and replication of orthohantaviruses are thought to occur 
on membranes due to the membrane-association of NP and the RdRp and 
the co-localisation of these proteins in a similar spatial location to the Golgi 
complex (Ravkov and Compans, 2001; Kukkonen et al., 2004). The RdRp 
initially carries out the primary transcription of the viral segments into mRNA 
which can be used as a template for viral protein synthesis. Segmented 
negative-sense RNA viruses (e.g. influenza virus) utilise a process called 
“cap-snatching” in which host-cell mRNAs are cleaved at a site close to their 
5’ ends by a RdRp-resident endonuclease, and the capped RNA 
oligonucleotide is then used as a primer for viral transcription (Bouloy et al., 
1978). For orthohantaviruses, this process has been suggested to occur via a 
“prime and re-align’ mechanism (Garcin et al., 1995) in cytoplasmic 
processing bodies (P bodies). NP-associated capped-mRNAs are targeted to 
P bodies, where they are cleaved by endonucleases (cellular or potentially 
RdRp endonuclease activity) at G residues resulting in an NP-associated 
capped-host mRNA primer (m7GpppN) that will be used for viral transcription 
(Mir et al., 2008; Cheng and Mir, 2012).  Orthohantavirus, replication occurs 
without the requirement for capped-mRNA primers, with both transcription and 
replication occurring through the prime-and-realign mechanism. The G of 
either the m7GpppN (transcription) or triphosphorylated G (pppG, replication) 
aligns to the C of the first AUC in the AUC repeat region located in the vRNA 
3’-end. Successive bases are added followed by a “slip” and realigning with 





Figure 8 Orthohantavirus replication, transcription and translation.  
A) Negative-sense viral RNA (vRNA) is transcribed into viral mRNA and 
subsequently translated into viral protein. vRNA is also replicated into 
positive sense copy RNA (cRNA), which is used as a template for 
synthesis of nascent negative sense RNA. This is bound by NP and 
packaged into the mature virion as RNPs. B) Transcription and 
replication vRNA through the prime-and-realign mechanism. Guanosine 
(G) from guanosine triphosphate (pppG) or capped-RNA primer 
(m7GpppN) align with cytosine (in AUC) within 3’-vRNA pan-handle. 
Elongation occurs, nascent RNA “slips” and realigns with preceding AUC 






1.2.5  Virus assembly and egress  
After replication, both vRNA and cRNA are encapsidated by NP. vRNA 
contains highly conserved 3’- and 5’- complementary sequences in the UTR 
which have the potential to form a structure known as the ‘panhandle’. It has 
been proposed that binding of trimeric NP to the panhandle results in a 
conformational change which may be essential for further NP oligomerisation 
and RNA encapsidation (Mir and Panganiban, 2005; Severson et al., 2005; 
Mir et al., 2006).  
The viral glycoprotein precursor (GPC) mRNA is targeted to the ER for 
translation via a signal motif, “YxxL”, located in the 5’-end. A second signal 
motif, “WAASA”, facilitates the cleavage of GPC into the glycoproteins Gn and 
Gc (Hepojoki et al., 2012). The glycoproteins are transported as a heterodimer 
to the Golgi complex, which is believed to be the site of assembly for old world 
(OW) hantaviruses. Assembled virions are trafficked to the plasma membrane 
via recycling endosomes, and mature orthohantavirus virions bud from the 
plasma membrane by exocytosis (Rowe et al., 2008; Vaheri, Strandin, et al., 
2013) (Figure 9). In contrast, new world (NW) hantaviruses are thought to 
assemble and bud from the plasma membrane (Elliott, 1990; Ravkov et al., 





Figure 9 Orthohantavirus cellular lifecycle.  
1. Orthohantavirus particle 2. Virus particle binds and attaches to the cell 
via interaction with host surface protein (e.g. β1/β3 integrin) 3a. Virion 
enters the cell by clathrin-dependent endocytosis 3b. Virion enters the 
cell by clathrin-independent mechanism (e.g. micropinocytosis, caveolin-
mediated endocytosis) 4. Virus particles are trafficked in early endosome 
5. Virus particle reaches late endosome 6. Low pH of late endosome 
induces a conformational change in viral glycoproteins causing the viral 
membrane to fuse with endosome releasing viral genomes and protein 
into the cytoplasm, some NP localises to P-bodies where “cap-snatching” 
occurs 7. Replication and transcription of viral genome products 8a. 
Assembly of old world (OW) orthohantaviruses occurs at the Golgi before 
transport of virions to plasma membrane 8b. New World (NW) 
Orthohantavirus replication products and proteins are transported to the 
plasma membrane where viral assembly occurs 9. Virus particles egress 





1.3 Proteins  
 
1.3.1   The nucleocapsid protein 
1.3.1.1 Structure 
The orthohantavirus NPs are encoded by the S segment ORF and are 429-
435 residues in length, with an average molecular weight of around 50 kDa. 
Several high resolution structures of the orthohantavirus NP have been solved 
by either X-ray crystallography analysis of truncated NP constructs (ANDV 
and SNV NPcore (111-399 residues) and HTNV the NP∆N (113-429 residues)) 
(Guo et al., 2016; Olal et al., 2016) or cryo-electron microscopy of helical NP 
oligomers (Arragain et al., 2019).  
The orthohantavirus NP is a compact protein mostly made up of α-helices. It 
is comprised of an N-terminal lobe domain and a C-terminal lobe domain, 
which together form the core region. The N-lobe is made up of a helical core 
of α-helices and a bulge structure (N-bulge) comprised of four anti-parallel β-
sheets. The C-lobe is made up α-helices and a bulge structure (C-bulge) 
formed of an α-helix with an extended structure (Guo et al., 2016; Olal et al., 
2016). The N-terminal is formed by an antiparallel coiled-coil stabilised by 
ionic bridges (Figure 10D) (Boudko et al., 2007). The N-terminal coiled-coil 
domain and the C-terminal domain are thought to be essential for NP 
oligomerisation (Alfadhli et al., 2001; Alfadhli et al., 2002). 
A flexible hinge from the core connects to the C-terminal helical arm which 
extends from the C-lobe and can interact with neighbouring molecules for 
oligomerisation. The C-terminal arm binds to a hydrophobic pocket located 
within the C-lobe of an adjacent NP molecule (Kaukinen et al., 2003a; 
Yoshimatsu et al., 2003; Kaukinen et al., 2004; Olal et al., 2016). The N-
terminal domain is thought to interact with a conserved hydrophobic surface 
of the N-lobe (Olal et al., 2016; Arragain et al., 2019) (Figure 11). NP 
oligomerisation with RNA results in the formation of a left-handed RNP helix 
formed of 3.6 NP subunits per turn (Figure 10). Electrostatic surface potential 
analysis of the crystal structure of NP revealed a positively charged cleft 
between the N-lobe and C-lobe. Residues thought to be involved in RNA 








Figure 10 Structure of the orthohantavirus nucleocapsid protein.  
A-B) HTNV nucleocapsid protein (PDB: 6I2N), residues 80-429 bound to 
RNA (orange), residues involved in RNA binding (red) and electrostatic 
surface representation displaying RNA binding cleft  (Arragain et al., 
2019), C) Sin Nombre virus N-terminal coiled-coil domain (PDB: 2IC6), 
residues pairs forming ionic bridges contributing to the structure of the 
coiled-coil are displayed in orange, blue and yellow (Boudko et al., 2007). 
Structures generated using PyMOL D) Helical organisation of HTNV 






Figure 11 Representation of NP-NP interaction and oligomerisation.  
NP oligomerisation occurs through interactions of the C-terminal and N-
terminal of the NP interacting with the hydrophobic surfaces of 
neighbouring NP’s C-lobe and N-lobe respectively. Viral RNA segments 
are packaged into NPs through interactions with the positively charged 
RNA binding groove. Figure adapted from Arragain et al., 2019.  
 
1.3.1.2 NP functions  
An important function of the orthohantavirus NP is its role as an RNA binding 
protein, where NP encapsidates the viral genome to form the RNP. The roles 
of the NP-RNA association are likely in the protection of the RNA from 
degradation from host cell nucleases, structural ordering of the RNA strand, 
and avoiding detection of the RNA by immune surveillance mechanisms. 
Cytosolic RNA sensors, RIG-I and MDA5, recognise viral RNAs as induce 
intracellular signalling pathways culminating in the expression of pro-
inflammatory cytokines and Type I interferons. These inflammatory molecules 
further induce activation of immune mechanisms for pathogen clearance (Tan 
et al., 2018).  Orthohantaviruses RNA contain a 5’-monophosphate which is 
linked to the ability of orthohantaviruses to avoid RIG-I recognition and fail to 
induce IFN signalling and in doing so avoid host immune surveillance 
mechanisms (Habjan et al., 2008).   
Selective encapsidation of viral RNA by the NP is potentially carried out due 
to the self-complimentary terminal structures with highly conserved 
sequences at the 3’ termini (3’-AUCAUCAUCUGAGG-5’) and 5’ termini (5’-
UAGUAGUAU(G/A)CUCC-3’) of the viral segments 5’- and 3’- UTRs 
(Muyangwa et al., 2015).  
Reportedly, NP contains independent sites for viral RNA and mRNA binding, 




generated by cap-snatching, undergoes a conformational change and further 
binds to vRNA at the highly conserved 3’ end. This function assists the viral 
RdRp in viral genome transcription and replication (Mir et al., 2010). NP also 
directly interacts with the RdRp to recruit the polymerase to viral genomes for 
transcription initiation (Cheng et al., 2014). NP is able to bind to multiple sites 
on the cytoplasmic tails of the glycoproteins, Gn and Gc and this interaction 
may direct trafficking to the Golgi apparatus for incorporation of the RNP 
segments within assembled virions (Shimizu et al., 2013).  
The orthohantavirus NP has been purported to possess other functions in 
addition to interactions with the Gn, Gc, RdRp and viral RNA. Orthohantavirus 
NP is thought to be involved in protein translation by replacing the eIF4F 
complex during translation initiation. In addition, NP may also interact with the 
S19 ribosomal protein, a component of the 43S pre-initiation complex, 
potentially recruiting the ribosome to capped viral mRNAs leading to the 
preferential translation of viral proteins (Mir and Panganiban, 2008; Haque 
and Mir, 2010). 
NP has been reported to have conserved DNA-specific metal-dependent 
endonuclease activity. This is proposed to function in immune evasion either 
preventing sensing of cytoplasmic ssDNA which can induce immune 
responses or preventing binding of cellular nucleic acids or DNA/RNA hybrids 
which may inhibit orthohantavirus replication (Möncke-Buchner et al., 2016). 
In addition, interaction of orthohantavirus NP with actin microfilaments or 
microtubules to assist viral assembly and release have been reported (Ravkov 
et al., 1998; Ramanathan et al., 2007; Ramanathan and Jonsson, 2008).  
Orthohantaviral NPs have also been implicated in other methods of immune 
evasion such as modulating apoptosis (Gupta et al., 2013). ANDV has been 
suggested to interfere with IFN signalling by inhibiting the dsRNA sensors 
RIG-1/MDA5 and by interfering with TBK1 phosphorylation (Cimica et al., 
2014). NP may also be involved in anti-apoptotic mechanisms such as the 
ubiquitination of the tumour suppressor p53 to target it for degradation (Park 
et al., 2013). HTNV NP has been shown to bind to and inhibit the nuclear 
import activity of importin α. This prevents the nuclear shuttling of nuclear 
factor kappa beta (NFκβ) and prevents its function as a transcription factor for 




been shown to prevent protein kinase R (PKR) dimerization avoiding host cell 
translation shutdown as this prevents the phosphorylation of eIF2α. The deficit 
in phosphorylated eIF2α aids efficient translation of viral proteins by 
preventing downregulation of protein synthesis by the host cell (Wang and Mir, 
2015).  
Orthohantavirus NP has been identified to interact with Daxx (dead domain 
associated protein-6), a Fas-death domain adaptor protein. Daxx is a pro-
apoptotic protein that promotes Fas-mediated apoptosis through activation of 
the JNK pathway. NP interaction with Daxx may interfere with the pro-
apoptotic function and promote survival of the infected cell (Li et al., 2002; 
Jang et al., 2002; Khaiboullina et al., 2013). Other proteins identified to interact 
with orthohantavirus NP are the small ubiquitin-related modifier-1 (SUMO-1) 
which has functions in sumoylation of proteins, and the SUMO-1 conjugating 
enzyme, Ubc9. SUMO-1 and Ubc9 have been shown to interact with Daxx 
and together they regulate NP localisation to the perinuclear region. 
Orthohantavirus NP also interacts with other SUMO-1 related proteins such 
as chromodomain helicase DNA-binding protein 3 (CHD3), human 
homeodomain-interacting protein kinase 2 (HIPK2) and TRAF and TNF 
receptor-associated protein (TTRAP) suggesting that sumoylation may be 
important for the orthohantavirus lifecycle specifically in host-cell survival 
mechanisms (Maeda et al., 2003; Kaukinen et al., 2003b; Lee et al., 2003).  
Other anti-apoptotic functions of the orthohantavirus NP have been reported. 
ANDV, DOBV, HTNV, PUUV, SEOV and TULV have all been shown to 
mediate apoptotic induction by interaction with activated caspase-3. In 
addition to this, ANDV, DOBV and PUUV NPs inhibit the action of granzyme 
B during NK mediated cell killing. ANDV NP contains the conserved caspase-
3 recognition site, DLID. Orthohantaviruses appear to inhibit apoptosis by 
interfering with the caspase cascade, where a series of cysteine-aspartate 
proteases are activated by sequential cleavage. Orthohantavirus NP interacts 
with cleaved, activated caspase 3 to prevent its downstream cleavage action 







Figure 12 Schematic of orthohantavirus NP interaction sites and 
functional domains.  
Predicted or confirmed interactions of NP with other proteins are 
depicted. NP-NP interactions are shown in blue (N-term) or green (C-
term) (Arragain et al., 2019). Figure adapted from Reuter and Krüger, 
2018 
 
1.3.1.3 The non-structural NSs protein  
The S segment in some orthohantaviruses (PUUV, TULV, PHV, SNV, ANDV) 
also contains a second ORF which encodes the small, ~11 kDa, non-structural 
protein (NSs). The NSs ORF is in the +1 register relative to the NP ORF and 
is proposed to be accessed through leaky ribosomal scanning. NSs localises 
to the perinuclear region during orthohantavirus infection. The NSs may have 
immune regulatory functions, where it can inhibit IFNβ expression and the 
action of NFκβ and type I IFN which may promote viral replication 
(Jääskeläinen et al., 2007; Jääskeläinen et al., 2008; Virtanen et al., 2010; 
Vera-Otarola et al., 2012). The cellular protein ACBD3 is thought to interact 
with NSs. ACBD3 is involved in Golgi structure maintenance and may also be 
involved in the immune response to viral infection. The NSs likely has a major 
role in immune evasion and promotes virus replication within the host cell 
(Rönnberg et al., 2012).   
 
1.3.2  The glycoprotein 
1.3.2.1 Structure and functions 
The orthohantavirus M segment encodes the glycoprotein precursor (GPC) 




into the glycoproteins Gn (~ 70 kDa) and Gc (~ 50-55 kDa) (previously G1 and 
G2) (Schmaljohn and Dalrymple, 1983; Löber et al., 2001; Spiropoulou et al., 
2003; Muyangwa et al., 2015). Gn and Gc interact to form a heterodimer which 
protrudes through the lipid bilayer of the viral envelope to form spikes on the 
mature virus particle. The glycoprotein spike ectodomain is formed from four 
globular domains connected to the viral membrane by a thin stalk, with a small 
endodomain that protrudes inside the virus particle (Huiskonen et al., 2010; 
Battisti et al., 2011) (Figure 10).  
Viral glycoproteins contain multiple highly conserved N-linked glycosylation 
sites which are required for correct folding of the protein and for intracellular 
transport to the cis-Golgi. Trafficking to the Golgi network is also dependent 
on the interaction of Gn and Gc (Ruusala et al., 1992; Shi and Elliott, 2002; 
Shi and Elliott, 2004; Deyde et al., 2005), which are transported as a 
heterodimer complex. The cytoplasmic tail of Gn for pathogenic 
orthohantaviruses has been implicated in the inhibition of IFNβ production. Gn 
prevents IRF3 from instigating the IFNβ anti-viral response by binding to 
TRAF3 which prevents interaction with TBK-1 and formation of the TBK1-
TRAF complex required for phosphorylation and activation of IRF3 (Alff et al., 
2008; Matthys et al., 2014; Mackow et al., 2014).  
Glycoprotein induced fusion of the viral membrane and endosomal membrane 
allows virus uncoating. Cell-surface glycoproteins can also mediate syncytia 
formation of an infected cell with both infected and uninfected neighbouring 
cells (Ogino et al., 2004; Barriga et al., 2016; Willensky et al., 2016). The 
glycoprotein Gn at neutral pH forms an outer layer which shields the fusion-
loop of Gc preventing premature membrane fusion. At acidic pH, 
conformational changes in the Gn exposes Gc which forms a fusion 
homotrimer which can insert into the target membrane and induce a 





Figure 13 Averaged structure of the orthohantavirus glycoprotein spike.  
A-C) Glycoprotein spike from TULV shown from the top (A), side (B) and 
below, scale bar 10 nM (C) viewpoints (Huiskonen et al., 2010) D-E) 
Glycoprotein spike from HTNV shown from the top (D) and side (E) 
viewpoint, scale bar 5 nM (Battisti et al., 2011) 
 
1.3.3  The RNA dependent RNA polymerase  
1.3.3.1 Structure and functions  
The L segment of orthohantaviruses encodes the RNA dependent RNA 
polymerase (RdRp). The RdRp is a 200-250 kDa protein which primarily acts 
to transcribe and replicate the viral genome. For orthohantaviruses, the RdRp 
is a membrane-associated protein which localises to the perinuclear region of 
the cell and co-localises with the Golgi network (Kukkonen et al., 2004). 
Virions contain a functioning RdRp which is required for initial primary 
transcription of the viral genome (Schmaljohn and Dalrymple, 1983). 
The orthohantavirus RdRp possesses conserved motifs of other bunyavirus 
RdRps and therefore it is likely that it shares similar structural features 
(Amroun et al., 2017). The only bunyaviral RdRp for which the high resolution 
structure has been solved to date, is for La Crosse virus. The bunyavirus 
RdRp contains a conserved N-terminal endonuclease domain which functions 
in the cap-snatching process to cleave 5’-capped RNAs from host cell mRNAs 
(Gerlach et al., 2015). The orthohantavirus RdRp has a highly conserved 




downstream of the cap. This capped-primer, used during transcription, allows 
the synthesis of 5’-capped viral mRNAs which can be further translated into 
the viral proteins (Rothenberger et al., 2016).  
Additionally, The RdRp has been shown to degrade viral and cellular nucleic 
acids, leading to a reduction in both host and viral mRNAs (Heinemann et al., 
2013; Rothenberger et al., 2016). This may help the virus evade host cell 
responses and select for viral protein translation by host cell ribosomes. 
The RdRp binds to the vRNA genome segment with a separate binding site 
for the 3’- and 5’-vRNA panhandles (Figure 14) (Gerlach et al., 2015).  The 
panhandle sequences were found to, in most cases, contain a mismatch at 
position 9 and a non-canonical U-G pair in position 10. These non-
complementary regions with the panhandle may serve to function as the 
polymerase binding site, as in influenza virus replication, and may act as 
transcription initiation signals (Tiley et al., 1994; Chizhikov et al., 1995; Meyer 
and Schmaljohn, 2000; Nichol et al., 2002). Several orthohantaviruses (e.g. 
TULV, HTNV PUUV) have been found to contain CCACCC motifs at the 3’-
end of the S viral RNA segment. These motifs are predicted to form stem-loop 
structures which may act as termination signals. The M segment mRNA was 
found to be polyadenylated, which may also act as a signal for transcription 









Figure 14 Structure of the La Crosse RdRp.  
Structure of the La Crosse RdRp (PDB: 5AMQ) as a representative 
structure of the Bunyavirus RdRp. The endonuclease domain in 
indicated in blue and vRNA indicated in orange (3’-vRNA) and red (5’-
vRNA). Arrows indicate where template vRNA enters and exits the 
polymerase as well as the exit of the newly synthesised RNA product. 
Figure adapted from Gerlach et al., 2015. 
 
The RdRp has also been associated with the increased genetic diversity in 
orthohantaviruses through the copy-choice mechanism leading to 
recombination of viral segments (Sironen et al., 2001; Plyusnin et al., 2002). 
The copy choice mechanism occurs when two viruses of different lineages co-
infect the same cell and replicate. During replication the RdRp switches from 
one viral template to the other, still attached to nascent RNA, resulting in a 
recombinant genome segment (Worobey and Holmes, 1999). This template 
switching has been shown to generally occur singly during replication in 
recombination ‘hot spots’ (Plyusnin et al., 2002). The RdRp is known to have 
a high error rate and these recombination events may help the virus overcome 





1.4 Project Aims 
Currently, many fundamental aspects of the orthohantavirus lifecycle are 
poorly understood and this is predominately due to difficulties in both the 
detection and quantification of hantavirus components. The generation of new 
and efficient techniques to quantify hantavirus proteins, RNAs and infectious 
particles will provide a more detailed understanding of the hantavirus life cycle 
and will aid in the development of therapeutics and antivirals that are currently 
lacking.  
 
Here, three experimental aims were identified: 
 
1). Development of new approaches for the detection of hantavirus 
protein and RNA components. Methodologies for detection and 
quantification of hantavirus components and infectivity are often laborious and 
inefficient. The first aim was to develop multiple complementary methods to 
allow quick and efficient quantification of orthohantavirus components that 
could produce a greater understanding of orthohantavirus replication kinetics. 
To this end, an antibody against the NP was generated to allow its detection 
by western blot or immunofluorescent analysis. This NP antiserum was 
subsequently used for an IF viral titration assay developed for infective particle 
quantification. In addition, a qRT-PCR was standardised for the quantification 
of viral genomes.  
 
2). Examining orthohantavirus-host cell interactions. The orthohantavirus 
NP is purported to have multiple functions within the viral lifecycle. Along with 
its function to bind to and encapsidate viral RNAs, the NP also has roles in 
viral transcription and translation and evasion of the host immune system. The 
interactions of TULV NP with host cell components, including the 
cytoskeleton, organelles and transport vesicles were assessed using co-
localisation analysis. As orthohantaviruses can form persistent infections in 
vitro without significant evidence of cytopathic effect, the induction of apoptotic 
factors and the interaction of NP with caspase-3 was examined to assess 





3). Identification of orthohantavirus replication sites. As of yet, the 
replication sites of orthohantavirus have not been identified. It has been 
suggested that like other Bunyaviruses, replication factories are associated 
with the Golgi network. However, this has not been experimentally proven. 
RNA labelling techniques were employed with the aim to identify viral 
replication sites by IF analysis. Nascent TULV RNA was labelled by 
incorporating a nucleoside analogue, 5EU, into the genome during replication 
and transcription. Subsequently, the localisation of RNA-FISH probes 
complementary to the sense and anti-sense S segment ORF was assessed 
by IF analysis in conjunction with TULV NP and previously identified 





Chapter 2 : Materials and Methods  
 
2.1 Materials  
 
2.1.1  Vectors 
Various recombinant cDNA plasmid constructs were generated for expression 
of the Seoul virus (SEOV) and Tula virus (TULV) nucleocapsid protein (NP) in 
both bacterial and mammalian cell systems. These proteins will be used for 
the generation of antisera against SEOV NP and to recombinantly express 
orthohantavirus NP in mammalian cell culture to examine interaction of the 
NP independent from other viral proteins. 
The NP open reading frame (ORF) from SEOV sub-strain Humber virus, was 
optimised for bacterial protein expression and synthesised by Thermo Fisher 
Scientific as an insert within the pMK-RQ vector. For protein expression in 
bacterial cultures, this ORF and a subsequently truncated ORF produced by 
polymerase chain reaction (PCR), were sub-cloned into a pET28a(+) SUMO 
expression vector. These vectors will be used for the bacterial cell expression 
of the SEOV NP. SEOV NP core region (NP amino acids 111-399) was sub-
cloned into a pET28a-SUMO expression vector in-frame with the coding 
sequence for biotin accepter peptide (BAP) tag. This vector will be used for 
the bacterial cell expression of a BAP-tagged SEOV NP.  
For expression of TULV NP in mammalian cells, the TULV NP ORF was 
isolated by reverse-transcriptase PCR (RT-PCR) from TULV infected cell 
culture supernatant. TULV NP ORF was sub-cloned into the pcDNA3.1(+) 
mammalian cell expression vector, under the control of the chicken actin pol 
II promoter.  
Relating to the production of SEOV NP specific affimers various affimer ORFs 
with alternative variable loop sequences were sub-cloned into a pET11a 
expression vector. This vector will be used for the bacterial cell expression of 





2.1.2  Bacterial Strains  
Plasmid constructs were amplified using by transformation and subsequent 
growth of Escherichia coli (E. coli), DH5α strain, produced in-house by Sue 
Matthews E. coli expression strains used are listed in Table 3.  
Abb. Host Strain Genotype 
Gold BL21-Gold(DE3)pLysS 
E. coli B F- ompT hsdS(rB-mB-) dcm+ 
Tetr gal λ(DE3) endA Hte [pLysS Camr] 
Star BL21-Star(DE3)pLysS 
E. coli F- ompT hsdSB(rB-mB-) gal 




E. coli F- ompT hsdSB(rB-mB-) gal dcm 





E. coli F- ompT hsdSB(rB-mB-) gal dcm 




E. coli B F- ompT hsdS(rB-mB-) dcm+ 
Tetr gal λ(DE3) endA Hte [argU proL 
Camr] [argU ileY leuW Strep/Specr) 
Table 3 Bacteria expression strains used for expression of 
recombinant protein  
 
2.1.3  Media  
Media used for the growth of E. coli bacterial strains were Luria-Bertani (LB) 
broth (10 g/L sodium chloride, 10 g/L tryptone, 5 g/L yeast extract), LB-agar 
(10 g/L sodium chloride, 10 g/L tryptone, 5 g/L yeast extract, 15 g/L agar) and 
2YT broth (5  g/L sodium chloride 16 g/L tryptone, 10 g/L yeast extract). Media 
used for the growth of cell lines included Dulbecco’s modified essential 
medium (DMEM) supplemented with foetal bovine serum (FBS) (Life 
Technologies), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma).  
 
2.1.4 Buffers 
2.1.4.1 Soluble protein purification buffers 
Buffers used for the purification of soluble recombinant SEOV NP are 
described in Table 4.  
 
2.1.4.2 Insoluble protein purification buffers  
Buffers used for the purification of insoluble recombinant SEOV NP are 




 Lysis Buffer 









1 M Wash High Salt Elution Dilution 
Sodium chloride 500 mM 500 mM 1 M 500 mM 
Tris-HCl 20 mM (pH 8.0) 20 mM (pH 7.4) 
Glycerol 5 % 5 % 
β-
mercaptoethanol 
5 mM 5 mM 
Imidazole 25 mM 25 mM 50 mM 75 mM 100 mM 1 M 25 mM 500 mM 20 mM 
RNase 2 U/mL  
DNase 1 U/mL  
Chicken egg 
white lysozyme 
1 mg/mL  
Triton X-100 1.0 %  
Protease 
inhibitor 
1 tablet  
























Sodium chloride 500 mM 1 M 500 mM  500 mM 
Tris-HCl 20 mM (pH 7.8) 




Imidazole  25 mM 50 mM 75 mM 100 mM 100 mM 
Triton X-100 2 % 1 %  
Guanidinium 
Hydrochloride 
 6 M 4.2 M 3.0 M 2.0 M 1.0 M  





2.1.5  Cell Lines 
Vero E6 cells (ATCC® CRL-1586™) were used for the propagation of TULV 
and expression of recombinant protein. Vero E6 cells were kindly provided by 
Dr Roger Hewson (PHE, UK). Vero E6 cells are a clone of Vero 76 cells 
isolated from Cercopithecus aethiops (African green monkey) kidney cells. 
Vero E6 cells are known to exhibit contact inhibition and can be used for the 
growth of slow replicating viruses, such as orthohantaviruses.   
 
2.1.6  Virus Strains  
Tula virus (TULV) was kindly provided by Dr Roger Hewson (PHE, UK). 
Sequence analysis of the TULV S segment ORF of this isolate confirmed the 
strain identity as Moravia/5302v/95 with two synonymous and one non-
synonymous differences in the coding sequence.  
 
2.1.7  Fluorescent in-situ hybridisation (FISH) Probes  
Fluorescent in-situ hybridisation DNA probes were designed against the 
sense and anti-sense TULV S segment ORF sequenced using the Stellaris® 
Probe Designer version 4.2. The Stellaris® Probe Designer provided 48 
oligonucleotide probe sequences that were 20 nucleotides in length with a 
minimum spacing of 2 nucleotides. Target TULV S segment ORF sequence 
was obtained from sequencing viral RNA isolated from TULV infected cell 
culture medium (Genewiz). Probes were assessed using NCBI Nucleotide 
Blast against C. aethiops (taxid:9534) mRNA and against the M and L 
segment sense and anti-sense sequences (strain: Tula/Moravia/5302v/95). 
Any probes with more than 15 consecutive complimentary nucleotides were 
discarded. TULV S segment sense and anti-sense probes were labelled with 
Quasar670. Custom-designed TULV S segment probes and ShipReady 
GAPDH probes labelled with Quasar570 were synthesised by 2B Scientific 





Probe Name Probe Sequence 5' – 3' 
TULV S Segment Sense 1 TGTTCATGGCGGGTGATTTC 
TULV S Segment Sense 2 TTGCCGGGCAATGACAATTT 
TULV S Segment Sense 3 CCGTCTTTTCTACATCTTTA 
TULV S Segment Sense 4 CTCCAATGCTGACACAGCTG 
TULV S Segment Sense 5 AACAGGCTTTTCACCCATTT 
TULV S Segment Sense 6 TGATCTCTCCTTGAGGTGAT 
TULV S Segment Sense 7 CTGTAATGTACTGGCCGATA 
TULV S Segment Sense 8 ATGCCTTCAAGATTATTGCA 
TULV S Segment Sense 9 CCTCTAGTTGACAGCATATA 
TULV S Segment Sense 10 CTTAAACCGGATTCTTGTCC 
TULV S Segment Sense 11 GATGTTTCGGGCGTCTAATG 
TULV S Segment Sense 12 GCTGTTGGCATAGACACATA 
TULV S Segment Sense 13 AATTCATCGGCTTTCATGGT 
TULV S Segment Sense 14 TGAGCAGGAAAGAGTCCACA 
TULV S Segment Sense 15 TCTTTTCAGGCCAATCTTTA 
TULV S Segment Sense 16 AATCTTCTTCCTTACTAGGA 
TULV S Segment Sense 17 GGTAAGCATCATTACTCACA 
TULV S Segment Sense 18 AATGCCTTTTCACGTCCTAA 
TULV S Segment Sense 19 TATCTCAGCAAGGTGTGACT 
TULV S Segment Sense 20 AGCTGCAAGGTCAATCAAGT 
TULV S Segment Sense 21 GTGCTTGTGGTGACTTTATA 
TULV S Segment Sense 22 AAAAATGCTCCCAACTCTGC 
TULV S Segment Sense 23 GTTTTGGATGCCATAATCGT 
TULV S Segment Sense 24 GAGTGCGTCTCAGATATGAC 
TULV S Segment Sense 25 GTTGACAATATCAGAACCCC 
TULV S Segment Sense 26 GACTTTGTGCAAGTGTTCTG 
TULV S Segment Sense 27 TAGATTTTTAGCGGTTCCTG 
TULV S Segment Anti-Sense 1 GATTTCAAACCAGGAACCGC 
TULV S Segment Anti-Sense 2 GAGCTCAGAACACTTGCACA 
TULV S Segment Anti-Sense 3 TCTGGGTGATGATATGGACC 
TULV S Segment Anti-Sense 4 CTGATATTGTCAACCACTTC 
TULV S Segment Anti-Sense 5 AGACGCACTCAATCTATGGG 
TULV S Segment Anti-Sense 6 GGGCACAGCAGAGGAAAAAT 
TULV S Segment Anti-Sense 7 CGATTATGGCATCCAAAACT 
TULV S Segment Anti-Sense 8 CAGAGTTGGGAGCATTTTTT 




TULV S Segment Anti-Sense 10 TGACTTGATTGACCTTGCAG 
TULV S Segment Anti-Sense 11 GATGCTTACCTTTTAGGACG 
TULV S Segment Anti-Sense 12 TTCGTTAAAGATTGGCCTGA 
TULV S Segment Anti-Sense 13 GGGTGTGATTGGATTTTCTT 
TULV S Segment Anti-Sense 14 GAAACATCATAAGTCCTGTC 
TULV S Segment Anti-Sense 15 GACTCTTTCCTGCTCAAATT 
TULV S Segment Anti-Sense 16 TCTACCATGAAAGCCGATGA 
TULV S Segment Anti-Sense 17 TGTATGTGTCTATGCCAACA 
TULV S Segment Anti-Sense 18 AATCAATGGCATTAGACGCC 
TULV S Segment Anti-Sense 19 TAAGGGGACAAGAATCCGGT 
TULV S Segment Anti-Sense 20 GGCTTTGCACTTGCAATAAT 
TULV S Segment Anti-Sense 21 AGTGGACAGACAGCAGATTG 
TULV S Segment Anti-Sense 22 CCTTCGATATGGAAATGTCC 
TULV S Segment Anti-Sense 23 ATCACCTCAAGGAGAGATCA 
TULV S Segment Anti-Sense 24 TGGGTGAAAAGCCTGTTGAC 
TULV S Segment Anti-Sense 25 TGGCAGACTTCAAGAGGCAG 
TULV S Segment Anti-Sense 26 GTGTCAGCATTGGAGGACAA 
TULV S Segment Anti-Sense 27 ACTACAGAGTAGACGGGCAG 
TULV S Segment Anti-Sense 28 TAGAAAAGACGGTGGAAGCC 
TULV S Segment Anti-Sense 29 CATTGCCCGGCAAAAACTTA 
 
Table 6 RNA FISH Probes designed against TULV S Segment ORF 






2.2.1  Cloning Strategies  
2.2.1.1 The Polymerase Chain Reaction (PCR)  
PCR was used to modify and truncate various cDNA. SEOV NP ORF, SEOV 
NPcore (111-399 amino acids), TULV NP ORF and anti-SEOV NPcore affimer 
cDNAs were amplified using PCR. PCR was carried out in 50 µL reaction 
volumes containing; 50 ng template DNA, 200 µM dNTPs, 0.5 µM forward 
primer, 0.5 µM reverse primer, 1X Q5® Reaction Buffer (New England 
Biolabs) and 0.02 U/µL Q5® High Fidelity DNA Polymerase (New England 
Biolabs). PCR cycling was carried out in a thermocycler (Eppendorf) with 
cycling conditions; 98 °C for 2 minutes, followed by 40 cycles of 98 °C for 30 
seconds, 58 °C for 30 seconds, 72 °C for 1 minute, followed by 72 °C for 10 
minutes. Oligonucleotide primers are shown in Table 7 and were designed to 
incorporate terminal restriction endonuclease recognition sites for insertion 
into expression vectors. PCR products were purified using the QIAquick PCR 
Purification Kit (Qiagen).  
 
Primer Name Primer Sequence 5’ – 3’ 
SEOV NP Forward GTTGGATCCATGGCAACCATGGAAG 
SEOV NP Reverse GTGCTCGAGTTACAGTTTCATCGGTTCTTG 
SEOV NPcore Forward TGTTGGATCCGAACCGACAGGTCAGACCGCAGATTG 
SEOV NPcore Reverse GGTGCTCGAGTTAACCCAGGTGAAAGTTATCCACGGC 
SEOV NPcore BAPtag Forward TGTTGGATCCGAACCGACAGGTCAGACCGCAGATTG 









TULV S Segment Forward GTTGGATCCATGAGCCAACTCAAAG 
TULV S Segment Reverse GTGCTCGAGTTAGATTTTTAGCGG 
Affimer Forward TTCTGGCGTTTTCTGCGTCTGC 
Affimer Reverse  TACCCTAGTGGTGATGATGGTGATGC 





2.2.1.2  Dpn1 Digest 
In order to remove dam methylated template DNA from PCR products, 10 U 
DpnI (New England Biolabs) was added to each PCR reaction used for 
production of cDNA inserts for ligation and incubated for 1 hour at 37 °C.  
 
2.2.1.3 Restriction Digest 
Restriction enzyme digests were carried out to facilitate sub-cloning into 
expression vectors or for diagnostic purposes. Restriction digests were carried 
out in 20 µL volumes containing 1 µg DNA, 1X CutSmart® buffer (New 
England Biolabs) and 10 U restriction enzyme. Digests were incubated at 37 
°C for 1-2 hours and analysed by agarose gel electrophoresis. Products of 
digestion for sub-cloning were purified by gel extraction using the NEB 
Monarch® gel extraction kit (New England Biolabs) as per the manufacturer’s 
instructions.  
 
2.2.1.4 Agarose gel electrophoresis  
Separation of DNA fragments resulting from restriction digest were carried out 
using 1 % or 2 % agarose gels containing 1 X TAE (40 mM Tris-acetate, 1 mM 
ethylene-diamine-tetra acetic acid (EDTA)) with SYBR Safe DNA stain (Life 
Technologies) diluted 1:10,000. DNA samples were mixed with 1X DNA gel 
loading dye (New England Biolabs) before loading onto gel. Hyperladder I 
(Bioline) was used as a molecular maker. Electrophoresis was carried out at 
100 V for 30-90 minutes in 1 X TAE buffer. Blue light transillumination was 
used for the visualisation of DNA.  
 
2.2.1.5 Ligation  
Ligations were carried out in 20 µL reaction volumes containing 7:1 molar ratio 
of insert: vector DNA, 1 X T4 DNA ligase reaction buffer (50 mM Tris-HCl, 10 
mM magnesium chloride, 10 mM dithiothreitol, 1 mM ATP, pH 7.5) and 2.5 % 
poly(ethylene glycol) (PEG) 6000 and 10 U T4 DNA ligase (New England 
Biolabs). Ligase reactions were either incubated on ice for 1 hour and then at 
room temperature for 1 hour or overnight at 4 °C before being transformed 





2.2.1.6 Bacterial transformations  
Bacterial transformations were carried out by adding 50-100 ng plasmid DNA 
or 5-10 µL of ligation mixture to 50 µL competent E. coli cells that were thawed 
on ice. Transformation mixtures were incubated on ice for 20 minutes before 
being heat-shocked at 42 °C for 45 seconds and then cooled on ice for 5 
minutes. To the transformed mixes, 400 µL LB broth was added and incubated 
at 37 °C with shaking for 1 hour. Either 50 µL or 200 µL transformation mixture 
was spread onto LB agar plates supplemented with appropriate antibiotic-
selection (50 µg/mL kanamycin or 100 µg/mL ampicillin) and incubated at 37 
°C overnight.  
 
2.2.1.7 Plasmid DNA amplification  
Single colonies were picked from transformation plates and used to inoculate 
10 mL (small-scale), 50 mL (large-scale high copy number) or 200 mL (large-
scale low copy number) LB broth with appropriate antibiotic-selection and 
incubated at 37 °C with shaking overnight. Bacterial cells were pelleted by 
centrifugation at 4000 g at 4 °C for 20 minutes. Plasmid DNA was isolated 
using QIAprep Spin Miniprep Kit (Qiagen) or QIAGEN Plasmid Midi Kit 
(Qiagen) following the manufacturer’s instructions. Purity and quantity of DNA 
through spectrophotometry using a NanoDrop 1000 (Thermo Scientific).  
 
2.2.2  Recombinant Protein Expression and Purification  
2.2.2.1 Starter cultures 
pET28a-SUMO-SEOV NP and pET28a-SUMO-SEOV NPcore plasmids were 
transformed into E. coli Gold, Star, Rosetta, Rosetta-2 and CD+ expression 
strains. pET11a-affimer plasmids were transformed into E. coli Rosetta-2 
expression strains.  Single colonies were picked from transformation plates 
and used to inoculate 10-75 mL LB broth with appropriate antibiotic-selection 
and incubated at 37 °C with shaking overnight. 0.1 mL of starter culture or 10 
mL of starter culture were used to inoculate 10 mL or 1000 mL 2YT broth for 






2.2.2.2 IPTG Induction 
Protein expression cultures were grown to OD600nm 0.6-0.8 shaking at 37 °C 
before being induced with 100-500 µM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) and incubated at 18 °C or 12 °C with shaking for 18-24 hours.  
 
2.2.2.3 Soluble protein isolation 
Bacterial cells were pelleted by centrifugation at 4000 g for 20 minutes at 4 
°C. Each 1 L bacterial pellet was resuspended in 25 mL bacterial cell lysis 
buffer (Table 4) and incubated for 30 minutes on ice. Cell lysates containing 
affimers were incubated at 50 °C for 20 minutes to heat denature non-specific 
proteins.  Sonication was carried out on ice using 20 cycles of 20 seconds on 
and 40 seconds off at 6 micron amplitude. Cell lysates were clarified by 
centrifugation at 20,000 g for 1 hour at 4 °C. Supernatant contained soluble 
protein and the pellet contained insoluble protein. Soluble protein was filtered 
through 0.45 µm filter to remove large protein aggregates and remaining cell 
debris. Recombinant SEOV NPcore was isolated from both soluble and 
insoluble protein using nickel affinity chromatography. Recombinant SEOV 
NPcore with BAPtag were isolated from soluble protein using nickel affinity 
chromatography. Anti-SEOV NPcore affimers were isolated from soluble 
protein using batch nickel affinity chromatography.  
 
2.2.2.4 Nickel affinity chromatography purification of soluble 
SOEV NPcore 
Clarified bacterial supernatant containing soluble protein was applied to nickel 
Sepharose™ pre-packed 5mL HisTrap HP column (GE Healthcare) at 4 °C 
for 1 hour using a peristaltic pump. Resin was washed with 5 column volumes 
of 25 mM imdazole wash buffer followed by 5 column volumes of high salt 
wash buffer. Contaminating proteins were removed by washing with 5 column 
volumes of increasing concentration of 25-100 mM imidazole wash buffers. 
Recombinant protein was removed with 2-10 successive 5 mL washes with 
elution buffer. Any remaining bound protein was removed by washing with 5 
column volumes of 1M imidazole wash buffer. Eluted protein was pooled and 
6xHis-SUMO tag removed by overnight cleavage at 4 °C with 10 U Ubl-




filtered through a 0.45 µm filter to remove protein aggregates before dilution 
1:10 in diluting buffer. Diluted protein was applied to a to nickel Sepharose™ 
pre-packed 5ml HisTrap HP column (GE Healthcare) at 4 °C for 1 hour using 
a peristaltic pump and the unbound protein collected. Any remaining bound 
protein was removed by washing with 5 column volumes of 1M imidazole 
wash buffer. Eluted protein concentration was determined by diluting 1:10 in 
25 mM wash buffer and reading absorbance at 280nm (A280nm) using the 
NanoDrop 1000 (Thermo Scientific). Protein was concentrated to >0.5 mg/mL 
using a Vivaspin 10,000 MWCO spin concentrator (Sartorius). Composition of 
buffers used are described in 2.1.4.1.  
 
2.2.2.5 Insoluble protein isolation 
Each 1 L of insoluble pellet was resuspended in 30 mL of IB wash buffer I and 
incubated on ice for 10 minutes. Sonication was carried out on ice using 3 
cycles of 10 seconds on and 10 seconds off at 6 micron amplitude followed 
by centrifugation at 20,000 g for 15 minutes at 4 °C. Pellet was resuspended 
in 30 mL of IB wash buffer II and incubated on ice for 10 minutes. Sonication 
was carried out on ice using 3 cycles of 10 seconds on and 10 seconds off at 
6 micron amplitude followed by centrifugation at 20,000 g for 15 minutes at 4 
°C. Pellet was resuspended in 30 mL of IB wash buffer III and centrifuged at 
20,000 g for 15 minutes at 4 °C. Remaining pellet was resuspended in IB 
solubilisation buffer overnight at 4 °C with rotation to dissolve inclusion bodies. 
Dissolved protein was centrifuged at 20,000 g for 45 minutes at 4 °C to remove 
undissolved protein. Supernatant contains dissolved insoluble protein and 
was filtered through 0.45 µm filter to remove large protein aggregates and 
remaining cell debris. Composition of buffers used are described in 2.1.4.2.  
 
2.2.2.6 Nickel affinity chromatography purification of insoluble 
SOEV NPcore 
Gu-HCl dissolved insoluble protein purified from inclusion bodies was applied 
to Super Ni-NTA Agarose Resin (Generon) pre-washed in 25 mM imidazole 
wash buffer and incubated at 4 °C for 2 hours with rotation before applying to 
a gravity-flow column. Resin was washed successively with IB refolding 




concentration to refold protein on the column. Resin was incubated with 50 
mL of 25 mM imidazole wash buffer containing 10 U Ulp1 protease at 4 °C for 
4 hours with rotation before applying to a gravity-flow column and collecting 
the flow-through containing the cleaved protein. Resin was washed with 5 x 
10 mL of 25 mM imidazole wash buffer followed by 2 x 10 mL of 100 mM 
imidazole wash buffer to remove any remaining unbound protein. Any 
remaining bound protein was removed from the resin by washing with 20 mL 
of 1 M imidazole wash buffer. A sample of the resin was collect to analyse 
remaining bound protein. Eluted protein concentration was determined by 
diluting 1:10 in 25 mM wash buffer and reading A280nm using the NanoDrop 
1000 (Thermo Scientific). Protein was concentrated to >0.5 mg/mL using a 
Vivaspin 10,000 kDa molecular weight cut offspin concentrator (Sartorius). 
Composition of buffers used are described in 2.1.4.2. 
 
2.2.2.7 Antibody production and validation  
The identity of purified SEOV NPcore was confirmed using mass spectrometry 
carried out by the mass spectrometry facility (University of Leeds). Purity of 
SEOV NPcore was confirmed to be >85% using densitometry (ImageJ). Protein 
samples were sent to Alta Biosciences in 0.25 mg aliquots on dry ice. A goat 
was inoculated with give injections of antigen were carried out over 6 month 
programme. Sera was collected one week after each booster injection of 
antigen. Polyclonal antibody was validated by testing by western blot against 
recombinant SEOV NPcore, TULV infected cell lysates, transfected TULV NP 
cell lysates and by examination of infected and TULV NP transfected cells by 






2.2.3  Affimer Production and Purification  
2.2.3.1 Generating BAP-tagged protein  
The purification of SEOV NPcore specific affimers through phage display using 
streptavidin-coated strips required the production of purified biotinylated 
SEOV NPcore. In order to generate this biotinylated protein, a biotin accepter 
peptide tag was engineered to the C-terminus coding-region of the SEOV 
NPcore protein. This was achieved by introducing a unique restriction cleavage 
site, HindIII, at the C-terminus of SEOV NPcore and generating an BAPtag 
insert with between a HindIII and XhoI restriction enzyme site by PCR 
amplification. The BAPtag was then sub-cloned into the pET28(a)-SUMO-
SEOV NPcore vector which was then used for subsequent protein expression 
and purification as described previously (2.2.3.8) 
 
2.2.3.2 Affimer panning – Round One  
Panning and selection for SEOV NPcore specific affimers was carried out by 
phage display in accordance with protocols developed at the University of 
Leeds. Target protein (SEOV NPcore) produced with BAPtag was 
enzymatically biotinylated during production in expression E. coli cells and 
checked by western blot using an streptavidin conjugated Alexa Fluor 647 
antibody.  
Streptavidin coated (high binding capacity (HBC)) 8-well strips (Thermo Fisher 
Scientific) were incubated overnight at 37 °C with 300 µL of 2 X casein 
blocking buffer (BB) diluted in PBS supplemented with 0.1 % Tween-20 
(PBST).  Each well was washed three times in 300 µL of PBST before adding 
100 µL of 2 X BB. To pre-pan the phage 5 µL of the phage library (University 
of Leeds) was added to the first pre-pan well and incubated on a vibrating 
platform shaker (Heidolph) for 40 minutes. Buffer containing phage library was 
pre-panned three times. To the final well, 20 µL of SEOV NPcore + BAPtag was 
added and incubated for 1 hour at room temperature on a vibrating platform 
shaker before washing six times with 200 µL PBST. Buffer containing pre-
panned phage library was added to well containing streptavidin-bound target 
and incubated for 2 hours at room temperature on a vibrating platform shaker. 
An 8 mL culture of ER2738 E. coli cells were set up by diluting an overnight 




Panning wells were washed twenty-seven times in 300 µL PBST and bound 
phage were eluted by adding 100 µL 0.2 M glycine pH 2.2 and incubating for 
10 minutes at room temperature. Glycine was neutralised by adding 100 µL 
of 1 M Tris-HCl pH 9.1 and eluted phage immediately added to the ER2738 
cells. To elute remaining phage triethylamine (Sigma-Aldrich) diluted 1:70 with 
PBS was added to the well and incubated for 6 minutes at room temperature. 
Triethylamine was neutralised by adding 50 µL of 1 M Tris-HCl pH 7 and 
immediately added to ER2738 cells. ER2738 cells with phage were incubated 
for 1 hour at 37 °C without shaking before plating LB agar plate supplemented 
with 100 µg/mL ampicillin (LB-Amp) and incubated overnight at 37 °C.  
Colonies were counted and found to be 2.96 x 105 cells per 8 mL. Colonies 
were scraped into 7 mL of 2YT media supplemented with 100 µg/mL 
carbenicillin. Absorbance at 600nm (A600nm) was measured and culture was 
diluted so A600nm = 0.2 in 2YT media and incubated for 1 hour at 37 °C with 
shaking. 3.2 x 1010 M13K07 helper phage was added to culture and incubated 
for 30 minutes at 37 °C with shaking at 90 revolutions per minute (rpm). 
Kanamycin was added to 25 mg/mL and incubated overnight at 25 °C. 
Cultures were centrifuged at 3500 g for 10 minutes at room temperature and 
supernatant containing phage was transferred to fresh tubes and retained for 
a second panning round.   
 
2.2.3.3 Affimer panning – Round Two  
A 20 µL aliquot of Dynabeads® MyOne™ Streptavidin T1 (Invitrogen) were 
blocked by incubating overnight at room temperature with 100 µL of 2 X BB 
on a Stuart SB2 rotor at 20 rpm. For panning, wells of a deep well 96-well 
plate (Thermo Scientific) were blocked using 1 mL 2 X BB for panning or 300 
µL of 2 X BB for elution for 2 hours at 37 °C. The pre-blocked Streptavidin 
beads were centrifuged at 800 g for 1 minute at room temperature before 
immobilising on a magnet. Streptavidin beads were resuspended in 100 µL 
fresh 2 X BB. To pre-pan the phage, 125 µL of phage-containing supernatant 
from the first panning round was mixed with 125 µL of 2 X BB and 25 µL of 
pre-blocked Streptavidin beads in Protein LoBind Tubes (Eppendorf) and 
incubated for 1 hour at room temperature with rotation. Streptavidin beads 




on a magnet. Pre-panning was repeated. A 15 µL aliquot SEOV NPcore + 
BAPtag was mixed with 200 µL of 2 X BB and 50 µL of pre-blocked 
Streptavidin beads and incubated for 30 minutes at room temperature with 
rotation. Streptavidin  beads bound to target were centrifuged at 800 g for 1 
minute at room temperature and immobilised on a magnet and washed three 
times in 500 µL 2 X BB. Beads were centrifuged at 800 g for 1 minute at room 
temperature and supernatant containing pre-panned phage was added and 
transferred to the pre-blocked deep well 96-well plate. The KingFisher Flex 
(Thermo Scientific) was used for panning following the standard phage display 
protocol as described below.  
Streptavidin beads were collected and bound by fast mixing for 10 seconds 
followed by slow mixing for 1 minute. Beads were washed in four times in 2 X 
BB with slow mixing for 1 minute. Phage was eluted from the beads by slow 
mixing for 7 minutes and 30 seconds in 100 µL of 0.2 M Glycine pH 2.2 and 
remaining phage was eluted by slow mixing for 3 minutes and 30 seconds in 
100 µL in triethylamine diluted 1:70 in PBS.  
An 8 mL culture of ER2738 E. coli cells were set up by diluting an overnight 
culture of ER2738 cells 1:15 and incubating for 1 hour at 37 °C with shaking. 
Phage elutions were neutralised as previously described in 2.2.3.2 before 
mixing to the ER2738 cells and incubated for 1 hour at 37 °C without shaking 
before plating onto LB-Amp and incubated overnight at 37 °C. Phage were 
prepared as previously described in 2.2.3.2.  
 
2.2.3.4 Affimer panning – Round Three 
NeutrAvidin coated HBC 8-well strips (Thermo Fisher Scientific) were 
incubated overnight at 37 °C with 300 µL of 2 X BB.  Each well was washed 
three times in 300 µL of PBST before adding 200 µL of 2 X BB. To pre-pan 
the phage, 200 µL of phage-containing supernatant from the second panning 
round was added to one well with 20 µL of 10 X BB and incubated for 1 hour 
at room temperature on a vibrating platform shaker. Pre-panning was 
repeated three times. To the final well, 10 µL of SEOV NPcore + BAPtag was 
added with 100 µL of 2 X BB and incubated for 1 hour at room temperature 
on a vibrating platform shaker. Target well and the negative control blank pre-




pre-panned phage was transferred to the target and negative control wells and 
incubated for 30 minutes at room temperature with shaking. An 8 mL culture 
of ER2738 E. coli cells were set up by diluting an overnight culture of ER2738 
cells 1:15 and incubating for 1 hour at 37 °C with shaking.  Panning wells were 
washed twenty-seven times in 300 µL PBST and bound phage were eluted by 
adding 100 µL 0.2 M glycine pH 2.2 and incubating for 10 minutes at room 
temperature. Glycine was neutralised by adding 100 µL of 1 M Tris-HCl pH 
9.1 and eluted phage immediately added to the ER2738 cells. To elute 
remaining phage triethylamine (Sigma-Aldrich) diluted 1:70 with PBS was 
added to the well and incubated for 6 minutes at room temperature. 
Triethylamine was neutralised by adding 50 µL of 1 M Tris-HCl pH 7 and 
immediately added to ER2738 cells. ER2738 cells with phage were incubated 
for 1 hour at 37 °C without shaking before plating on LB-amp plates and 
incubated overnight at 37 °C.  
 
2.2.3.5 Preparing individual phage binders  
A 200 µL aliquot of 2TY media supplemented with 100 µg/mL carbenicillin was 
aliquoted into a deep well 96-well plate. From the final panning round of phage 
display (2.2.3.4)  48 individual colonies were used to inoculate each well and 
incubated overnight at 37 °C with shaking. 200 µL of 2TY media supplemented 
with 100 µg/mL carbenicillin was aliquoted into a deep well 96-well plate and 
25 µL of overnight cultures were added and incubated for 1 hour at 37 °C with 
shaking. 1 x 109 M13K07 helper phage in 2YT media were added to each well 
and incubated for 30 minutes at room temperature with shaking. A 10 µL 
aliquot of kanamycin (1.25 mg/mL) was added to each well and incubated 
overnight at room temperature with shaking. The phage-infected culture plate 
was centrifuged at 3500 g for 10 minutes at room temperature. Phage-
containing supernatant was collected.  
 
2.2.3.6 Phage ELISA 
Lyophilised streptavidin was reconstituted in distilled water to a final 
concentration of 5 mg/mL and then diluted to 5 µg/mL in PBS. 50 µL of 
streptavidin solution was added to each well of F96 Maxisorp Nunc-Immuno 




Streptavidin coated wells were blocked overnight at 37 °C with 200 µL of 2 X 
BB and washed once with 300 µL PBST. SEOV NPcore + BAPtag was diluted 
1:1000 in 2 X BB and 50 µL was aliquoted into 48 wells of the 96-well plate. 
For the negative control, 50 µL of 2 x BB was added to the remaining 48 wells 
of the 96-well plate and incubated for 1 hour at room temperature with shaking. 
Wash once with 300 µL of PBST before aliquoting 10 µL of 10 X BB per well. 
To each well, 40 µL of phage containing supernatant was added and 
incubated for 1 hour at room temperature with shaking. Wells were washed 
once with 200 µL of PBST and 50 µL of anti-Fd-bacteriophage-HRP diluted 
1:2000 in 2 X BB was added per well and incubated for 1 hour at room 
temperature with shaking. Wells were washed ten times with 300 µL of PBST 
and 50 µL of SeramunBlau® fast 3,3’,5,5’-tetramethylbenzidine (TMB) 
substrate solution (Seramun) was added per well and allowed to develop for 
around 3 minutes. Absorbance at 620nm (A620nm) was measured. A620nm was 
compared between target and negative control wells to identify unique 
binders.  
 
2.2.3.7 Unique Binders  
The first set of panning rounds did not produce unique anti-SEOV NP binding 
affimers a second set was carried out by Dr Christian Tiede, University of 
Leeds, which produced two unique binders.  
 
2.2.3.8 Batch nickel affinity chromatography purification of 
affimers  
Affimers selected were identified by sequencing (GeneWiz) and cDNA inserts 
generated by PCR amplification. Inserts were sub-cloned into pET11a 
expression vector, confirmed by sequencing (GeneWiz). Protein expression 
and soluble protein isolation was carried out as previously described (2.2.2.1, 
0, 2.2.2.3). Clarified bacterial supernatant containing soluble protein was 
applied to 150 µL Super Ni-NTA Agarose Resin (Generon) pre-washed in 20 
mM imdazole wash buffer and incubated at room temperature for 2 hours with 
rotation before centrifugation at 1000 g for 1 minute to remove unbound 
protein. Resin was washed in 1 mL 25 mM wash buffer until A280nm using the 




was resuspended in 500 µL 300 mM elution buffer and incubated for 5 minutes 
at room temperature. Resin was centrifuged at 1000 g for 1 minute to 
sediment resin. Eluted protein concentration was reading A280nm using the 
NanoDrop 1000 (Thermo Scientific). Composition of buffers used are 
described in 2.1.4.1. 
 
2.2.4 Cell Culture Methods  
2.2.4.1 Continuous cell culture 
Vero E6 cells were cultured in DMEM with 10% v/v FBS and supplemented 
penicillin and streptomycin, referred to as complete media. Vero E6 cells were 
sub-cultured when approaching confluency using trypsin-EDTA (Sigma) to 
detach cells from flask. Detached cells were gently pelleted by centrifugation 
at 500 g at 4 °C for 5 minutes and resuspended in fresh complete media. Cells 
were seeded at the following densities; 96-well plate (5 x 104 cells/well), 12-
well plate (105 cells/well), 6-well plate (5 x 105 cells/well), 75 cm2 flask (105 – 
2 x 106 cells/flask) and 175 cm2 flask (5 x 105 – 106 cells/flask). Glass 
coverslips were sterilised by submerging in 100% ethanol and washing in 
sterile PBS prior to seeding for immunofluorescence (IF) experiments. Cells 
were maintained in a humidified incubator at 37 °C with 5 % CO2 
 
2.2.4.2 Freezing and thawing cells  
Cells were frozen for long-term storage at -80 °C. Cells were trypsinised and 
washed 3-times in PBS with centrifugation at 500 g at 4 °C for 5 minutes 
between each wash step. Cells were counted and resuspended in ice-cold 
FBS supplemented with 10% DMSO to a final concentration of 5 x 106 
cells/mL. Cell suspension was aliquoted into cryovials which were cooled in 
an isopropanol chamber to -80 °C overnight. Frozen cells were rapidly thawed 
at 37 °C and added to 10 mL complete media then centrifuged at 500 g at 4 
°C for 5 minutes. Cell pellet was gently resuspended in complete media and 
transferred to a 25 cm2 flask. After 48 hours incubation in a humidified 
incubator at 37 °C with 5 % CO2, cell culture medium was removed and 
attached cells gently washed in PBS before addition of fresh complete media. 




2.2.5  Transfections  
2.2.5.1 Lipofectamine mediated transfection of Vero E6 cells with 
pcDNA3.1 (+)-TULV NP  
Vero E6 cells were transfected with pcDNA3.1(+)-TULV NP cells for both IF, 
protein analysis by western blot. Lipofectamine 2000 (Life Technologies) was 
used to mediate transfection. Cells were seeded in 12-well plates (for IF), 6-
well plates (for protein analysis) and 75 cm3 flasks (for transfection) 24 hours 
before transfection so cell confluency was 60-80 % confluent. For 12- and 6-
well plates, 1 µg DNA was added to 100 µL Opti-MEM (Gibco) and in a 
separate microfuge tube 3 µL lipofectamine 2000 was added to 100 µL Opti-
MEM. For 75cm2 flasks, 25 µg DNA was added to 2.5 mL Opti-MEM and in a 
separate tube, 60 µL lipofectamine 2000 was added to 2.5 mL Opti-MEM. 
Solutions were mixed and allowed to equilibrate for 5 minutes. The Opti-MEM-
DNA solution was added to the Opti-MEM-lipofectamine 2000 solution and 
mixed gently. Opti-MEM-DNA-lipofectamine 2000 solution was incubated at 
room temperature for 20 minutes before being added dropwise to cells that 
have been prewashed in PBS. After 4 hours of incubation in a humidified 
incubator at 37 °C with 5 % CO2, medium was removed and cells washed with 
PBS. Complete media was added and cells incubated overnight in a 
humidified incubator at 37 °C with 5 % CO2. After 18 hours, cells were 
harvested for analysis either by fixation of coverslips in 100 % methanol (IF) 
or by cell lysis (protein analysis and IP).  
 
2.2.6 Virological Techniques  
2.2.6.1 Virus infection and propagation by sub-culturing infected 
Vero E6 cells 
Infectious TULV was diluted to the desired MOI (0.1-1.0) in serum free DMEM 
(SFM) and added to Vero E6 cells which had been washed once in sterile 
PBS. Cells were incubated with TULV at 37 °C with gentle rocking for 90 
minutes to allow TULV to adsorb to cells. After adsorption, DMEM with 2 % 
FBS and supplemented with 100 U/mL penicillin and 100 µg streptomycin (2% 
DMEM) was added to cells and cultures were incubated in a humidified 
incubator at 37 °C with 5 % CO2. Mock infections were carried out as 




TULV was propagated in Vero E6 cells seeded in a 175 cm2 flask and when 
cells reached 70-80 % confluency they were infected as above with TULV at 
an MOI of 0.01. When infected cells reached 90% confluency they were sub-
cultured as described previously (2.2.4.1) but retaining cell culture growth 
medium. Cells and cell culture growth medium were seeded at 1:5 into fresh 
175 cm2 flasks supplemented with fresh 2% DMEM. When infected cells 
reached 90% confluency they were sub-cultured as described into fresh 175 
cm2 flasks. When infected cells reached 100% confluency, TULV was 
harvested by freeze-thawing at -80 °C for a minimum of 1 hour and then 
incubating 37 °C for 1 hour. Cell culture medium was removed and clarified 
by centrifuging at 4000 g for 30 minutes at 4 °C. Supernatant was collected 
and aliquoted into 1 mL, 5 mL or 10 mL aliquots and stored at -80 °C. Clarified 
supernatants were used for the infection of Vero E6 cells. Typical yields from 
virus propagation experiments were between 1 x 104 – 1 x 105 
immunofluorescent units (IU)/mL.  
 
2.2.6.2 TULV titre determination by neutral red uptake plaque 
assay  
Neutral red uptake plaque assays were performed in duplicate in 6-well plates 
seeded with 5 x 105 cells/well. TULV was serially diluted into 450 µL SFM to 
generate 10-1-10-4 dilutions. As described in 2.2.6.1, 200 µL of these dilutions 
were used to infect Vero E6 monolayers. After TULV adsorption, cells were 
overlaid with 2% media diluted 1:1 with 4 % agarose (w/v). The agarose 
overlay prevented TULV migration through the media and ensured released 
virus would only infect cells neighbouring the previously infected cell. After 
agarose overlay had set, 2 mL of 2 % media was added on top of overlay to 
prevent agarose overlay from drying out. Cells were incubated for 7 days in a 
humidified incubator at 37 °C with 5 % CO2. After 7 days, the liquid overlay 
was removed and replaced with 3 mL of 2 % media diluted 1:1 with 4 % 
agarose (w/v) supplemented with 0.16 mM neutral red. After agarose overlay 
had set, 2 mL of 2 % media was added on top of overlay and cells were 
incubated for 3 days in a humidified incubator at 37 °C with 5 % CO2. Cells 
were examined each day for the formation of plaques. TULV is not cytopathic 




plaques. Neutral red uptake assay utilises the ability of cells to incorporate 
and bind the dye. Neutral red dye binds to anionic sites in lysosomes through 
electrostatic hydrophobic bonds. Damaged and dead cells do not retain the 
neutral red dye and therefore can be distinguished from viable cells through a 
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2.2.6.3 TULV titre determination by immunofluorescent assay  
Immunofluorescent assays were performed in triplicate in 96-well plates 
seeded with 5 x 104 cells/well. TULV was serially diluted into 350 µL SFM to 
generate 10-1-10-5 dilutions. 100 µL of these dilutions were used to infect Vero 
E6 cells as described in 2.2.6.1. After TULV adsorption, 100 µL of 2 % media 
was added. Cells were incubated for 72 hours in a humidified incubator at 37 
°C with 5 % CO2 and then fixed and permeabilised in ice-cold methanol at -20 
°C for at least 1 hour. Cells were washed in 1 X PBS before staining by 
immunofluorescence. Cells were blocked in 1 X PBS with  5 % bovine serum  
albumin (BSA) for 1 hour before probing with 50 µL anti-SEOV NP primary 
antibody diluted 1:2000 in 1 X PBS with 1 % BSA for 1 hour. Cells were 
washed three times 1 X PBS before probing with 50 µL donkey anti-sheep 
Alexa Fluor 488 secondary antibody diluted 1:1000. Cells were washed three 
times in 1 X PBS. Cells were imaged using the Incucyte Zoom instrument 
(Essen Bioscience) using a 10x objective lens. The Incucyte ZOOM software 
was used to calculate the number of infected cells per well by extrapolating 
an average value from three fluorescent images of each well. As infectious 
often form several foci within a cell which can each be counted separately, 
quantified virus is represented as an immunofluorescent unit per mL (IU/mL).  
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2.2.6.4 TULV sample collection  
TULV-infected cell cultures were harvested for analysis by scraping cell 
monolayers into supernatant after desired infection time and collected into 2 
mL cryovial and stored at -80 °C until analysis and for freeze-thaw lysis. For 
analysis, cell cultures were incubated at 37 °C for 1 hour. Sample volumes 
were adjusted to 2 mL to account for evaporation and centrifuged at 13,000 g 
for 10 minutes at 4 °C to pellet cells. Supernatants were analysed for viral 
RNA by qRT-PCR or infectious virus particles by immunofluorescent assay. 
Cell pellets were resuspended in 25 µL 1 x PBS and analysed for TULV NP 
by western blot.  
 
2.2.6.5 Routine Mycoplasma Testing  
TULV stocks were routinely tested and confirmed to be mycoplasma free 
using MycoAlert™ (Lonza). Mycoplasma testing was carried out by Carsten 
Zothner. 
 
2.2.6.6 Metabolic labelling viral RNA using 5-Ethynyl Uridine 
TULV viral RNA was labelled using the Click-iT® RNA Imaging kit (Invitrogen) 
utilising click chemistry. 5-ethynyl uridine (5-EU) is an alkyne-modified 
nucleoside is incorporated into nascent RNA and is detected utilising 
chemoselective ligation (“click” reaction) with an azide-conjugated Alexa 
Fluor. In order to specifically label only viral RNA, actinomycin D (ActD) was 
used to inhibit transcription of host cell DNA into RNA. ActD binds to DNA and 
inhibits RNA synthesis by interfering with elongation of RNA chains by the 
RNA polymerase (Sobell, 1985). TULV RNA is generated from an RNA 
template and so neither TULV replication nor transcription is inhibited by ActD.  
Vero E6 cells were seeded onto coverslips as described in 2.2.4.1 and 
infected with TULV MOI 0.1 as described in 2.2.6.1. One hour before the 
specified time-point cell culture medium was replaced with 250 µL 2 % media 
supplemented with 10 µg/mL actinomycin D and incubated for 1 hour at 37 
°C. A 250 µL aliquot of 2% media supplemented with 2 mM 5-EU and 
incubated for 3 hours in an humidified incubator at 37 °C with 5 % CO2. Media 
was removed and replaced with 1 mL 4 % formaldehyde (BHD Chemicals) 




check incorporation of 5-EU, mock Vero E6 cells were treated with 5-EU 
without addition of ActD. Cells were permeabilised by incubating with 0.5 % 
Triton X-100 diluted in 1 X PBS for 15 minutes. The click-iT® reaction cocktail 
was prepared according to the manufacturers’ instructions and contained 1 X 
Click-iT® RNA reaction buffer, 4 mM copper (II) sulphate, 1 X Alexa Fluor® 
594 azide and 20 mg/mL Click-iT® reaction buffer additive. The click-iT® 
reaction cocktail was added immediately to each well and incubated for 30 
minutes at room temperature with protection from light. Reaction cocktail was 
removed and each well washed with 1 mL click-iT® reaction rinse buffer 
before washing with 1 mL PBS. Nuclei were stained by incubating with 300 
nM 4',6-Diamidino-2-Phenylindole (DAPI) (Thermo Fisher) for 3 minutes at 
room temperature. Coverslips were mounted onto microscope slides using 
antifade mounting medium (Vectashield).  
 
2.2.7  Immunofluorescence 
2.2.7.1 Seeding persistently infected Vero E6 cells  
Persistent infections were carried out in Vero E6 cells seeded into 75 cm2 
flasks as described in section 2.2.6.1. Infections were carried out for 7 or 30 
days post infection. At 24 hours before desired time point, cells were 
trypsinised and pelleted by centrifuging at 500 g for 5 minutes at 4 °C. The 
cell culture supernatant was retained. TULV infected Vero E6 cells were 
seeded onto coverslips at 5 x 105 cells per well along with 1:100 dilution of 
infected cell culture supernatant diluted in 2 % media. Cells were incubated 
overnight in an humidified incubator at 37 °C with 5 % CO2 and fixed in 4 % 
formaldehyde for 20 minutes and permeabilised in ice-cold methanol for at 
least 1 hour.  
 
2.2.7.2 Indirect immunofluorescence  
Immunofluorescence experiments were used to visualise the subcellular 
localisation of host cell proteins and TULV NP. Vero E6 cells were grown on 
coverslips as described in 2.2.4.1 and 2.2.7.1. Media was removed from cells 
before fixation in 4 % formaldehyde diluted in 1 X PBS for 20 minutes at room 
temperature. Cells were permeabilised in ice-cold methanol for at least 1 hour. 




at -20 °C wrapped in parafilm to prevent evaporation. Permeabilised cells 
were washed twice in 1 X PBS, then blocked in 5 % (w/v) BSA for 1 hour.  
After blocking, cells were incubated with 50 µL of primary antibody diluted to 
the appropriate concentration for 2 hours at room temperature or overnight at 
4 °C. Incubations were carried out in humidified chambers on droplets on 
parafilm. Cells were washed three times in 1 X PBS and incubated with 200 
µL fluorescently labelled antibody for 1 hour at room temperature with shaking, 
protected from light. Cells were washed three times in 1 x PBS before 
incubating with 300 nM DAPI for 3-5 minutes at room temperature. Cells were 
washed four times in 1 X PBS and once in distilled water before mounting onto 
glass microscope slides using hard-set antifade mounting media 
(Vectashield). Slides were cured for 15 minutes at room temperature and 
stored at 4 °C overnight until visualisation, protected from light.  






2.2.7.3 RNA fluorescent in-situ hybridisation (FISH)  
IF was carried out as described in section 2.2.7.2 with reduced incubation 
times. Cells were blocked for 30 minutes and antibody incubations were 
carried out 1 hour each. After IF, cells were fixed in 4 % formaldehyde for 20 
minutes. Formaldehyde was replaced with 1 x PBS treated with 0.1% 
diethylpyrocarbonate (DEPC) and cells were stored at 4 °C overnight, 
protected from light. 
FISH probes were reconstituted to 12.5 mM in RNase free 1 X TE buffer (10 
mM Tris-HCl, 1 mM EDTA pH 8.0 (G Biosciences) diluted in UltraPure™ 
DNase/RNase-Free Distilled water (Thermo Fisher Scientific) and stored at -
20 °C. Probes were warmed to room temperature and thoroughly mixed. For 
each coverslip, 1 µL probe stock was used per 100 µL hybridisation buffer  
(Stellaris® RNA FISH hybridisation buffer (2B Scientific) diluted with deionised 
formamide (Severn Biotech LTD) in 9:1 ratio).  
Cells were incubated in wash buffer A (Stellaris® RNA FISH wash buffer A 
diluted with deionized formamide and UltraPure™ DNase/RNase-Free 
Distilled water in a 2:7:1 ratio) for 5 minutes at room temperature. 100 µL 
hybridisation buffer with probes was dispensed into a droplet onto parafilm in 
a humidified chamber. Coverslips were incubated cell-side down onto probe 
mix for 4 hours at 37 °C, protected from light. Cells were incubated in 1 mL 
wash buffer A for 30 minutes at 37 °C, protected from light and then incubated 
in 1 mL wash buffer A with 300 nM DAPI for 5 minutes at room temperature. 
Buffer was removed and cells were incubated in 1 mL wash buffer B 
(Stellaris® RNA Fish wash buffer B) for 5 minutes before mounting onto glass 
microscope slides using hard-set antifade mounting media (Vectashield). 
Slides were cured for 45 minutes at room temperature, protected from light, 
and imaged within 24 hours.   
 
2.2.8  RNA Generation and Quantification   
2.2.8.1 Viral RNA isolation  
TULV RNA was isolated from 140 µL of clarified freeze-thawed cell culture 
supernatant using the QIAamp® viral RNA mini kit (Qiagen) following the 
manufacturers’ instructions. Viral RNA was eluted with 50 µL nuclease-free 





2.2.8.2 Reverse transcriptase PCR (RT-PCR) 
TULV S segment cDNA was transcribed from viral RNA isolated in 2.2.8.1 
using the ProtoScript® II First Strand cDNA synthesis kit (NEB) where 5 µL 
TULV RNA was mixed with 5 mM oligo d(T)23 VN (V: A, G or C and N: A, G, 
C or T), 1 X ProtoScript® II Reaction Mix and 1 X ProtoScript® II Enzyme Mix 
in a total reaction volume of 20 µL. Reaction mix was incubated at 42 °C for 1 
hour followed by incubating at 80 °C for 5 minutes to inactivate enzymes. 
cDNA generated from RT-PCR was amplified through PCR as described in 
2.2.1.1 using TULV S Segment primers shown in Table 7. 
 
2.2.8.3 In-vitro RNA transcription  
TULV S Segment cDNA isolated in 2.2.8.2 was sub-cloned into pcDNA3.1 (+) 
vector under the control of the T7 RNA polymerase. pcDNA3.1 (+) + TULV S 
Segment was linearized using Xho1, located immediately after the S segment 
ORF stop codon, following conditions described in 2.2.1.3. RNA was 
transcribed using the MEGAscript® T7 Transcription Kit following the 
manufacturer’s instructions; 1.5 µg linear DNA was mixed with 2 µL of ATP, 
GTP CTP and UTP stock solutions (75 mM), 2µl of T7 enzyme mix, 1 X 
reaction buffer in a total volume of 20 µL. Reaction mix was incubated at 37 
°C for 3 hours followed by incubation with 2 U of TURBO DNase for 15 minutes 
at 37 °C. RNA was purified using the RNeasy Mini Kit (Qiagen) following the 
manufacturer’s instructions and eluted in 30 µL RNase-free water and stored 
at -80 °C. Quantity of RNA was assessed through spectrophotometry using a 
NanoDrop 1000.  
 
2.2.8.4 RNA agarose gel electrophoresis  
Separation of RNA fragments for assessment of RNA was carried out using 1 
% agarose 1 X 4-morpholinepropanesulfonic acid (MOPS) gel (1 % agarose, 
1 X MOPS, 4.7 % formaldehyde) with SYBR Safe stain diluted 1:10,000. RNA 
samples were diluted 1:10 and mixed with 1 X RNA gel loading dye (New 
England Biolabs) and denatured by incubating at 65 °C for 5-10 minutes. 
before loading onto gel. Ambion Millenium™ RNA marker (Thermo Fisher) 




80 minutes in 1 X MOPS buffer. Blue light transillumination was used for the 
visualisation of RNA. Purity of RNA was assessed by examining RNA MOPS 
gel for contaminating bands or smears.  
 
2.2.8.5 Generating RNA standards  
RNA generated through in-vitro transcription was adjusted to 138.2 ng/µL 
RNA by diluting in RNase-free water and quantifying using a NanoDrop 1000. 
138.2 ng/µL RNA is equivalent to 1012 copies of TULV S segment RNA per 5 
µL based on the molecular weight of the TULV S segment RNA ORF. RNA 
was further diluted to 108, 106, 104, 102 genome copies/5 µL to generate a 
standard curve.  
 
2.2.8.6 Quantitative reverse transcriptase real-time PCR (qRT-PCR)  
Quantitative reverse transcriptase real-time PCR was carried out in 
accordance with previously described methods with adaptions to the GoTaq® 
1-step RT-qPCR kit (Promega) (Kramski et al., 2007). Briefly, each reaction 
contained 1 X reaction buffer, 625 nM forward primer, 625 nM reverse primer, 
1 X RT enzyme mix, mixed thoroughly. To each reaction mix 5 µL sample 
RNA or standard RNA was added to each well. The PCR thermal cycle used 
was as follows: 37 °C for 10 minutes, 95 °C for 10 minutes, 45 cycles of 95 °C 
for 10 seconds, 60 °C for 40 seconds and 72 °C for 30 seconds. Cycle 
threshold (Ct) values were measured at the end of each cycling step. For each 
qRT-PCR run the following standards of TULV S segment RNA were used: 
108, 106, 104, 102 genome copies/5 µL. These standards were used to 
generate a standard curve from which sample relative genome copies per mL 
could be calculated.   
 
Primer Name Primer Sequence 5’ – 3’ 
TULV S Forward GCCGACCCRGATGATGTTAA 
TULV S Reverse CAAGYTGYCTCTTGAADTCTGCCA 






2.2.9  Analysis of Protein Expression  
2.2.9.1 Preparation of cell lysates  
Mammalian cells were collected by centrifugation at 20,000 g for 10 minutes 
at 4 °C and resuspended in 50 µL PBS. Bacterial protein samples were 
collected in 50 µL at each stage of purification for analysis by SDS-PAGE. An 
equal volume of 2 X loading buffer (4 X NuPage loading buffer (Thermo Fisher 
Scientific), 10 X DTT, water) was added and samples heated to 95 °C for at 
least 5 minutes. Samples were centrifuged at 10,000 g for 10 minutes at room 
temperature to pellet debris.  
 
2.2.9.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE)  
Cell lysates were analysed by SDS-PAGE. SDS-PAGE gels were made with 
either 10%, 12 % or 15 % resolving gels (10/12/15 % bis-acrylamide, 750 mM 
Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate (APS), 
0.001% (v/v) tetramethylethylenediamine (TEMED)) and a 5 % stacking gel (5 
% bis-acrylamide, 126 mM Tris-HCl pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, 
0.001% (v/v) TEMED). Electrophoresis was carried out in a 1 X SDS running 
buffer (25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS) at 180 V for 60-90 
minutes. Colour Prestained Protein Standard, Broad Range (11–245 kDa) 
(New England Biolabs) molecular weight marker was used. Proteins were 
visualised by colloidal Coomassie stain or by western blot.  
 
2.2.9.3 Colloidal Coomassie stain  
SDS-PAGE gels to be visualised by colloidal Coomassie were fixed in gel 
fixative solution (40 % ethanol, 10 % acetic acid) for at least 30 minutes at 
room temperature and replaced with colloidal Coomassie stain (20 % 
methanol, 8 % (w/v) ammonium sulphate, 1.6 % phosphoric acid, 0.08 % 
coomassie brilliant blue G250). Gels were stained overnight at room 
temperature with rocking before being de-stained with 1 % acetic acid 
overnight with rocking.    
 
2.2.9.4 Western blot analysis  
Protein samples separated by SDS-PAGE were transferred to an Immobilon-




Trans-Blot semi-dry cell (Bio-Rad) in Towbin buffer (25 mM Tris, 192 mM 
glycine, 20 % (v/v) methanol) at 20 V for 90-120 minutes. Membranes were 
blocked for 1 hour at room temperature in Odyssey® Blocking buffer (LI-COR) 
diluted 1:1 in PBS. Membranes were probed with primary antibody (see Table 
9) in Odyssey® Blocking buffer diluted 1:4 in PBS for 1-16 hours. Membranes 
were washed 3-5 times in PBS before probing with secondary antibodies 
(Table 8) in Odyssey® Blocking buffer diluted 1:4 in PBS for 1 hour. 
Membranes were washed 3-5 times in PBS before drying. Protein samples 
were visualised using the Odyssey Sa imaging system (LI-COR).  
 
2.2.10 Immunoprecipitations  
2.2.10.1 Preparation of cell lysates  
Three T175 cm3 flasks of Vero E6 cells were infected at MOI 0.1. Cells were 
harvested by centrifugation at 4000 g for 10 minutes at 4 °C. The cell pellet 
was washed in ice-cold PBS and pellet collected by centrifugation at 4000 g 
for 10 minutes at 4 °C. Cells were lysed by resuspending in ice-cold 100 µL 
RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 % NP-40 alternative, 
0.1 % sodium dodecyl sulphate, 1 X protease-inhibitor cocktail EDTA-free 
(Roche)) and incubated on ice for 30 minutes. Lysate was clarified by 






2.2.10.2 Dynabead™ IPs 
Immunoprecipitation (IP) was carried out using the Dynabead™ Protein G 
immunoprecipitation kit (Thermo Fisher Scientific). A 50 µL aliquot of 
Dynabeads™ were bound to TULV NP antisera by incubating with NP antisera 
diluted 1:200 in PBS with rotation for 1 hour at 4 °C. Beads were immobilised 
using a magnet and antisera removed. Beads were washed once in 200 µL 
PBS before adding clarified lysate and incubating overnight at 4 °C with 
rotation. Beads were immobilised using a magnet and cell lysate removed 
before washing three times in 200 µL Washing Buffer. 2 X protein loading 
buffer (see section 2.2.9.1) was added directly to beads in an equal volume 
before heating to 95 °C for 5 minutes. Samples were centrifuged at 10,000 g 
for 5 minutes to pellet beads before loading onto a 12-15 % SDS-PAGE gel. 
Immunoprecipitated protein was analysed by western blot.  
 
2.2.11  Inhibitor Studies  
2.2.11.1 Inhibition of intermediate filaments 
Vero E6 were infected with TULV at MOI of 0.5 as previously described in 
sections 2.2.6.1 and 2.2.7.1 in a 6-well plate. Infected cells were harvested for 
immunofluorescent at 72 hours p. i. and harvested for immunofluorescent and 
qRT-RT PCR analysis at 30 days p. i. (see sections 2.2.7.2 and 2.2.8.6). Prior 
to harvesting, cells were treated with the following cytoskeletal inhibitors; 10 
µM cytochalasin D (CytD) for 60 minutes, 17 µM nocodazole (NOC) for 60 
minutes, 100 µM  erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) for 24 hours, 
and 400 nM okadaic acid (OA) for 30, 60 or 90 minutes. Infected Vero E6 cells 
treated with OA were also recovered by removing inhibitor and incubating 
overnight with fresh media before harvesting. Mock treatments were carried 






2.2.12  Microscopy 
2.2.12.1 Laser scanning confocal microscopy  
Laser scanning confocal imaging was carried out using the Zeiss LSM700 
confocal microscope using the 40X/1.3 Oil DIC Plan Apochromat, M27 
objective lens with the diode 405 nm, 488 nm, 55 nm and 639 nm lasers or 
the Zeiss LSM880 + Airyscan upright confocal microscope using the Plan-
Apochromat 40X/1.4 Oil DIC objective lens with the diode 405 nm, argon 488 
nm, DPSS 561 nm and HeNe 633 nm lasers. Image analysis was carried out 
in Fiji is just ImageJ (FIJI).  
 
2.2.12.2 Widefield fluorescence deconvolution microscopy  
Widefield fluorescence deconvolution microscopy was carried out using the 
Delta Vision widefield deconvolution microscope using the 100X/1.4 Oil Iris, U 
Plan Apo objective lens with the following filter sets; DAPI, FITC, TRITC and 







2.3  List of Antibodies  










In house 1:2000 1:2000 4 °C overnight 
RT 1-2 hours 
GAPDH (GT239) 
Mouse 
GeneTex 1:10 000 N/A 4 °C overnight 
RT 1-2 hours 
Rab5 #2143 
Rabbit 
NEB 1:200 1:50 4 °C overnight 
RT 1-2 hours 
Rab7 (D95F2) XP® 
Rabbit 
NEB 1:200 1:50 4 °C overnight 
RT 1-2 hours 
Rab11 (D4F5) XP® 
Rabbit 
NEB 1:200 1:50 4 °C overnight 
RT 1-2 hours 
LAMP1 (D2D11) XP® 
Rabbit 
NEB 1:200 1:50 4 °C overnight 
RT 1-2 hours 
DCP1a (56-Y) Mouse Santa Cruz 1:200 1:50 4 °C overnight 
RT 1-2 hours 
TIA-1 (G-3) Mouse Santa Cruz 1:200 1:50 4 °C overnight 
RT 1-2 hours 
Golgi Marker (AE6) 
Mouse 
Santa Cruz 1:200 1:50 4 °C overnight 
RT 1-2 hours 
Concanavalin A, Alexa 
Fluor 594  
Thermo 
Fisher 
1:200 1:30 4 °C overnight 
RT 1-2 hours 
Vimentin (D21H3) XP® 
Rabbit 
NEB 1:200 1:50 4 °C overnight 
RT 1-2 hours 
β-Tubulin (9F3) Rabbit NEB 1:200 1:100 4 °C overnight 
RT 1-2 hours 
β-Actin (D6A8) Rabbit NEB 1:200 1:100 4 °C overnight 
RT 1-2 hours 
Caspase-3 (D3R6Y) 
Rabbit 
NEB 1:200 n/a 4 °C overnight 
RT 1-2 hours 
Cleaved Caspase-3 
(Asp175) (5A1E) Rabbit 
NEB 1:200 1:50 4 °C overnight 
RT 1-2 hours 
Cleaved PARP (Asp214) 
(D64E10) XP® Rabbit 
NEB 1:200 n/a 4 °C overnight 
RT 1-2 hours 
 














anti-mouse IgG (H+L) 
LI-COR 1:10,000 n/a RT 1-2 hours 
IRDye800CW donkey 
anti-goat IgG (H+L) 
LI-COR 1:10,000 n/a RT 1-2 hours 
IRDye800CW donkey 
anti-rabbit IgG (H+L) 
LI-COR 1:10,000 n/a RT 1-2 hours 
Donkey anti-Goat IgG 





RT 1-2 hours 
Donkey anti-Rabbit IgG 
(H+L), Alexa Fluor 647 
Thermo 
Fisher 
n/a 1:500 RT 1-2 hours 
Donkey anti-Mouse 




n/a 1:500 RT 1-2 hours 
Donkey anti-Rabbit IgG 
(H+L), Alexa Fluor 555 
Thermo 
Fisher 
n/a 1:500 RT 1-2 hours 
Donkey anti-Mouse 




n/a 1:500 RT 1-2 hours 







Chapter 3 : Development of molecular tools for the detection 
and quantification of orthohantaviruses 
 
3.1 Chapter Introduction  
This chapter describes the development of molecular tools used to explore 
the lifecycle of the orthohantaviruses in cultured cells. As funding for this 
project was obtained by agreement to produce an anti-SEOV NP antibody for 
Public Health England (PHE), recombinant SEOV NP was bacterially 
expressed, purified and used as an antigen for the generation of both 
antibodies and non-antibody binding proteins known as Affimers. Generated 
antibody was provided to PHE to be used in the surveillance of SEOV in the 
UK. In addition, a reliable, fast and high-throughput virus titration assay was 
developed to permit the quantification of infectious virus as well as modifying 
an existing qRT-PCR assay to allow numerical quantitation of viral RNA.  
 
3.2 Results: Generation of polyclonal anti-SEOV NP 
antibody  
 
3.2.1  Introduction to bacterial-expression of recombinant 
proteins  
Antigen for the generation of a polyclonal anti-SEOV NP antibody was 
produced utilising an E. coli based expression system. Modified pET vectors 
(pET28a(+) and pET11a) containing viral sequences were transformed into 
expression competent E. coli strains, and used for the inducible expression of 
recombinant viral protein. These vectors contain the promotor region for 
bacteriophage T7 RNA polymerase paired with the lac operator, which 
together control the T7 RNA polymerase-driven transcription of the target 
gene (i.e. SEOV NP).  The lac repressor (lacI) represses transcription of the 
T7 RNA polymerase at the lac UV5 promoter and at the lac operator to block 
transcription by any basally produced T7 RNA polymerase in the E. coli 
expression host (Dubendorf and Studier, 1991).  
Expression vectors were transformed into BL21 (DE3) E. coli expression 




promotor. In the presence of an inducer (e.g. IPTG), T7 RNA polymerase is 
produced and begins expression of the target gene. The BL21 (DE3) 
expression strains also contain the pLysS plasmid which encodes a T7 
lysozyme which acts to reduce basal expression of the T7 RNA polymerase 
(Studier and Moffatt, 1986). 
SEOV NP ORF was cloned into the pET28a(+) expression vector in-frame 
with a 6x His SUMO tag fused to its amino terminus. The 6x His-tag allows 
purification of the expressed protein via metal affinity chromatography (nickel 
or cobalt). The small ubiquitin-related modifier (SUMO) fusion tag has been 
documented to increase the solubility of bacterially expressed proteins. The 
6x His-SUMO tag is removed using the Ulp1 protease which recognises the 
tertiary structure of SUMO and cleaves at the C-terminus of the molecule 
(Mossessova and Lima, 2000; Malakhov et al., 2004). 
Other systems can be utilised for recombinant protein expression such as 
yeast, baculovirus-infected insect cells and mammalian cells. Advantages of 
E. coli recombinant protein expression over these options include fast growth, 
high density cultures, inexpensive growth medias and easy transformation. 
However, there are several disadvantages of using a prokaryotic system to 
produce eukaryotic proteins. One issue can be the lack of proper folding 
leading to the formation of insoluble protein aggregates known as inclusion 
bodies. Some proteins require specific post-translational modifications such 
as N- and O-linked glycosylation, phosphorylation, methylation and 
ubiquitination. However, E. coli expression systems do not support all required 
modifications and lack of proper post-translational modification could lead to 
protein aggregation and misfolding (Cain et al., 2014). Another issue is the 
codon usage bias where if the gene to be expressed uses codons rare in E. 
coli, only suboptimal expression will be achieved. However, this issue can be 
overcome, in part, by the use of codon optimisation and by using E. coli strains 
such as Rosetta or Codon Plus, which encode for some of these rare codons.  
 
3.2.2  Expression and purification of SEOV NP  
3.2.2.1 Cloning SEOV NP ORF into the pET28a(+) expression vector 
A cDNA representing the full-length SEOV NP ORF optimised for bacterial 




truncated cDNA named SEOV NPcore comprising NP residues 111-399 using 
PCR. Full-length SEOV NP and truncated SEOV NPcore cDNA fragments were 
isolated by agarose gel electrophoresis and ligated into an empty pET28(+) 
SUMO vector to generate pET28a(+) SUMO + SEOV NP and pET28a(+) 
SUMO + SEOV NPcore expression plasmids, designed to express either full-
length or SEOV NPcore with their respective N-termini fused to 6x His, and 
SUMO tags (Figure 15).  
 
Figure 15 Plasmid map of the pET28a(+) SUMO + SEOV NP constructs.  
Schematic of SEOV NP constructs displaying Ulp1 cleavage site after 
the 6x His SUMO tag at the N-terminus of the SEOV NP construct. 
Plasmid map was generated using SnapGene® software. 
 
3.2.2.2 Optimising expression of SEOV NP  
To identify the optimal expression conditions for recombinant full-length SEOV 
NP and the truncated SEOV NPcore derivative, first, the most suitable 
expression host strain was chosen by examining expression of soluble or 
insoluble protein in a variety of E. coli strains, namely Gold, Star, Rosetta, 
Rosetta 2 and Codon Plus (Table 3; Figure 16A, Figure 17A). His-SUMO 
SEOV NP was predicted to have a mass of ~61.2 kDa (Figure 16) and a band 
of this size was clearly detected in the insoluble fraction from all strains, 




expressed. Rosetta cells were identified as producing the most full-length 
protein (Figure 16A) and were carried forward to test if alteration of IPTG 
concentration or temperature could further increase the quantity of soluble 
protein (Figure 16B and C). IPTG concentrations of 0.5 mM, 0.4 mM, 0.3 mM, 
0.2 mM and 0.1 mM were tested at both 18 °C and 12 °C, with 12 °C and 
induction with 0.2 mM IPTG concentration resulting in optimal soluble protein 
expression.  
The SEOV NPcore expression construct was designed to express a truncated 
version of NP in which the N- and C- terminal oligomerisation domains were 
removed to leave the compact globular core domain (residues 111-399), 
based on the previously described crystal structure of the Sin Nombre virus 
and Andes virus NP (Guo et al., 2016). Optimal conditions for the expression 
of His-SUMO SEOV NPcore were determined as described for the full length 
SEOV NP construct, above, with the expected mass of the His-SUMO SEOV 
NPcore protein predicted to be ~45.4 kDa. Codon Plus cells were identified as 
producing the largest quantity of His-SUMO SEOV NPcore (Figure 17A), and 
optimal conditions for expression was identified to be incubation at 18 °C with 
expression induced with 0.5 mM IPTG (Figure 17B, C).   
In addition to optimising conditions for expression, nickel-affinity purification of 
His-SUMO SEOV NP and His-SUMO SEOV NPcore was carried out using 
small-scale cultures. Following SDS-PAGE analysis of eluted proteins, the 
abundance of His-SUMO SEOV NPcore was significantly higher than that of 
full-length His-SUMO SEOV NP. Based on this, only large-scale purification 
of SEOV NPcore was attempted. Other methods used to produce larger 
amounts of soluble protein included using a glutathione S-transferase (GST) 






Figure 16 Expression profile of His-SUMO SEOV NP. 
 Analysis of His-SUMO SEOV NP expression by SDS-PAGE followed by 
colloidal Coomassie staining A) Expression of His-SUMO SEOV NP in 
various E. coli strains, B) Expression of His-SUMO SEOV NP in Rosetta 
cells at 18 °C with altered IPTG concentration C) Expression of His-
SUMO SEOV NP in Rosetta cells at 12 °C with altered IPTG 





Figure 17 Expression profile of His-SUMO SEOV NPcore.  
Analysis of His-SUMO SEOV NPcore expression by SDS-PAGE followed 
by colloidal Coomassie staining A) Expression of His-SUMO SEOV 
NPcore in various E. coli strains, B) Expression of His-SUMO SEOV NPcore 
in Codon Plus cells at 18 °C with altered IPTG concentration C) 
Expression of His-SUMO SEOV NPcore in Codon Plus cells at 12 °C with 
altered IPTG concentration. His-SUMO SEOV NPcore has a predicted 




3.2.2.3 Metal affinity purification of soluble SEOV NPcore 
His-SUMO SEOV NPcore was expressed by overnight induction with 0.5 mM 
IPTG at 18 °C in Codon Plus cells. Soluble recombinant protein was harvested 
from cell lysates by applying the clarified supernatant fraction containing 
soluble His-SUMO SEOV NPcore to nickel sepharose (6% agarose) resin, with 
binding for 1 hour at 4 °C. Contaminating proteins were removed by washing 
with increasing concentrations of imidazole wash buffer (Figure 18A) and 
subsequently the His-SUMO SEOV NPcore was eluted using elution buffer 
containing imidazole at 500 mM (Figure 18B). All fractions were analysed by 
SDS-PAGE and visualised using colloidal Coomassie (Figure 18). Fractions 
containing His-SUMO SEOV NPcore were pooled and incubated with Ulp1 
protease overnight to cleave the His-SUMO tag from SEOV NPcore. Cleaved 
SEOV NPcore has a predicted molecular weight of 32.3 kDa (ProtParam) and 
was further purified away from any uncleaved His-SUMO SEOV NPcore, His-
SUMO and the Ulp1 protease (containing a His-tag) by a second round of 
nickel affinity chromatography, with pooled fractions diluted 1:10 in low 
imidazole buffer prior to applying to nickel sepharose resin (Figure 18C). 
Alternatively, dialysis of fractions as a means to reduce imidazole 
concentration was tested prior to application to nickel sepharose resin, but 
was found to cause precipitation of the protein. Flow-through, containing 
purified SEOV NPcore, was collected (Figure 18C) and concentrated to 0.82 
mg/mL using a spin concentrator. This resulted in the isolation of >85% pure 
SEOV NPcore, as analysed by densitometry of Coomassie-stained proteins 
following SDS-PAGE (Figure 18D). Purification of soluble SEOV NPcore was 
also attempted using batch purification on loose nickel agarose resin (7.5% 
agarose), however, SEOV NPcore was found to bind directly to agarose resin 
and with only a small percentage of protein recovered during elution (data not 
shown). Other methods of purifying SEOV NPcore were attempted including 
cationic exchange chromatography and size exclusion chromatography, but 





Figure 18 Purification of soluble His-SUMO SEOV NPcore using nickel 
affinity chromatography.  
Analysis of purified His-SUMO SEOV NPcore expression by SDS-PAGE 
followed by colloidal Coomassie staining A-B) Purification of His-SUMO 
SEOV NPcore using nickel affinity chromatography and subsequent 
cleavage of the His-SUMO tag using Ulp1 protease. C) A second nickel 
affinity chromatography step was used to remove 6x His tagged 
contaminants, which resulted in >85 % purification of SEOV NPcore. D) 




3.2.2.4 Metal affinity purification of insoluble SEOV NPcore 
As the majority of His-SUMO SEOV NPcore was found to be insoluble, an 
alternative purification protocol was adopted in which recombinant protein was 
purified from inclusion bodies. Inclusion bodies were isolated by centrifugation 
of the cell lysate and collection of the insoluble pellet (Figure 19A, left panel). 
His-SUMO SEOV NPcore was solubilised by dissolving in 8M GuHCl and 
applied to loose nickel agarose resin in batch. His-SUMO SEOV NPcore was 
refolded on the column in combination with removal of contaminating proteins 
by washing in increasing imidazole and decreasing GuHCl wash buffers 
(Figure 19A, right panel). To remove the His-SUMO tag, refolded His-SUMO 
SEOV NPcore bound to resin was incubated with Ulp1 protease overnight and 
SEOV NPcore was eluted by washing in low imidazole wash buffer. Any protein 
remaining bound to resin was removed using high concentration imidazole 
wash buffers and resin was examined for remaining protein (Figure 19B). As 
seen in Figure 19B, a high amount of cleaved SEOV NPcore remained bound 
to the resin. Fractions containing purified SEOV NPcore, were pooled and 
concentrated to 0.8 mg/mL using a spin concentrator. This resulted in the 
isolation of >85% pure SEOV NPcore determined by densitometry (Figure 








Figure 19 Purification of insoluble His-SUMO SEOV NPcore using nickel 
affinity chromatography.  
Analysis of insoluble His-SUMO SEOV NPcore purification by SDS-PAGE 
followed by colloidal Coomassie staining A) Insoluble His-SUMO SEOV 
NPcore was isolated by harvesting inclusion bodies from bacterial cells, 
followed by solubilisation using GuHCl and purification using nickel 
affinity chromatography and on-column refolding. B) Cleavage of the His-
SUMO tag using Ulp1 protease on column overnight followed elution 
from the column to produce >85 % pure SEOV NPcore. C) Purified SEOV 






3.2.3 Anti-SEOV NP antibody  
3.2.3.1 Generating polyclonal anti-SEOV NP antisera 
Prior to immunization of animals for antibody production, the identity of purified 
SEOV NPcore protein was confirmed using mass spectrometry (Figure 20). 
Subsequently, 1.25 mg of purified soluble SEOV NPcore was used as antigen 
to produce a polyclonal antisera against SEOV NPcore utilizing an 
immunization regimen comprising five spaced injections of a goat with SEOV 
NPcore. Goat sera was collected one week after each booster immunisation, 
and samples were tested for the ability to specifically recognise SEOV NP.  
 
3.2.3.2 Validating the anti-SEOV NP antisera  
Anti-SEOV NP polyclonal antisera was validated by measuring reactivity 
against a panel of various antigens, namely, purified SEOV NPcore (Figure 
21A), transfected recombinant TULV NP (Figure 21B), TULV-infected Vero 
E6 cell lysates (Figure 21C) and by laser-scanning confocal microscopy 
(LSCM) utilising immunofluorescence of TULV infected monolayers (Figure 
21D). The generated antibody displayed good reactivity to SEOV NP and also 
showed cross-reactivity to TULV NP, which belongs a different phylogroup of 






Figure 20 Mass spectrometry analysis of purified SEOV NPcore.  
Mass spectrometry was carried out on purified His-SUMO SEOV NPcore 
resolved by SDS-PAGE and stained using InstantBlue™. The SEOV 
NPcore band was excised from the gel prior to analysis by mass 
spectrometry. The start and end of the SEOV NPcore sequences is 







Figure 21 Validation of anti-SEOV NP polyclonal antibody.  
A) Analysis of purified SEOV NPcore by SDS-PAGE followed by colloidal 
Coomassie staining and western blotting. B) Western blot analysis of 
transfected TULV NP cell lysates. C) Western blot analysis of TULV 
infected cell lysates at 120 hpi. D) Indirect immunofluorescence of TULV 





3.2.4 Section summary  
This section describes the generation of SEOV NP antisera, to be used to 
facilitate the analysis of orthohantavirus infection kinetics, to identify the 
location of NP within infected cells, and for the precipitation of NP from 
infected cells to study its binding partners. Expression and purification of 
recombinant SEOV NP from E. coli cells was optimised and SEOV NP was 
used as an antigen in the production of a polyclonal antibody. This antibody 
proved to be cross-reactive against E. coli expressed SEOV NPcore in addition 
to mammalian cell transfected TULV NP and TULV NP in TULV-infected cell 




3.3 Results: Generation of an anti-SEOV NP Affimer  
 
3.3.1  Introduction to Affimers  
Polyclonal antibodies can be generated against specific antigens and used as 
an important tool in research and diagnostic assays and for immunotherapies. 
In the context of this current study, the production of virus-specific antibodies 
can be used as a measure of virus multiplication, to identify the location of 
viral components within infected cells, and as a means to purify virus 
components with a view to studying virus-host interactions. Polyclonal 
antibodies can be generated by inoculation of various animals (e.g. sheep, 
rabbits, goats, chickens) with antigen over a specified time frame. Serum is 
collected after each antigen booster inoculation. Antibodies have several 
disadvantages including batch-to-batch variability, reliance on animals for 
production and expense. 
 
  
Figure 22 Crystal structure of an Affimer protein.  
Crystal structure of the Affimer protein (PDB: 4N6T) (Tiede et al., 2014). 







Affimers are non-antibody binding scaffold proteins with two randomised 
peptide loops which can be selected for to provide high-specificity binding 
against the target antigen (Figure 22). Affimers display several advantages 
over traditional antibodies: Their production does not involve the use of 
animals, but instead relies on expression from cloned cDNAs, most commonly 
using a prokaryote-based expression system. Affimers are relatively small and 
tend to be both highly soluble, and highly thermostable, allowing heat 
purification and no requirement for cold storage. Affimers can also be biotin- 
or fluorescently-labelled by utilising an incorporated C-terminal cysteine 
residue, proving especially useful for super-resolution microscopy (Tiede et 
al., 2014; Tiede et al., 2017). 
 
3.3.2  Expression and purification of SEOV NPcore + BAP tag  
3.3.2.1 Cloning BAP tag into the pET28a(+) SUMO + SEOV NPcore 
expression vector 
To act as bait for the selection of Affimers by phage display the SEOV NPcore 
was first appended to a BAP tag at its C-terminus, which allows attachment to 
a streptavidin coated binding matrix. The SEOV NPcore insert was amplified 
through PCR using the SEOV NPcore BAP tag Forward and SEOV NPcore BAP 
tag Reverse primers allowing addition of a Hind III site upstream of the Xho1 
site with the generated fragmented ligated into the pET28a(+) SUMO vector. 
The BAP tag sequence was synthesised by PCR amplification with Forward 
and Reverse BAP tag primers containing Hind III and Xho I restriction sites 
and the subsequently generated fragment was ligated into Hind III and Xho I 
sites within the previously described plasmid pET28a(+) SUMO + SEOV 






Figure 23 Plasmid map of the pET28a(+) SUMO + SEOV NPcore + BAP tag 
constructs.  
Schematic of SEOV NPcore + BAP tag construct displaying Ulp1 cleavage 
site after the 6xHis SUMO tag at the N-terminus of the SEOV NPcore 
construct and displaying the BAP tag at the C-terminus of SEOV NPcore. 
Plasmid map was generated using SnapGene® software. 
 
3.3.2.2 Metal affinity purification of soluble SEOV NPcore + BAP tag 
Expression of His-SUMO SEOV NPcore + BAP tag was performed using the 
same optimized expression conditions identified for His-SUMO SEOV NPcore, 
namely overnight expression at 18°C in Codon Plus cells, with induction using 
0.5 mM IPTG. Soluble protein was isolated from lysed cells by centrifugation 
and the clarified soluble protein from the supernatant was bound to nickel 
resin for 1 hour at 4 °C. Contaminating proteins were removed by washing 
with increasing concentrations of imidazole wash buffer (Figure 24A), and the 
His-SUMO SEOV NPcore + BAP tag was eluted using an elution buffers 
containing 1M imidazole (Figure 24B). Eluted protein was pooled and 
incubated with Ulp1 protease overnight to remove the His-SUMO tag, after 
which cleaved protein was diluted 1:10 in low imidazole buffer and re-applied 
to a pre-packed nickel resin column. Flow-through containing purified SEOV 
NPcore + BAP tag was collected (Figure 24C) and concentrated to 0.93 mg/mL 
using a spin concentrator, and all fractions were analysed by SDS-PAGE, 




and un-cleaved forms of the His SUMO + SEOV NPcore + BAP tag were 
predicted to be 47.9 kDa and 34.8 kDa, respectively, and bands 
corresponding to these products were identified in the appropriate lanes 
(Figure 9C and D). Purified and concentrated SEOV NPcore + BAP tag protein 
showed good reactivity for streptavidin (essential for phage display panning) 
by western blot analysis using a streptavidin-conjugated antibody (Figure 
24D).  
 
3.3.3  Phage display selection of unique Affimers binders  
3.3.3.1 Phage display panning for Affimers 
Affimers which displayed unique SEOV NP binding were selected using three 
consecutive rounds of phage display. A phage-display library generated from 
the phagemid vector pBSTG1-Adh (Tiede et al., 2014), containing an Affimer 
library of 1010 random binding sequences, were incubated with the target 
protein SEOV NPcore + BAP tag. Phages which do not bind to the target protein 
were washed away, whereas binders were eluted using glycine (pH 2.2) and 
triethylamine. Each consecutive panning round was carried out utilising a 
different binding matrix to reduce off-target binding. The first round used 
streptavidin coated strips, the second round used streptavidin dynabeads and 
the third round used NeutrAvidin coated strips. Selected phage were 
transformed into ER2738 cells and plated onto LB-agar, with each resulting 
colony representing an individual phage binder. Individual binders were tested 
for specific binding by phage ELISA against either a blank well or a well bound 
with SEOV NPcore + BAP tag. Binding was confirmed by probing using an anti-
Fd-bacteriophage-HRP in conjugation with 3,3′,5,5′-Tetramethylbenzidine 
(TMB) SeraminBlau®, which produces a soluble blue product which can be 
quantified by measuring absorbance at 620nm, with comparison between 
target and negative control wells. A total of 10 phages were identified that 
displayed greater binding to the target protein than the negative control wells, 
although sequence analysis revealed 9 of the 10 binders comprised the same 
binding sequences (Figure 25A). The two unique Affimer sequences and 
resulting proteins are referred to as Affimer 2 and Affimer 16, and their 






Figure 24 Purification of SEOV NPcore + BAP tag using nickel affinity 
chromatography.  
Analysis of His-SUMO SEOV NPcore  + Bap tag purification by SDS-
PAGE followed by colloidal Coomassie staining (A-D) or western blot E) 
Purification of His SUMO + SEOV NPcore + BAP tag using nickel affinity 
chromatography and subsequent cleavage of the His SUMO tag using 
Ulp1 protease followed by a second nickel affinity chromatography step 
to remove his tagged contaminants E) Purified SEOV NPcore + BAP tag 







Figure 25 Phage ELISA of 24 randomly picked Affimers after 3 
consecutive panning rounds to select for SEOV Humber NP 
binders.  
A) Affimers were tested against target SEOV Humber NP and a negative 
control (no target). Unique binders showing more binding to target wells 
compared to negative wells are highlighted with an asterix. B) Pairwise 
sequence alignment of uniquely binding Affimers, boxes denote the 
variable loops (red) and 8 X His-tag (blue). Sequences were aligned in 





3.3.4  Expression and purification of Affimers 
3.3.4.1 Cloning Affimer into the pET11a expression vector 
The cDNAs encoding Affimers were synthesised by PCR amplification of 
Affimer sequences within a phagemid vector using Affimer Forward and 
Reverse primers (Table 7) and resulting fragments were sub-cloned into an 
empty pET11a vector utilising the Not I and Nhe I restriction sites. The pET11a 
+ Affimer vector resulted in the expression of a C-terminal 8x His tagged 
Affimer (Figure 26).  
 
Figure 26 Plasmid map of the pET11a Affimer construct..  
Schematic of Affimer construct with 8x His tag at the C-terminus. Plasmid 
map was generated using SnapGene® software 
 
3.3.4.2 Batch purification of soluble Affimers  
Expression of Affimer 2 and Affimer 16 was carried out using optimal 
expression conditions previously defined (Tiede et al., 2014). Briefly, pET11a 
+ Affimer vectors were transformed into the Rosetta 2 E. coli expression strain 
and induced using 0.1 mM IPTG at 25 °C for 6 hours. Clarified supernatants 
containing soluble protein was applied to loose nickel resin and allowed to 
bind for 1 hour. Resin was washed in 20 mM imidazole wash buffer and 
Affimers were eluted using 300 mM elution buffer. Eluted Affimers were found 
to be 0.9 mg/mL (Affimer 2) and 2.1 mg/mL (Affimer 16). SDS-PAGE analysis 




a predicted weight of 12.5 kDa (Figure 27). Further purification and analysis 
may be carried out at a later time.   
 
3.3.5  Section summary  
This section describes the expression and purification of a BAP-tagged 
recombinant SEOV NP from E. coli cells. This purified protein was used as a 
target in three successive Affimer panning rounds and two unique Affimer 
binders were selected for. The selected Affimers were sub-cloned into a pET 
expression vector and purified.  
 
 
Figure 27 Purification of Affimers using nickel affinity chromatography.  
Purification of Affimer 2 (A) and Affimer 16 (B) through nickel affinity 





3.4 Results: Quantitative RT-PCR assay to detect TULV RNA 
 
3.4.1   Introduction to quantitative RT-PCRs  
Along with the measurement of virus infectivity, the ability to quantify the 
abundance of products of viral RNA replication is of fundamental importance 
in the study of virus multiplication cycles. Measurement of specific viral RNA 
can be achieved in real-time by quantifying reverse transcribed cDNA as a 
proxy, utilising a variety of fluorescent compounds in a PCR reaction to 
measure the amplification of DNA at the end of each thermal cycle, called 
qRT-PCR. This reporter can either be a fluorescent dye which is incorporated 
into double stranded DNA (e.g. SYBR Green; Life Technologies or BRYT 
Green; Promega) or by using a fluorescently- and quencher-labelled 
oligonucleotide primer specific to target (e.g. 6-Carboxyfluorescein (6-FAM) 
and Black Hole Quencher® (BHK) dye). The fluorescent oligonucleotide is 
quenched when unbound to DNA, but upon binding a fluorescent signal is 
emitted due to separation of the fluorescent label from the quencher.  
A specific and sensitive diagnostic real-time reverse transcriptase PCR (RT 
PCR) has been developed allowing specific detection of different hantaviruses 
(Kramski et al., 2007). Here, this protocol was modified to allow the 
quantification of TULV genomes throughout the course of both single step 
cycles of virus multiplication, and also long-term infection time courses.    
 
3.4.2  Comparison of laboratory TULV strain S segment ORF to 
wild type sequences  
TULV was propagated in Vero E6 cells and total viral RNA isolated from cell 
culture medium using viral RNA mini kit (Qiagen). Sequencing of the S 
segment was carried out to confirm the identity of the orthohantavirus species 
used in all experiments. TULV S Segment ORF was amplified from viral RNA 
using S segment specific primers (Chapter Two, Table 7) and inserted into the 
pcDNA3.1 (+) vector. The S Segment ORF was sequenced using the T7 and 
T7Term primers (GeneWiz). NCBI nucleotide blast revealed the closest 
related sequence to be from Tula/Moravia/5302v/95 (GeneBank: Z69991). 




and 3 nucleotide substitutions: A24G, C931G, G932C (Figure 29). The R311A 
substitution is within a conserved region of the orthohantavirus sequence but 
is located within the NP ORF (Figure 30). The impact of this mutation is not 
known. As infectious virus particles have been isolated from this strain this 
mutation does not affect the essential functions of the NP.  
 
 
Figure 28 Alignment of laboratory strain and wild type TULV S segment 
residues.  
Alignment was carried out using ClustalW, with the mismatched residues 






Figure 29 Alignment of laboratory strain and wild type TULV S segment 
nucleotide sequences.  
Alignment was carried out using ClustalW, with the mismatched residues 





Figure 30 Location of TULV NP R311A mutation within the 
orthohantavirus NP structure.  
HTNV nucleocapsid protein (PDB: 6I2N) residues 80-429. A311 is 





3.4.3  Generating a standard curve  
TULV S segment RNA was in vitro transcribed from the pCDNA3.1 (+) + TULV 
S segment ORF vector utilising the upstream T7 RNA polymerase. 
Transcribed RNA was analysed by agarose gel electrophoresis to estimate 
purity (Figure 31). TULV S segment RNA was diluted to estimated 108, 106, 
104 and 102 copies/5 µL and used in qRT-PCR to generate a standard curve 
with an Rsq value of >0.9 (Figure 32). These standards were used for every 
qRT-PCR analysis which allowed quantification of TULV in relative genomes 
copies/mL and comparison between separate qRT-PCR reactions. qRT-PCR 
were carried out based on previously described protocols (Kramski et al., 
2007) adapted to using the BYRT green fluorescent dye as a way of 
quantification of genome copies. Briefly, 5 µL of sample RNA was mixed with 
qRT-PCR mix. Reverse transcriptase was carried out followed by 45 PCR 
cycles. Cycle threshold (Ct) values were obtained for each sample and 
genome copies per 5 µL sample were calculated from the standard curve. 
Genome copies per mL cell culture supernatant was calculated.  
 
 
Figure 31 Electrophoresis of in vitro transcribed TULV S segment RNA. 
 TULV S segment RNA generated through in vitro RNA transcription was 






Figure 32 Example qRT-PCR detection of TULV RNA and example 
standard curve generated from in vitro transcribed TULV S segment 
RNA.  
A) Example time course of TULV RNA production during infection of Vero 
E6 cells at MOI 0.1 B) Example standard curve based on serially diluted 
in vitro transcribed TULV S segment RNA generated through qRT-PCR. 
Graphs are for demonstrative purposes and are based of one replicate.  
 
3.4.4  Section summary  
This section describes the development of a rapid PCR based assay for the 
quantitative detection of TULV RNA replication products by generating a 
calibration curve from in vitro transcribed RNA allowing fast, accurate and 




reliable comparison of TULV S segment RNA quantities even obtained 
through separate qRT-PCR runs. As the numerical value of each sample is 
quantified against a standard curve the values obtained are unlikely to be 
exact. However as every condition remains the same, save the initial template 
RNA concentration, this assay is a reliable method of detecting TULV RNAs 
under experimental conditions. Further applications of this method, for viral 
diagnostics, would require further quality control mechanisms such as 
detection of an endogenous housekeeping or reference gene for example 








3.5 Results: Developing assays to detect infectious TULV   
 
3.5.1  Introduction to virus titration assays  
There are many different methods used for the quantification of infectious 
virus. Traditional methods include tissue culture infective dose assay 
(TCID50), focus forming assay (fluorescence or colourimetric), crystal violet 
plaque assay, neutral red uptake plaque assay, flow cytometry based assay 
and focus reduction neutralisation (FRNT) assay (Cooper, 1962; McCormick 
et al., 1982; Tanishita et al., 1984; Gavrilovskaya et al., 1998; Bharadwaj et 
al., 2000; Tischler et al., 2005; Ramanathan et al., 2007; Barriga et al., 2013; 
Baer and Kehn-Hall, 2014).  
Orthohantaviruses are not known to cause lytic infections in vitro or in vivo 
(Vapalahti et al., 1996; McElroy et al., 2004; Mackow et al., 2014; Ermonval 
et al., 2016). This prevents the use of traditional plaque assays in which areas 
of cell death are counted, as measured by the appearance of plaques against 
a densely-stained crystal violet monolayer. However, orthohantaviruses-
infected cells show growth impairment, and can be stained using the neutral 
red uptake plaque assay, in which growth-impairment can be visualized by 
reduced uptake of the stain compared to un-infected cells (McElroy et al., 
2004). However, this assay is time-consuming (10-17 days) with plaques that 
are not easily distinguishable from surrounding cells (especially in comparison 
to the crystal violet plaque assays) (Schmaljohn et al., 1983; McElroy et al., 
2004). Here, a fast and high-throughput immunofluorescence-based assay 
was developed utilising the polyclonal antisera generated against SEOV NP, 
which displayed cross-reactivity against TULV NP allowing discrete infectious 
centres to be stained and counted.  
 
3.5.2  Neutral red uptake plaque assay 
Neutral red uptake plaque assay is a common method used for the titration of 
orthohantaviruses. Plaque assays were performed in duplicate in 6-well plates 
using TULV serially diluted from 100-10-4. After adsorption, monolayers were 
overlaid with using a 2 % agarose overlay. After 7 days of incubation, a second 




3 days post staining. A typical TULV stock was estimated to have a titre of 1.2 
x 105 pfu/mL (Figure 33).  
 
 
Figure 33 Example neutral red uptake plaque assay.  
TULV viral titres were assessed using neutral red uptake plaque assay. 
Plaques were counted in the well containing TULV diluted 10-3 where 
plaques are most easily distinguished. 
 
3.5.3  Immunofluorescent assay 
 The neutral red uptake plaque assay method is time-consuming, taking over 
10 days, and produces poorly-visible plaques. An improved 
immunofluorescence-based assay was developed based on detection of viral 
NP for the titration of TULV, for TULV infection kinetics and for measuring 
virus production. The immunofluorescence assay was carried out in triplicate 
in 96-well plates using TULV serially diluted from 100-10-5. After adsorption, 2 
% media was added to each well and infection was carried out for 72 hours. 
Cells were fixed and stained for indirect immunofluorescence using SEOV NP 
antisera. Infected cells were imaged using the Incucyte ZOOM software and 
quantified using masking software (Figure 34). An example TULV dilution 
series was examined by this method and was shown to describe a linear range 
with an Rsq value of 0.9862 (Figure 34). This methods allows accurate, high-






Figure 34 Example immunofluorescence assay.  
Example images of infected or mock wells used for the 
immunofluorescence assay using the Incucyte ZOOM instrument and 
showing subsequent analysis using masking software to count 
immunofluorescent units per well. The linear range describing the dilution 




3.5.4  Section summary  
This section describes development of methods to titrate infectious TULV. A 
neutral red uptake plaque assay (Schmaljohn et al., 1983) and an 
immunofluorescence assay were developed in order to facilitate the titration 





Chapter 4   : Examining the life cycle and persistence of 
TULV  
 
4.1 Chapter Introduction 
The previous chapter described the development of molecular tools to allow 
examination of the TULV lifecycle based on the detection of both viral RNA 
and protein products, specifically the nucleocapsid protein (NP). Here, these 
tools are exploited to examine the kinetics of TULV multiplication within 
cultured cells, in which TULV establishes a long-term infection. The 
localisation of TULV NP during early, peak and persistent stages of infection 
was examined along with the ability of NP to interact with various host-cell 
proteins using IF analysis.  
 
4.2 Results: Quantification of TULV replication products 
 
4.2.1 Introduction to the orthohantavirus lifecycle  
The lifecycle of the orthohantaviruses is poorly understood and many 
fundamental questions surrounding their multiplication still remain 
unanswered. Important questions include where is the site of the replication 
factory within the cytosol, what is the identity of host-cell components that are 
required for formation of the viral factory, and what mediates hantavirus 
persistence in vivo and in vitro?  
During infection of the host cell, viruses often induce the formation of viral 
factories where the production of viral RNA and protein components take 
place, and in some but not all cases, virus particles are assembled. These 
cellular inclusions often comprise specific cell organelles or modified 
membranes where host proteins are recruited, which may aid the virus 
replication cycle and protect the virus from the host immune responses. For 
orthohantaviruses the location and composition of the viral factory is still 
unknown. It is likely that the NP is a major structural component of the 
hantaviral factory, being the most abundant protein that builds up the RNP, 
which acts as the template for all viral RNA synthetic activities. NP may also 




host interactions are required for formation of viral factories (Ding et al., 2016). 
Examining the interaction of NP with host cell components in cells may reveal 
the specific requirements for establishment of the orthohantavirus replication 
factory as well as provide information about its location.  
Examining NP interactions may also aid understanding of why orthohantavirus 
infections in cell culture and the natural rodent hosts leads to persistence, 
particularly in view of the increasing body of evidence showing the hantaviral 
NP possesses anti-apoptotic functions. However, the molecular and cellular 
basis for orthohantavirus persistence both in vivo and in vitro is poorly 
understood.  
 
4.2.1.1 Orthohantavirus life cycle in vivo  
Viral persistence in a natural host or reservoir may be an evolutionary 
adaptation developed by the viruses after millions of years of virus-host co-
evolution. Syrian hamsters, macaques (rhesus and cynomolgus), ferrets and 
marmosets have all be used as a model of orthohantavirus infection in vivo. 
Infection with HFRS-causing orthohantaviruses (e.g. HTNV/PUUV) leads to a 
similar disease to humans in macaques (Groen et al., 1995), whereas 
infection in Syrian hamsters, ferrets and marmosets, while susceptible to 
HTNV and PUUV infection, showed asymptomatic infections with either no 
symptoms of infection or subclinical manifestations of pathogenesis (Perley et 
al., 2019). These asymptomatic infections of animal models show little 
evidence of systemic viremia despite a detectable immune response and the 
detection of virus in organs and excretions of infected animals (Perley et al., 
2019). Asymptomatic models of HFRS-infection are similar to orthohantavirus 
infection of rodents, the natural host, and can be a model for viral persistence 
in the host animal (Sanada et al., 2011). However, immunosuppression of 
Syrian hamsters and ferrets leads to the development of a disease phenotype 
for HFRS- and HCPS-causing orthohantaviruses suggesting immune 
involvement is required for the regulation of asymptomatic, persistent infection 
(Hooper et al., 2001; Brocato et al., 2014; Vergote et al., 2017; Perley et al., 
2019).  
In the orthohantavirus reservoir host, asymptomatic virus infections follow 




virus shedding in excreta is high. The acute phase is followed by a persistent 
phase of reduced virus replication and shedding but with high antibody titres. 
These kinetics have been experimentally demonstrated for HFRS/NE and 
HCPS with mice, voles and rats. Virus can be detected in excreta up to at 
least a year post infection (detected at experimental end point). 
Orthohantaviruses can persist and remain infectious in the environment for 
significant periods, which allow efficient transmission to rodent or human hosts 
(Kallio et al., 2006). Horizontal transfer due to exposure and inhalation of 
infective excreta appears to be the common way virus is transmitted (Lee et 
al., 1981; Gavrilovskaya et al., 1990; Hutchinson et al., 1998; Botten et al., 
2002). Hantavirus maintenance in reservoir hosts is likely due to a 
combination of exposure to infected excreta through bedding, grooming and 
fighting (Ermonval et al., 2016). Vertical transfer has been shown not to occur 
as the placenta acts as a barrier to transmission. The progeny of infected 
mothers have shown congenital and post-natal immunity to orthohantavirus 
infection for at least 20 days post birth (Yanagihara et al., 1985). 
Virus persistence may be due to a specific immune response induced in the 
reservoir host. The development of regulatory T cells and production of TGF-
β may limit a pro-inflammatory response and prevent viral clearance, as seen 
in persistent (but not acute) orthohantavirus infections of Norway rats. In 
contrast, during human orthohantavirus infection pro-inflammatory cytokines 
such as TNFα, IFNγ and IL-2 are upregulated in addition to increased numbers 
of CTLs implicated in inflammatory responses and viral pathogenesis 
(Schountz et al., 2007; Easterbrook and Klein, 2008; Spengler et al., 2013). 
Orthohantaviruses can be separated into clades which correlate well with 
host-species and pathogenicity in humans (Chapter One, Figure 2, Table 2). 
Persistent infection of the host allows greater opportunity for reassortment and 
genetic drift which are beneficial traits for overcoming any deleterious 
mutations introduced during viral replication (Plyusnin et al., 1996; Plyusnin et 
al., 2002). Several other zoonotic viruses have displayed persistent 
phenotypes in their reservoir hosts such as simian immunodeficiency virus 
(SIV) infections of primates and arenavirus (e.g. Lassa and Junín viruses) 
infection of rodents by inducting regulatory immune mechanisms (Vitullo et al., 




4.2.1.2 Orthohantavirus life cycle in vitro  
The replication kinetics of orthohantavirus infections and their persistence in 
cell culture has not been described in detail. Several studies have been 
conducted examining either genome production, infectious virion production 
or viral protein production but few have studied these in combination. For both 
New World and Old World orthohantaviruses, reports have described a slow 
but steady increase in viral replication products from 24 hpi up to 10 dpi by 
observing levels of infectious virus, viral genomes or levels of viral NP (Jin et 
al., 2001; Li et al., 2010; Shim et al., 2011; I.N. Gavrilovskaya et al., 2012; 
Witkowski et al., 2017). In addition to lifecycle kinetics, the localisation of 
orthohantavirus NP has been briefly assessed. Orthohantavirus NP has been 
described to form puncta at early time points and perinuclear “crescents” or 
“filaments” at later time points (Vapalahti et al., 1996; Ramanathan and 
Jonsson, 2008). 
Orthohantaviruses have been implicated in both the induction and evasion of 
apoptosis in cell culture. The lack of cytopathology in cell culture is well 
described through the inability to titrate the virus through traditional crystal 
violet methods and development of alternative non-lytic based methods of 
virus titration have been developed (McElroy et al., 2004). Infectious virus and 
viral RNA have been detected up to 139 dpi from SEOV infected Vero E6 cells 
(Meyer and Schmaljohn, 2000) and up to 55 dpi from TULV infected Vero E6 
cells without observing cytopathic effects (Vapalahti et al., 1996). Additionally, 
endothelial cells are known to be the primary sites of orthohantavirus 
multiplication but are not associated with cell lysis (Cosgriff, 1991).  
The evasion of host cell apoptosis may be mediated through several 
mechanisms. The NSs protein, encoded by several members of the 
Orthohantavirus genus, is capable of suppressing antiviral immune responses 
and can reduce IFNβ expression which contributes to virus survival 
(Jääskeläinen et al., 2007; Jääskeläinen et al., 2008). Additionally, defective 
interfering particles (DIs) have been suggested to be a factor in viral 
persistence. DIs have been identified within the majority of RNA and DNA 
families and are virus-like particles with mutated or shortened genomes which 
render them incapable of autonomous replication. They infect cells 




competing for host resources (Strauss and Strauss, 2008). DIs are associated 
with increased IFN production, which may aid the development of persistent 
infections through reduction of the inflammatory response (Sekellick and 
Marcus, 1978; Manzoni and López, 2018). However, as of yet, no role for DIs 
in orthohantavirus persistence has been demonstrated and instead 
persistence has been linked to accumulation of terminally deleted RNAs which 
still are capable of replication (Meyer and Schmaljohn, 2000). This suggests 
that other mechanisms, alternative to DIs, are involved in the induction of 
orthohantavirus persistence.  
 
4.2.2 Introduction to laser scanning confocal microscopy (LSCM) 
and widefield fluorescence deconvolution microscopy 
(WFDM) 
Florescent microscopy is a powerful technique which can be utilised for the 
examination of the localisation of subcellular structures. Fluorescent 
microscopy relies on the use of antibodies which target the protein of interest 
and use a conjugated fluorophore to provide a localised signal. LSCM or 
WFDM can be used for visualisation of fluorophore signal.  
In LSCM, a laser of a specific wavelength is used as a light source with 
fluorescent emission detected through a specific filter set. The emitted light is 
passed through a pinhole (aperture) reducing the amount of light reaching the 
light detector (photomultiplier). This reduces the out-of-focus light giving a 
sharply focused image of one focal plane of the specimen (Ferrando and 
Spiess, 2000; Földes-Papp et al., 2003; Nwaneshiudu et al., 2012). Widefield 
fluorescent deconvolution microscopy (WFDM) in contrast utilises either light-
emitting diodes (LEDs), mercury or xenon arc-lamps as a light source, with 
both excitation and emission filters used. In WFDM, the entire specimen is 
illuminated by the light source and as a result the emitted light can be 
scattered producing a blurred image. No pinhole is employed in WFDM and 
instead a mathematical algorithm, deconvolution, is used where out-of-focus 
light is returned to its estimated point source. Images are recorded over a 
series of focal planes and deconvolution is applied to give an image with 
higher contrast and resolution than the raw data would normally allow (Shaw, 




image capture, higher resolution, sensitivity and improved signal-to-noise 
ratio. The advantages of LSCM are sharper optical sectioning, reduced 
background, increased cross talk elimination and capture of more than one 
fluorophore simultaneously. However, with LSCM there is usually a trade-off 






4.2.3 TULV RNA replication kinetics in Vero E6 cells through a 10 
day time course  
The multiplication of TULV in Vero E6 cells was examined over an extended 
time course when incubated at 37 °C. Growth of TULV in Vero E6 cells 32 °C 
was examined due to previous work carried out on Hazara virus where 32 °C 
growth achieved significantly higher viral titres (Emma Punch, unpublished 
data). Vero E6 cells were infected with TULV at MOI 0.1 and the supernatants 
and cell lysates were collected at specified time points and assessed 
separately for production of viral RNA and infectious particles. Analysis of 
sense and anti-sense RNA from 37 °C culture lysates using qRT-PCR 
revealed a lag phase of up to 30 hpi where no increase in viral RNA replication 
products was detected. This lag-period was followed by an exponential phase 
of rapid viral RNA production which lasted for around 12 hours (Figure 35A, 
B, Figure 36A, B). This was followed by a period with a much slower RNA 
replication rate, eventually leading to a plateau in RNA abundance at around 
168 hpi at 37 °C (Figure 36B). This plateau was not reached during the 32 °C 
time course, with quantities continuing to rise, suggesting slower replication 
kinetics (Figure 35B).   
The production of infectious virus particles was also examined to assess 
whether infectious virus production reflected increasing genome abundance. 
This measurement would also allow us to examine whether our measurement 
of viral RNA was influenced by the production of defective RNA genomes 
within DIs, a known characteristic of RNA virus infections (Rima et al., 1977; 
Sekellick and Marcus, 1978). Assessment of infectivity was performed using 
the same time points as previously used for RNA analysis, which revealed the 
overall pattern of infectious virus release mirrored that of viral RNA abundance 
as measured by qRT-PCR. There was an initial lag period of around 48 hpi at 
37 °C (Figure 36C) and 60 hpi at 32 °C (Figure 35C) followed by a period of 
increased infectious virus production up to 144 hpi at 37 °C (Figure 36C) and 
168 hpi at 32 °C (Figure 35C). As viral genomes and infectious virus 
concentrations follow similar growth patterns this suggests that there may be 
no production of DIs during long-term orthohantavirus infection. DI 




compared to viral protein or viral genome levels as demonstrated with LCMV 






Figure 35 Examination of TULV replication kinetics in Vero E6 cells at 32 
°C by qRT-PCR and IF assay.  
A) TULV infectious titres/mL determined by IF assay using SEOV NP 
antisera B) TULV RNA genome copies/mL determined by qRT-PCR C) 
TULV RNA genome copies/mL displaying lag and exponential phase 





Figure 36 Examination of TULV replication kinetics in Vero E6 cells at 37 
°C by qRT-PCR and IF assay.  
A) TULV infectious titres/mL determined by IF  assay using SEOV NP 
antisera B) TULV RNA genome copies/mL determined by qRT-PCR C) 
TULV RNA genome copies/mL displaying lag and exponential phase 





During TULV infection the concentration of viral RNAs compared to infectious 
viral particles decreases as infection progresses, the opposite to what is 
expected with DIs contamination (Figure 37). 
 
 
Figure 37 Ratio of viral genomes to titre in Vero E6 cells at 37°C.  
Ratio of viral RNA genomes and infectious virus detected over 30 days 
post infection in Vero E6 cells at 37°C 
 
Alongside the quantification of TULV replication, SEOV NP antisera was used 
to assess TULV  NP accumulation in Vero E6 cells infected at MOI 0.1 by 
western blotting of cell lysates. Intracellular NP was detected 36-48 hpi (1.5-2 
dpi) with a significant increase in NP detection occurring between 60 (2.5 dpi) 
and 72 hpi (3 dpi). NP could be detected in cell lysates at consistent levels up 
until the final harvest of the time course of 240 hpi (10 dpi) (Figure 39). Taken 
together, these results suggest that the replication of TULV genomes and 
production of infections TULV particles is relatively slow when compared to 
other RNA viruses. For example, Nipah virus begins exponential replication of 
genomes 8 hpi and reaches peak virus production at around 32 hpi (Chang et 
al., 2006) and influenza virus begins genome replication very soon after 
infection and reaches peak virus levels at 4-10 hpi after which virus genomes 
and virus titres decrease (Schulze-Horsel et al., 2009; Frensing et al., 2016). 
This immediate decrease in replication products after peak production is not 
observed during orthohantavirus infection of Vero E6 cells. Instead a plateau 
phase is reached after peak virus production where the rate of production of 




be due to the lack of CPE induced by orthohantaviruses. Viruses displaying 
decrease in viral genomes and infectious particles after peak virus production 
often induce apoptosis to aid virus dissemination, such as during influenza 
virus infection (Herold et al., 2012).  
 
4.2.4 TULV replication during persistent infections  
As TULV replication products and infectious TULV could be detected in an 
extended time course of up to 240 hpi (10 dpi) , the time course was extended 
up to 30 dpi to assess TULV replication in persistently infected cell cultures. 
After 10 dpi, there was a slow decreases in viral RNA up to the end of the time 
course at 30 dpi but genome levels still remain approximately one log higher 
than initial values (Figure 38B). Assessment of infectious TULV also revealed 
a slow decrease in infectious particle counts from 10-30 dpi (Figure 38A). The 
larger decrease in viral genomes compared to infectious virus particles is not 
distinctive of persistence induced by the presence of DIs where the ratio would 
be expected to be reversed (Ziegler et al., 2016) suggesting an alternative 






Figure 38 Examination of persistent TULV infection replication kinetics 
in Vero E6 cells at 37°C by qRT-PCR and IF assay.  
A) TULV infectious titres/mL determined by IF  assay using SEOV NP 









Figure 39 Examination of TULV replication kinetics at 32 °C and 37 °C by 
western blot  
A) Accumulation of NP in TULV infected Vero E6 cell lysates at 32 °C 
assessed by western blot using SEOV NP antisera alongside a GAPDH 
loading control. B) Accumulation of NP in TULV infected cell lysates at 
37 °C assessed by western blot C) Normalised NP values as a 




4.2.5 Detection of TULV NP localisation in infected and transfected 
cell cultures  
4.2.5.1 Localisation of TULV NP in infected Vero E6 cell cultures  
The location of TULV NP in TULV infected cells at 36 hpi (early), 7 dpi (peak) 
and 30 dpi (persistent) was examined by IF analysis using SEOV NP antisera. 
LSCM revealed at least three distinct patterns of NP accumulation at these 
specific time points. At 36 hpi, NP was observed throughout the cytoplasm as 
predominantly punctate bodies, 0.3-2.7 µm diameter, and also thin tubular 
structures, with dimensions of approximately 4-7.5 µm long and 0.5-1.5 µm in 
width (Figure 40, top panel). At 7 dpi, NP was observed in the cytoplasm as 
punctate bodies (0.3-2.7 µm) in addition to an accumulation of NP as filaments 
in the perinuclear region. At 7 dpi, TULV NP filaments are around 6.0-20.0 µm 
in length and 0.5-5.0 µm in diameter (Figure 40, middle panel). At 30 dpi, the 
location of NP was similar to that observed at 7 dpi, forming large filaments 
and macromolecular complexes in the perinuclear region, and punctate 
bodies in the cytoplasm. TULV NP filaments in persistently infected cells were 
6.0-25.0 µm in length and 2.0-6.0 µm in diameter and puncta ranged between 
1.0-3.5 µm in diameter. Though NP filaments and puncta gradually increase 
in size throughout infection their locations remain fairly consistent with tubular 
NP localising in the perinuclear region and punctate NP throughout the 
cytoplasm. Due to the resolution limits of LSCM it was not determined whether 
TULV NP filaments were composed of multiple thin filaments of NP or were 
larger accumulations or aggregations of NP. However, the increased size of 
these large structures as the infection progressed through the time course 
suggests they may represent important sites of viral activity, and are 
candidates for the viral factory. Viral NP found in punctate form may be 
contained within membranous vesicles such as endosomes or lysosomes, but 





Figure 40 Detection of TULV NP in early, peak and persistently infected 
Vero E6 cells.  
LSCM images of TULV infected cells at 36 hpi, 7 dpi and 30 dpi using 40 
X magnification. Characteristic punctate and tubular NP staining at these 
time points is shown. The white bar represents 30 µm and 10 µm in 
zoomed images. Nuclei were stained with DAPI (blue) and TULV NP 
detected using NP antisera (green)  
 
4.2.5.2 Persistent TULV infection induces syncytia  
To confirm the appearance of syncytia in 30 dpi persistently infected cell 
cultures the use of differential interference contrast (DIC) microscopy was 
employed where visualisation of cells using polarized light allows increased 
contrast and the perception of depth. In the context of this experiment, DIC 
microscopy allowed cell boundaries to be more easily identified, and revealed 
that while some cells were uninucleate (Figure 41, black arrow) others were 
clearly multinucleate (Figure 41, white arrow) with evidence of a single 
membrane around multiple nuclei (Figure 41, bottom panel). Large structures 
of NP within multinucleate cells were often found localised between the nuclei 
within the multinucleate cell (Figure 41, bottom panel).  
To assess whether the ratio of cells to nuclei changes throughout infection, 




cells to nuclei would give a ratio of 1, whereas increased nuclei per cell would 
result in a ratio of <1. A total of 18 cells were counted at 36 hpi, 132 counted 
at 7 dpi and 35 counted at 30 dpi (Figure 42). At 36 hpi, no multinucleate cells 
were observed, at 7 dpi the majority of cells were uninucleate with a few cells 
containing two nuclei. At 30 dpi a high proportion of multinucleate cells 
contained 2-3 nuclei (but sometimes upward of 4) and  displayed mostly 
normal nuclear morphology, but with some nuclei occasionally appearing as 
fragmented (Figure 40, bottom panel, Figure 41).  
 
 
Figure 41 Formation of multinuclear cells during persistent TULV 
infections in Vero E6 cells.  
LSCM images with DIC microscopy using 40 X magnification to assess 
formation of multinuclear cells during persistent infections in Vero E6 
cells. The white bar represents 30 µm. White arrows point to 
multinucleate cells and black arrows point to uninucleate cells. Nuclei 
were stained with DAPI (blue), TULV NP detected using NP antisera 






Figure 42 Histogram of the ratio of cells to nuclei in early, peak and 
persistently TULV infected Vero E6 cells.  
The ratio of the number of cells to the number of nuclei identified is 
displayed for TULV infected cells at 36 hpi, 7 dpi and 30 dpi. Cells were 
counted from LSCM images. 169 cells were counted in total (18 (36 hpi), 
































Figure 43 Distribution of TULV NP in transfected Vero E6 cells.  
LSCM images taken of Vero E6 cells transfected with pcDNA3.1 (+) 
TULV NP at 18 hours post transfection using 63 X magnification. Three 
distinct phenotypes of recombinantly expressed TULV NP are shown. 
The white bar represents 30 µm. Nuclei were stained with DAPI (blue) 
and TULV NP detected using NP antisera (green).  
 
4.2.5.3 Localisation of TULV NP in transfected Vero E6 cells  
The phenotype of TULV NP in Vero E6 cells transfected with pcDNA3.1 (+) 
TULV NP was examined by IF  analysis. LSCM revealed several distinct 
patterns of NP accumulation in transfected cells. Recombinantly expressed 
TULV NP was observed in the cytoplasm either dispersed (Figure 43, top 
panel), in discrete puncta (Figure 43, middle panel) or in large structures in 
the perinuclear region (Figure 43, bottom panel). This is similar to 
observations of TULV infected cells, apart from disperse NP phenotype, 
suggesting the formation of these structures is not reliant on the expression 





4.2.6 Section summary 
This section describes the distribution of TULV NP in Vero E6 cells during 
early, peak and persistent infections and in TULV NP transfected cells. TULV 
NP shows distinct localization phenotypes at early, peak and persistent stages 
on infection notably the formation of large tubular structures in the perinuclear 
region in addition to the establishment of multinucleate cells. TULV NP 
transfected cells show similar NP phenotypes to infected cells at 36 hpi and 7 





4.3 Results: Analysis of TULV NP co-localisation with host 
cell components 
 
4.3.1 Introduction to orthohantavirus NP co-localisation with 
cellular components 
The previous section described the appearance and distribution of TULV NP 
in both infected and transfected cells. Next, the location of TULV NP in relation 
to cellular components was examined. This would provide information that 
would aid in identifying and characterising interactions between TULV NP and 
various cellular components and, in addition, improve understanding of where 
within the infected cell the various stages of the hantavirus life cycle occur. 
Little is known of how hantavirus NP interacts with other cellular components, 
and the site of hantavirus replication factories remains elusive. Previous work 
by others has shown hantavirus NP localises in punctate granules in the 
cytoplasm at early stages of infection but by later time points, NP localises to 
the ER-Golgi intermediate compartment (ERGIC) in the perinuclear region. 
HTNV, SEOV, BCCV and ANDV NPs have been described to traffic after entry 
along microtubules with a requirement of the molecular motor dynein for 
transportation to the perinuclear region (Ramanathan et al., 2007; 
Ramanathan and Jonsson, 2008). BCCV NP may utilise transport along actin 
filaments for assembly and release, however this may not be ubiquitous over 
all orthohantavirus species as HTNV NP transportation post-entry shows no 
requirement for actin filaments, but instead actin may be necessary for early 
entry and replication (Ravkov et al., 1998; Ramanathan and Jonsson, 2008). 
Orthohantavirus NP has also been reported to co-localise with processing (P) 
bodies, which are the sites of sequestered cellular mRNAs. Recombinantly 
expressed SNV NP was found to co-localise with the P body marker, DCP1a 
in addition to co-immunoprecipitation of this host protein with orthohantavirus 
NP (Mir et al., 2008). Additionally, HTNV and SEOV NP have been described 







4.3.2 Interactions of TULV NP with the host cell cytoskeleton  
4.3.2.1 TULV NP co-localisation with actin, tubulin and vimentin 
There are three major types of cytoskeletal filaments in the cell; actin 
filaments, microtubules and intermediate filaments. These are organised into 
a highly ordered network which controls cell shape and directs the movement 
of cellular components. Actin filaments are involved in cell motility and cell-to-
cell communication and as a result constantly reassembles as directed 
through cell signalling. Microtubules are made up of α- and β-tubulin units and 
form rigid linear tracks throughout the cell. These tracks are used for trafficking 
of cellular components by molecular motors such as dynein. Intermediate 
filaments, as the name suggests, are intermediate in diameter (10 nm) 
between actin (7 nm) and tubulin (25 nm) and are formed from a diverse 
collection of filament proteins that share the ability to polymerize into long 
chains. The intermediate filaments are the least rigid of the cytoskeletal 
elements and are involved in diverse cellular roles including providing 
structural support, organelle tethering, cell signalling, and resistance to 
cellular stresses (Fletcher and Mullins, 2010). Previous results have 
suggested orthohantaviruses utilise the host cytoskeleton post-entry for 
trafficking, assembly and release (Ravkov et al., 1998; Ramanathan et al., 
2007; Ramanathan and Jonsson, 2008).  
To assess the interaction of the host cell cytoskeleton with TULV NP the 
intracellular localisation of actin filaments, microtubules and the intermediate 
filament, vimentin, was examined alongside TULV NP by IF analysis and 
fluorescent line scan. Line scan was chosen as a method of choice for co-
localisation analysis. There is previous precedent for using the line-scan 
technique for both viral protein localisation (King et al., 2017) and cellular 
compartments (Bolte and Cordelières, 2006). Antisera against the β-actin 
subunit, the β-tubulin subunit and intermediate filament protein vimentin 
(residues surrounding Arg45 of vimentin) were used for analysis. The 
distribution of NP generated during TULV infection was examined at early (36 
hpi), peak (7 dpi) and persistent (30 dpi) infection time points for co-
localisation with host cytoskeleton components.  
At 36 hpi, staining for TULV NP, actin, tubulin and vimentin revealed low levels 




structures but not punctate NP displayed high levels of co-localisation with 
tubulin and vimentin (Figure 45, Figure 46, middle panels). Fluorescent line 
scan analysis of vimentin and tubular TULV NP co-localisation at 7 dpi (Figure 
45) reveals near-perfect co-localisation suggesting close interaction of NP 
with this intermediate filament component at peak (7 dpi) infection. Later in 
infection, at 30 dpi, staining with vimentin showed low levels of co-localisation 
and instead large ultrastructural assemblies of vimentin were observed 
surrounding multimeric NP structures (Figure 46). Spatial distribution analysis 
of cytoskeletal proteins and TULV NP revealed low counts of co-localisation 
with actin filaments and vimentin at all time points. The low count number with 
vimentin at 7 dpi is due to a large amount of NP found in punctate form which 
does not co-localise well with vimentin staining, whereas the few tubular 
structures of NP co-localise well with vimentin (Figure 48). 
Next, the location of NP expressed from a recombinant source was examined. 
pcDNA 3.1 (+) TULV S ORF was transfected into Vero E6 cells resulting in 
the expression of recombinant TULV NP. As above, co-localisation of the host 
cytoskeleton with recombinantly expressed TULV NP was assessed using IF 
analysis. In agreement with observations above with peak and persistently 
TULV infected Vero E6 cells, co-localisation was observed between TULV NP 
structures or tubules with tubulin but not with actin. Additionally, recombinantly 
expressed TULV NP co-localises with vimentin but without the observation of 
the vimentin “cage” around sites of NP accumulation suggesting a 






Figure 44 Co-localisation of actin filaments, microtubules and vimentin 




Figure 44 Co-localisation of actin filaments, microtubules and vimentin 
with TULV NP in Vero E6 cells at 36 hpi. 
The spatial distribution of the cytoskeletal markers (magenta) was 
observed alongside TULV NP (green) in TULV infected Vero E6 cells 
(MOI 0.1) at 36 hpi by LSCM at 40 X magnification. The white bar 
represents 30 µm and 10 µm (zoom). Fluorescent line scans taken 
using Fiji software. Nuclei were stained with DAPI (blue), TULV NP 
detected using NP antisera and cytoskeleton detected using antibodies 






Figure 45 Co-localisation of actin filaments, microtubules and vimentin 






Figure 45 Co-localisation of actin filaments, microtubules and vimentin 
with TULV NP in Vero E6 cells at 7 dpi. 
The spatial distribution of the cytoskeletal markers (magenta) was 
observed alongside TULV NP (green) in TULV infected Vero E6 cells 
(MOI 0.1) at 7 dpi by LSCM at 40 X magnification. The white bar 
represents 30 µm and 10 µm (zoom). Fluorescent line scans taken using 
Fiji software. Nuclei were stained with DAPI (blue), TULV NP detected 
using NP antisera and cytoskeleton detected using antibodies against β-






Figure 46 Co-localisation of actin filaments, microtubules and vimentin 





Figure 46 Co-localisation of actin filaments, microtubules and vimentin 
with TULV NP in persistently infected Vero E6 cells. 
The spatial distribution of the cytoskeletal markers (magenta) was 
observed alongside TULV NP (green) in TULV infected Vero E6 cells 
(MOI 0.1) at 30 dpi by LSCM at 40 X magnification. The white bar 
represents 30 µm and 10 µm (zoom). Fluorescent line scans taken 
using Fiji software. Nuclei were stained with DAPI (blue), TULV NP 
detected using NP antisera and cytoskeleton using antibodies against 






Figure 47 Location of cytoskeletal markers and transfected TULV NP within Vero E6 cells. 
LSCM images of Vero E6 cells transfected with pcDNA3.1 (+) TULV NP at 18 hours post transfection using 40 X magnification. 
The white bar represents 30 µm. Nuclei were stained with DAPI (blue), TULV NP detected using NP antisera (green) and 






Figure 48 Quantification of TULV NP puncta and structures co-localising 
with cytoskeletal markers.  
Co-localisation was assessed using Fiji software. For each time point (36 
hpi, 7 dpi and 30 dpi) at least 100 TULV NP puncta/filaments were 
examined for co-localisation with actin, tubulin or vimentin 
 
 
4.3.2.2 Inhibition of actin polymerisation and degradation on TULV NP 
localisation   
To further examine the interaction of the actin cytoskeleton on TULV NP 
localisation, TULV infected Vero E6 cells were treated for 60 minutes with 10 µM 
cytochalasin D (CytD) and examined for TULV NP and actin co-localisation by 
IF  analysis. CytD causes severe disruption of the actin network by breaking 
down actin filaments into smaller fragments and binding to filament ends 
preventing re-polymerisation (Schliwa, 1982). CytD treated Vero E6 cells 
displayed cellular retraction and arborisation (branching) previously described 
(Schliwa, 1982) for CytD treatment as well as displaying disrupted actin network 
organisation where actin appear aggregated and discontinuous in comparison to 
DMSO treated cells. TULV infected Vero E6 cells displayed less dispersed 
punctate NP when treated with CtyD in comparison to DMSO mocks.  TULV NP 
perinuclear structures were still observed but appeared more condensed and 
less tubular in nature (Figure 49). This suggests actin is involved in localisation 





4.3.2.3 Inhibition of tubulin polymerisation on TULV NP localisation  
To further examine the interaction of the tubulin cytoskeleton on TULV NP 
localisation, TULV infected Vero E6 cells were treated for 60 minutes with 17 µM 
nocodazole (NOC) and examined for TULV NP and tubulin localisation by IF  
analysis. Nocodazole causes the depolymerisation of tubulin by binding to 
tubulin and preventing polymerisation (Vasquez et al., 1997). NOC treated Vero 
E6 cells displayed a reduction in tubulin staining and showed a decrease in 
microtubule structure in comparison to DMSO treated cells. NOC did not appear 
to have significant impact on TULV localisation as TULV NP was still observed 
in discrete puncta in addition to compact and tubular macromolecular structures 
as observed in mock treated Vero E6 cells (Figure 50). This suggests there is no 
reliance on microtubules for the localisation of TULV NP despite the co-
localisation with tubulin in IF. It is likely that multiple mechanisms of TULV NP 
localisation are employed where if microtubule transportation is inhibit another 
mechanism may be able to compensate.  
  
4.3.2.4 Inhibition of the motor protein dynein on TULV NP localisation 
Dynein, a cytoskeletal motor protein, transports various cargos along 
microtubules. To examine if dynein had an impact on the localisation of TULV 
NP, TULV infected Vero E6 cells were treated with 100 µM of EHNA for 24 hours 
and examined by IF . EHNA is an adenosine deaminase inhibitor which blocks 
ATPase function of dynein (Bouchard et al., 1981). EHNA treatment did not 
appear to have a significant impact on the cytoplasmic distribution of TULV NP 







Figure 49 Actin filament depolymerisation and degradation may impact TULV NP localisation at 30 dpi.  
Actin filaments were depolymerised and degraded by treating Vero E6 cells with 10 µM cytochalasin D (CytD) and observing the 
effect of this on TULV NP localisation using LSCM at 40 X magnification. The white bar represents 30 µm and 10 µm in zoomed 
images. Nuclei were stained with DAPI (blue), TULV NP detected using NP antisera (green) and actin filaments detected using 







Figure 50 Microtubule depolymerisation does not alter TULV NP localisation at 30 dpi.  
Microtubules were depolymerised by treating Vero E6 cells with 17 µM for 60 minutes. The effect of TULV NP localisation under 
these conditions was assessed by LSCM at 40 X magnification. The white bar represents 30 µm and 10 µm in zoomed images. 
Nuclei were stained with DAPI (blue), TULV NP detected using NP antisera (green) and microtubules detected using antibodies 







Figure 51 Inhibition of dynein does not alter TULV NP localisation at 30 dpi.  
The function of the motor protein dynein was inhibition by treating Vero E6 cells with 100 µM erythro-9-(2-hydroxy-3-nonyl)adenine 
(EHNA) for 24 hours. The effect of TULV NP localisation was examined using LSCM at 40 X magnification. The white bar represents 
30 µm and 10 µm in zoomed images. Nuclei were stained with DAPI (blue), TULV NP detected using NP antisera (green) and 





4.3.2.5 Effect of vimentin reorganisation on TULV NP localisation 
To further examine the interaction between vimentin filaments and TULV NP, 
and how this association influences NP localisation, TULV infected Vero E6 cells 
were treated with 400 nM okadaic acid (OA) and examined for TULV NP and 
vimentin localisation by IF  analysis at 0, 60 and 90 minutes and after recovery 
by removal of OA. OA is a 38-carbon polyether monocarboxylic acid which 
induces increased phosphorylation of vimentin Ser56 by inhibiting cellular 
phosphatases (potentially protein phosphatase 1) which induces a 
reorganisation of the vimentin network. OA mode-of-action is reversible and after 
OA removal vimentin filaments have been shown to return to normal cellular 
morphology (Lee et al., 1992; Candenas et al., 1992). 
OA had a significant impact on vimentin organisation and caused reorganisation 
of the intermediate filament at 60 and 90 minutes post treatment as vimentin 
filaments appeared disassembled and vimentin staining was concentrated 
around the cell nucleus instead of in organised filaments throughout the cell. 
Vero E6 cells were recovered by removing OA and growing for 18 hours in 2% 
media. Recovered cells displayed a more normal phenotype of vimentin 
organisation where staining was less concentrated around the cell nucleus and 
the reappearance of vimentin filaments was observed (Figure 52). 
Depolymerisation of vimentin had a significant impact on TULV NP localisation; 
at 60 and 90 minutes post-treatment, the characteristic perinuclear structures of 
NP observed at 0 minutes post-treatment and in untreated cells were no longer 
apparent. Tubular structures of TULV NP could no longer be seen and there was 
a marked reduction in the number of punctate NP in the cytoplasm and puncta 
appeared less dispersed in the cytoplasm. These results suggest vimentin 
filaments are required for the maintenance of TULV NP filaments and 
macromolecular structures. 
OA treatment also resulted in a marked reduction in cytoplasmic punctate TULV 
NP. NP distribution was less perinuclear and instead was located towards the 
outer part of the cytoplasm. When OA was removed, vimentin filaments re-
polymerised and TULV NP regained its punctate distribution and reformed 
perinuclear tubular structures. Interestingly, these NP structures appear to be 




formation and maintenance of multimeric NP structures and filaments (Figure 
52). 
 
Figure 52 Vimentin dissassembly and reorganisation alters the localisation 
of TULV NP.   
Vimentin filaments were disassembled by treatment with 400 nM okadaic 
acid (OA) for 60 and 90 minutes. Recovery of vimentin filaments was 
induced by removal of OA. Inhibition of vimentin using okadaic acid (OA) 
on TULV NP localisation using LSCM at 40 X magnification. The white bar 
represents 30 µm and 10 µm in zoomed images. Nuclei were stained with 






4.3.2.6 Section Summary 
This section describes the co-localisation and interaction of TULV NP with 
components of the host cell cytoskeleton; actin, tubulin and vimentin. The 
interaction of TULV NP with components of the host cell cytoskeleton was 
examined through co-localisation analysis and fluorescent line scan. TULV NP 
was found to strongly co-localise with microtubules. Actin filaments showed no 
co-localisation with TULV NP, at any of the time points tested. Vimentin filaments 
showed high levels of co-localisation with TULV NP during peak infections (7dpi). 
These results suggests TULV NP is transported through cells on microtubules. 
However, inhibition of host-cell cytoskeletal components revealed microtubule 
depolymerisation did not alter the localisation of TULV NP. Instead, actin filament 
depolymerisation showed slight alteration in TULV NP localisation where NP was 
less dispersed in the cytoplasm. This suggests that TULV NP may be transported 
along microtubules but the maintenance of the TULV NP compartments may 
require actin in either a transient or indirect manner.   
The disassembly of vimentin filaments had the most striking impact on the 
localisation of NP, where formation of perinuclear tubular structures of NP were 
completely abrogated and the number of cytoplasmic puncta reduced. Recovery 
of the vimentin network lead to the reformation of cytoplasmic NP structures. 
Taken together these results suggest that the vimentin network is highly 





4.3.3 Interaction of TULV NP with host cell organelles 
4.3.3.1 Interaction between TULV NP and the ER and Golgi network 
To assess the interaction of host organelles with TULV NP, the intracellular 
localisation of the endoplasmic reticulum (ER) and Golgi network was examined 
alongside TULV NP by IF analysis and fluorescent line-scan. TULV infected Vero 
E6 cells were examined at predefined early (36 hpi), peak (7 dpi) and persistent 
(30 dpi) time points. To identify the location of the ER, a fluorescently labelled 
ER stain Concanavalin A (ConA) was used. ConA is a lectin which binds 
selectively to -mannopyranosyl and -glucopyranosyl residues in the ER. ER 
staining by ConA displays characteristic staining at all time points and no co-
localisation between the ER and TULV NP was observed when examined by IF 
analysis and fluorescent line scan (Figure 53, Figure 54, Figure 55).  
The Golgi network displayed characteristic Golgi staining at 36 hpi when using 
the Golgi marker and did not co-localise with TULV NP (Figure 53). At 7 dpi, the 
Golgi network retained some characteristic staining but also large perinuclear 
structures were observed which co-localised with TULV NP staining. In addition, 
some punctate NP bodies were observed to co-localise with Golgi staining 
(Figure 54). At 30 dpi, this effect was more pronounced with infected Vero E6 
cells displaying no typical Golgi network stain and instead strong co-localisation 
with TULV NP (Figure 55). Vero E6 cells showing high concentration of TULV 
NP were observed alongside several Vero E6 displaying no infection or very low 
level TULV infection (Figure 55B). Comparison between TULV-infected and 
uninfected cells revealed TULV infection induces a decrease in granular Golgi 
staining and increase in aggregated, tubular staining which co-localises well with 
TULV NP. This suggesting that TULV infection may interfere with, or remodel, 
organisation of the Golgi network. Analysis of the spatial distribution of the Golgi 
network alongside TULV NP revealed increasing co-localisation as infection 
progressed. At early time points, very little co-localisation was observed but by 7 
dpi around 50 % of the total punctate bodies of NP displayed co-localisation with 
the Golgi stain (Figure 56).  
Recombinantly expressed TULV NP achieved by transfection of Vero E6 cells 
with pcDNA 3.1 (+) TULV S ORF was examined for co-localisation with the ER 
and Golgi network by IF analysis. In agreement with previous results from TULV 




ER. However, recombinant TULV NP co-localized with the Golgi network, 
however only non-typical Golgi staining was observed. The morphology of Golgi 
staining in transfected cells was the same as described for persistently infected 
cell cultures. Neighbouring, non-transfected, cells displayed the normal granular 
phenotype expected for the Golgi. This suggests that TULV NP alone is involved 








Figure 53 Co-localisation between TULV NP, Endoplasmic reticulum and 
Golgi network in Vero E6 cells at 36 hpi.  
The spatial distribution of the endoplasmic reticulum and the Golgi network 
(magenta) was observed alongside TULV NP (green)  in TULV infected 
Vero E6 cells  at 36 hpi using LSCM at 40 X magnification. Vero E6 cells 
were infected at MOI 0.1. The white bar represents 30 µm and 10 µm in 
zoomed images. Fluorescent line scans taken using Fiji software. Nuclei 
were stained with DAPI (blue), TULV NP detected using NP antisera, 
endoplasmic reticulum was detected using ConA stain and Golgi network 






Figure 54 Co-localisation between TULV NP, Endoplasmic reticulum and 
Golgi network in Vero E6 cells at 7 dpi.  
The spatial distribution of the endoplasmic reticulum and the Golgi network 
(magenta) was observed alongside TULV NP (green)  in TULV infected 
Vero E6 cells  at 7 dpi using LSCM at 40 X magnification. Vero E6 cells 
were infected at MOI 0.1. The white bar represents 30 µm and 10 µm in 
zoomed images. Fluorescent line scans taken using Fiji software. Nuclei 
were stained with DAPI (blue), TULV NP detected using NP antisera, 
endoplasmic reticulum was detected using ConA stain and Golgi network 






Figure 55 Co-localisation between TULV NP, Endoplasmic reticulum and 
Golgi network in Vero E6 cells during persistent infection. 





Figure 55 Co-localisation between TULV NP, Endoplasmic reticulum and 
Golgi network in Vero E6 cells during persistent infection. 
A) The spatial distribution of the endoplasmic reticulum and the Golgi 
network (magenta) was observed alongside TULV NP (green)  in TULV 
infected Vero E6 cells  at 30 dpi using LSCM at 40 X magnification. Vero 
E6 cells were infected at MOI 0.1. B) TULV infected Vero E6 cells  at 30 dpi 
displaying a population of uninfected cells (white arrow) alongside an 
infected cell (yellow arrow) The white bar represents 30 µm and 10 µm in 
zoomed images. Fluorescent line scans taken using Fiji software. Nuclei 
were stained with DAPI (blue), TULV NP detected using NP antisera, 
endoplasmic reticulum was detected using ConA stain and Golgi network 






Figure 56 Quantification of TULV NP puncta and structures co-localising 
with Golgi markers.  
Co-localisation was assessed using Fiji software. For each time point (36 
hpi, 7 dpi and 30 dpi) at least 100 TULV NP puncta/filaments were 









Figure 57 Location of endoplasmic reticulum and Golgi network with transfected TULV NP within Vero E6 cells.  
LSCM images of Vero E6 cells transfected with pcDNA3.1 (+) TULV NP at 18 hours post transfection using 40 X magnification. The 
white bar represents 30 µm. Nuclei were stained with DAPI (blue), TULV NP detected using NP antisera (green), endoplasmic 





4.3.4 Interaction of TULV NP with host cell stress granules and P 
bodies  
4.3.4.1 Co-localisation between TULV NP, stress granules and P bodies 
TIA-1 is one of several proteins involved in the formation of stress granules and 
therefore can be used as a stress granule marker whereas DCP1a is an mRNA 
decapping enzyme and can be used as a positive marker for P bodies. Previous 
studies on orthohantaviruses have suggested NP localises to P bodies and binds 
to the capped 5’-ends of host cell mRNAs. The capped mRNAs are used as a 
substrate by the RdRp to act as primers for viral transcription. As TULV NP forms 
multiple puncta in the cytoplasm during infection it is likely a percentage of these 
puncta co-localise with P bodies to carry out this “cap-snatching” role (Garcin et 
al., 1995; Mir and Panganiban, 2010; Cheng and Mir, 2012). In addition, stress 
granule formation is a known response to viral infection. Several viruses have 
been shown to interact with components of stress granules such as DENV, 
CHIKV and WNV (Emara and Brinton, 2007; Fros et al., 2012).  
To examine the possibility of interaction between TULV NP with either stress 
granules or P bodies, IF  examination and fluorescent line scan analysis was 
carried out on TULV infected Vero E6 cells using specific antisera for NP, DCP1a 
and TIA-1.   
Throughout all time points examined, DCP1a retained its characteristic punctate 
distribution throughout the cytoplasm (Figure 58,Figure 59,Figure 60). TIA-1 
signal was barely detectable at early time points suggesting initial infection does 
not upregulate expression of TIA-1 (Figure 58) which is also consistent with the 
ability of TULV to avoid or supress host cell pathogen surveillance mechanisms. 
However, the TIA-1 signal increased throughout peak and persistent infection 
time points suggesting TULV infection had upregulated TIA-1 expression as 
infection progressed (Figure 59, Figure 60). The upregulation of TIA-1 is 
indicative of a cell undergoing the stress response due to viral infection.  
At 36 hpi, very little co-localisation was observed between TULV NP and the 
signal for DCP1a and TIA-1 (Figure 58). At 7 and 30 dpi, IF analysis showed TIA-
1 co-localised with TULV NP, especially in condensed TULV NP structures in the 
perinuclear region. TIA-1 structures observed in the cytoplasm during infection 
are punctate and granular which phenotypically resembles stress granules (Sola 




Stress Granule Assembly Factor) in these locations which would have led to 
positive identification of stress granule formation (data not shown). G3BP1 is a 
DNA-unwinding enzymes which localises to stress granules along with TIA-1.  
In contrast, DCP1a signals did not co-localise with TULV NP structures at either 
7 or 30 dpi time points, although DCP1a puncta were proximal to TULV NP 
puncta, as shown by fluorescent line scan (Figure 59, Figure 60). The distribution 
of DCP1a as distinct puncta throughout the cytoplasm remained constant 
throughout infection suggesting TULV infection does not upregulate formation of 
P bodies.  
In order to provide a quantitative measurement of the extent of co-localization, 
TULV NP in both puncta and macromolecular structures were examined for co-
localisation with TIA-1 or DCP1a by fluorescent line scan and counted. This 
revealed that low levels of TULV NP co-localised with DCP1a at all time points 
with little increase over the time course. However, TIA-1 co-localised with around 
40 % of TULV NP structures and puncta at 7 dpi and 30 dpi (Figure 59, Figure 
60).  
Recombinantly expressed TULV NP in Vero E6 was examined for interaction 
with stress granule marker, TIA-1, and P body marker, DCP1a, by IF analysis. In 
agreement with previous results from TULV infected Vero E6 cells, there was no 
co-localisation of recombinant TULV NP with DCP1a. However, recombinant 
TULV NP did co-localise with TIA-1 suggesting that TULV NP alone interacts 
with TIA-1 and may induce the formation of stress granules or stress granule like 







Figure 58 Co-localisation of stress granules and P bodies with TULV NP in 
Vero E6 cells at 36 hpi.  
The spatial distribution of stress granules (TIA-1) and P bodies (DCP1a) 
(magenta) was observed alongside TULV NP (green) in TULV infected 
Vero E6 cells at 36 hpi by LSCM at 40 X magnification. Vero E6 cells were 
infected at MOI 0.1. The white bar represents 30 µm and 10 µm in zoomed 
images. Fluorescent line scans taken using Fiji software. Nuclei are stained 
with DAPI (blue), TULV NP detected using NP antisera and cytoskeleton 






Figure 59 Co-localisation of stress granules and P bodies with TULV NP in 
Vero E6 cells at 7 dpi.  
The spatial distribution of stress granules (TIA-1) and P bodies (DCP1a) 
(magenta) was observed alongside TULV NP (green) in TULV infected 
Vero E6 cells at 7 dpi by LSCM at 40 X magnification. Vero E6 cells were 
infected at MOI 0.1. The white bar represents 30 µm and 10 µm in zoomed 
images. Fluorescent line scans taken using Fiji software. Nuclei are stained 
with DAPI (blue), TULV NP detected using NP antisera and cytoskeleton 






Figure 60 Co-localisation of stress granules and P bodies with TULV NP in 
Vero E6 cells during persistent infections.  
The spatial distribution of stress granules (TIA-1) and P bodies (DCP1a) 
(magenta) was observed alongside TULV NP (green) in TULV infected 
Vero E6 cells at 30 dpi by LSCM at 40 X magnification. Vero E6 cells were 
infected at MOI 0.1. The white bar represents 30 µm and 10 µm in zoomed 
images. Fluorescent line scans taken using Fiji software. Nuclei are stained 
with DAPI (blue), TULV NP detected using NP antisera and cytoskeleton 







Figure 61 Detection of stress granule and P body markers and transfected TULV NP.  
LSCM images of Vero E6 cells transfected with pcDNA3.1 (+) TULV NP at 18 hours post transfection using 40 X magnification. The 
white bar represents 30 µm. Nuclei were stained with DAPI (blue), TULV NP detected using NP antisera (green) and stress granule 





Figure 62 TULV NP puncta and structures co-localising with stress 
granule or P body markers.  
Co-localisation was assessed using Fiji software. For each time point (36 







4.3.5 Interaction of TULV NP with host cell trafficking proteins 
4.3.5.1 Co-localisation between TULV NP and endosomes, lysosomes 
and transport vesicles  
To further assess the intracellular location of TULV NP and examine whether 
it associated with trafficking proteins, IF analysis and fluorescent line scan 
analysis was carried out of TULV NP and the trafficking proteins Rab5 (early 
endosomes), Rab7 (early to late endosomes), Rab11, (early, late and 
recycling endosomes), LAMP1 (lysosomes) and clathrin (clathrin-coated 
vesicles). 
At 36 hpi and 30 dpi these various trafficking markers showed characteristic 
granular straining patterns expected of trafficking vesicles (Figure 63, Figure 
65). At 36 hpi, some puncta of TULV NP displayed co-localisation of puncta 
of Rab5, Rab11 and clathrin suggesting that these proteins may be utilised 
for the trafficking of TULV NP at early stages in the lifecycle. Co-localisation 
with Rab5, Rab11 and clathrin was only observed within cytoplasmic puncta 
and not within tubular structures in the perinuclear region (Figure 63 
Figure 63 Co-localisation of trafficking proteins with TULV NP in Vero E6 
cells at 36 hpi.   
, Figure 64). No co-localisation was observed for TULV NP with Rab7 or 
LAMP1. The lack of co-localisation with LAMP suggests, for TULV infections, 
entry into lysosomes is not required during the virus lifecycle (Figure 63, 
Figure 64). At 30 dpi, clathrin displayed co-localisation with a few TULV NP 
puncta within the cytoplasm. Puncta co-localising with clathrin tended to be 
larger in size. Clathrin vesicles observed in uninfected cells were on average 
~ 0.7 µm in diameter whereas the diameter of clathrin vesicles co-localising 
with TULV NP were 1.5-2.5 µm diameter. No other trafficking proteins were 








Figure 63 Co-localisation of trafficking proteins with TULV NP in Vero E6 





Figure 63 Co-localisation of trafficking proteins with TULV NP in Vero E6 
cells at 36 hpi.   
The spatial distribution of the trafficking proteins; Rab5 (early 
endosome), Rab7 (early/late endosome), Rab11 (early late, recycling 
endosome), LAMP1 (lysosome) and clathrin (coated vesicles) (magenta) 
was observed alongside TULV NP (green) in TULV infected Vero E6 
cells at 36 hpi by LSCM at 40 X magnification. Vero E6 cells were 
infected at MOI 0.1. The white bar represents 30 µm. Nuclei are stained 
with DAPI (blue), TULV NP detected using NP antisera and trafficking 
proteins detected using antibodies against Rab5, Rab7, Rab11, LAMP1 







Figure 64 Co-localisation of trafficking proteins with TULV NP in Vero E6 





Figure 64 Co-localisation of trafficking proteins with TULV NP in Vero E6 
cells at 36 hpi.   
The spatial distribution of Rab5, Rab7, Rab11, LAMP1 and clathrin 
(magenta) was observed alongside TULV NP (green) in TULV infected 
Vero E6 cells at 36 hpi by LSCM at 40 X magnification. Images are zoom 
versions of co-localisations seen in Figure 63. The white bar represents 
10 µm. Fluorescent line scans taken using Fiji software. Nuclei are 
stained with DAPI (blue), TULV NP detected using NP antisera and 
trafficking proteins detected using antibodies against Rab5, Rab7, 






Figure 65 Co-localisation of trafficking proteins with TULV NP in Vero E6 





Figure 65 Co-localisation of trafficking proteins with TULV NP in Vero E6 
cells during persistent infections.   
The spatial distribution of the trafficking proteins; Rab5 (early 
endosome), Rab7 (early/late endosome), Rab11 (early late, recycling 
endosome), LAMP1 (lysosome) and clathrin (coated vesicles) (magenta) 
was observed alongside TULV NP (green) in TULV infected Vero E6 
cells at 30 dpi by LSCM at 40 X magnification. Vero E6 cells were 
infected at MOI 0.1. The white bar represents 30 µm. Nuclei are stained 
with DAPI (blue), TULV NP detected using NP antisera and trafficking 








Figure 66 Co-localisation of trafficking proteins with TULV NP in Vero E6 





Figure 66 Co-localisation of trafficking proteins with TULV NP in Vero E6 
cells during persistent infections.  
The spatial distribution of Rab5, Rab7, Rab11, LAMP1 and clathrin 
(magenta) was observed alongside TULV NP (green) in TULV infected 
Vero E6 cells at 30 dpi by LSCM at 40 X magnification. Images are zoom 
versions of co-localisations seen in Figure 65. The white bar represents 
10 µm. Fluorescent line scans taken using Fiji software. Nuclei are 
stained with DAPI (blue), TULV NP detected using NP antisera and 
trafficking proteins detected using antibodies against Rab5, Rab7, 







4.3.6 Interaction of TULV NP with host cell cleaved caspase-3  
4.3.6.1 TULV infection interferes with apoptotic induction  
To examine the apoptotic response of Vero E6 cells to TULV infection, cell 
lysates were collected every 24 hpi up to 10 dpi and again at 30 dpi and 
examined for the presence of the apoptotic markers caspase-3 (casp-3), 
cleaved caspase-3 (casp-3C) and cleaved poly (ADP-ribosome) polymerase 
(PARP-C). Caspase-3 was detected in cell lysates and increased in 
abundance in later time points consistent with the GAPDH loading control. 
Active casp-3C, indicative of apoptosis induction, was detected in TULV cell 
lysates from 5-6 dpi and increased in abundance up to the final time point of 
30 dpi. This suggested that TULV was an inducer of apoptosis in cell culture, 
however a lack of PARP-C was evident at 6-10 dpi and only a moderate 
amount of PARP-C observed at 30 dpi. This further suggests, that although 
the apoptotic marker casp-3C was present in TULV infected cell cultures, it 
failed to trigger cell death. One possibility was that the activity of a TULV 
component suppressed or blocked the induction of apoptosis (Figure 67).  
 
 
Figure 67 Detection of TULV NP with caspase 3 and PARP during TULV 
infection.  
Left hand panel displays TULV cell lysates collected from 0-10 dpi and 
30 dpi examined for the presence on casp-3, casp-3C, PARP-C and 





4.3.6.2 Interaction between active caspase-3 and TULV NP  
The results described above suggest that the activity of the executioner casp-
3C may be supressed in TULV-infected cells. Thus, the intracellular location 
of both active caspase-3 and TULV NP was examined in individual TULV 
infected Vero E6 cells using indirect IF and fluorescent line scan analysis 
within cells at early, peak and persistent infection time points. At 36 hpi, TULV 
NP staining was abundant within infected cells whereas minimal signal for 
casp-3C was observed. However, casp-3C was abundant in uninfected 
bystander cells suggesting apoptotic induction (Figure 68, Figure 70). This 
may be due to these bystander cells receiving indirect recognition signals from 
adjacent TULV-infected cells, thus inducing an apoptotic state. Fluorescent 
line-scan analysis revealed clear segregation of TULV NP staining from casp-
3C staining in the adjacent TULV-infected and bystander cells (Figure 68). To 
quantify this observation, the number of infected (TULV NP stained) cells and 
uninfected cells were counted, which revealed casp-3C staining in over 60 % 
of bystander cells but only in 4 % of TULV-infected cells (Figure 70). This is 
supported by imaging of TULV infected cells using WFDM where increased 
signal for casp-3C can be detected in uninfected bystander cells and low 
signal casp-3C is detected in TULV infected cells (Figure 69A). 
At 7 dpi and 30 dpi, TULV NP punctate bodies and perinuclear cytoplasmic 
structures exhibited co-localisation staining with casp-3C, and fluorescent line 
scan analysis revealed that this co-localisation was consistent between the 
two markers (Figure 68). Further examination of co-localisation of TULV NP 
and casp-3C in persistently infected cells was carried out using WFDM to 
enhance detection sensitivity. WFDM revealed that TULV infected cells 
exhibited casp-3C staining within discrete cytoplasmic puncta. While some 
casp-3C staining were distinct from TULV NP localisation, a high level of co-
localisation was observed to be contained within TULV puncta. Analysis of the 
spatial distribution of the two proteins using fluorescent line scan revealed 
confirmed co-localising signals. Interestingly, TULV NP puncta display the 
characteristic ‘M’ shape of a hollow vesicle with casp-3C localising within this 











Figure 68 Co-localisation of cleaved caspase 3 with TULV NP in Vero 
E6 cells.  
The spatial distribution of casp-3C (magenta) observed alongside TULV 
NP (green) in TULV infected Vero E6 cells at 36 hpi, 7 dpi and 30 dpi by 
LSCM at 40 X magnification. Cells infected at MOI 0.1. The white bar 
represents 30 µm and (10 µm). Fluorescent line scans taken using Fiji 
software. Nuclei are stained with DAPI (blue), TULV NP detected using 






Figure 69 Co-localisation of cleaved caspase 3 with TULV NP in Vero E6 




Figure 69 Co-localisation of cleaved caspase 3 with TULV NP in Vero E6 
cells during early and persistent infections through WFDM. 
The spatial distribution of casp-3C (magenta) observed alongside TULV 
NP (green) in TULV infected Vero E6 cells at 36 hpi and 30 dpi WFDM 
100 X magnification. Cells were infected at MOI 0.1. The white bar 
represents 30 µm and (10 µm zoom). Fluorescent line scans taken using 
Fiji software. Nuclei are stained with DAPI (blue), TULV NP detected 






4.3.6.3 TULV NP is cleaved in infected cells and associates with casp-
3C 
The interaction of TULV NP and casp-3C is not unique among the 
hantaviruses. For other orthohantavirus species; ANDV, DOBV and PUUV, 
recombinant casp-3C has been shown to mediate cleavage of NP in cell-free 
assays (Solà-Riera et al., 2019). For ANDV, casp-3C cleaves ANDV at the 
sequence, DLID285, which conforms to the DXXD consensus motif for 
caspase-3 cleavage (Gupta et al., 2013). Analysis of the TULV NP sequence, 
revealed the presence of an identical DLID motif. However, while this DLID 
motif was represent in the NP sequence from ANDV and TULV it was absent 
in HTNV, PHV and SEOV (Figure 71A). Cleavage at this site was predicted to 
generate TULV NP fragments of approximately 32 kDa and 16 kDa. TULV cell 
lysates were examined for NP-derived cleavage products by western blotting 
using anti-NP antisera which revealed the presence of NP cleavage products 
matching the predicted masses (Figure 71B). The 16 kDa fragment was 
detected with high abundance from 3 dpi suggesting NP cleavage occurs early 
during TULV infection. This represents the first detection of caspase-mediated 
hantavirus NP cleavage in infected cells. 
To further examine the TULV NP and casp-3C interaction, co-
immunoprecipitation analysis was performed. Western blot analysis revealed 
the presence of full-length NP and the NP cleavage products (32 kDa and 16 
kDa) along with abundant casp-3C (Figure 72) suggesting that the interaction 






Figure 70 Bystander cells display signal for cleaved caspase 3.  
LSCM images of TULV infected cells examined for cleaved caspase 3 
signal at 36 hpi. The white bar represents 30 µm. Nuclei were stained 
with DAPI (blue), TULV NP detected using NP antisera (green) and casp-
3C (magenta). TULV infected cells are highlighted using the dotted white 
line. Percentage of TULV infected cells and bystander cells displaying 






Figure 71 TULV NP possesses a caspase-3 cleavage site.  
A) Multiple sequence alignment of TULV, SEOV, HTNV, PHV and ANDV 
NP protein sequences carried out in Clustal W and analysed using 
Jalview software. Red box highlights the identified caspase-3 cleavage 
sites B) TULV cell lysates examined for the presence of TULV NP (FL 
NP) and the cleavage products at 32.4 kDa (*) and 16 kDa (**) assessed 
by western blot using SEOV NP antisera  
 
 
Figure 72 Co-immunoprecipitation of TULV NP with cleaved caspase-3.  
Co-immunoprecipitation of full length TULV NP and NP cleavage 
products from cell lysates from TULV 30 dpi and mock-infected cells. Full 
length NP (FL NP) (50 kDa) and casp-3C (17 kDa) were detected, along 
with TULV NP cleavage products with molecular masses of 32.4 kDa (*) 
and 16 kDa (**) assessed by western blot using SEOV NP antisera and 




4.3.7 Section summary 
This section describes the co-localisation and interaction of TULV NP with 
host cell components including the endoplasmic reticulum, Golgi network, 
Stress granules, P bodies and trafficking proteins. TULV NP forms distinct 
punctate granules throughout the cytoplasm of infected cells and additionally 
forms filaments in the perinuclear region. These structures are likely to co-
localise with compartments, vesicles or organelles within the host cell as 
viruses are required to co-opt host cell functions in order to carry out their 
lifecycles. In order to explore which host cell components might interact with 
these NP structures and co-localisation analysis. It was found that perinuclear 
TULV NP structures and some punctate NP co-localised with the Golgi 
network through early, peak and persistent time points. During later time 
points, the characteristic granular Golgi network staining was reduced in 
infected cells and instead co-localised with tubular formations of TULV NP. 
This suggests that NP may accumulate in and alter the organisation of the 
Golgi.  Additionally, NP was found to co-localise with the stress granule 
marker, TIA-1, which may act to sequester TIA-1 away from other components 
required for stress granule formation and in doing so inhibit the cellular stress 
response to infection.  
TULV infected cell lysates were found to contain the presence of casp-3C from 
5-6 dpi but not the presence of PARP-C suggesting a block in the apoptotic 
cascade. TULV NP was found to co-localises with casp-3C and sequesters it 
in NP-coated vesicles which may spatially separate it from its downstream 
effector PARP and delay apoptosis. Additionally, the TULV NP ORF was 
found to contain the casp-3C consensus motif ‘DLID’ and to form predicted 
cleavage products of ~32 kDa and ~16 kDa. These results suggest TULV NP 











Chapter 5 : Identifying the replication sites of TULV in vitro  
   
5.1 Chapter introduction  
This chapter describes an investigation into the location of orthohantavirus 
replication factories, where viral RNA synthesis and possibly virion assembly 
takes place. In order to identify these replication sites, the localisation of newly 
synthesised TULV RNA was attempted by labelling viral RNA using click-
chemistry to incorporate an alkyne-tagged uridine analogue (5EU) which 
could be detected using an aldehyde-tagged fluorophore. In addition to this, 
the localisation of accumulated viral RNAs was identified using RNA-FISH 
probes designed against the sense and anti-sense TULV S segment RNA 
sequences. Furthermore, TULV infected Vero E6 cells were analysed for the 
localisation of RNA and TULV NP alongside target host components identified 
in the previous chapter, namely the Golgi network marker and stress granule 
marker TIA-1. 
 
5.2 Results: Identification of TULV replication sites  
 
5.2.1 Introduction to methods for labelling viral RNA 
5.2.2 Click-IT(TM) RNA Imaging  
Click-IT™ RNA imaging utilises click chemistry, which relies upon an azide-
alkyne coupling reaction to specifically label nascent RNA within cells (Jao 
and Salic, 2008). This is achieved using an alkyne-labelled nucleoside, 5-
ethynyl uridine (5EU) that is recognised by cellular and viral RNA polymerases 
and is metabolically-incorporated into growing RNA strands. The subsequent 
addition of an azide-labelled fluorophore allows the location of the newly 
synthesised 5EU-incorporated RNA to be identified by confocal microscopy 
within fixed and permeabilized cells (Jao and Salic, 2008) (Figure 73). As 5EU 
is recognized as a substrate by both cellular and viral RNA polymerases, 
selective incorporation into viral transcripts is achieved by incubating cells with 
actinomycin D to inhibit host cell DNA-directed RNA synthesis. The azide-
alkyne coupling reaction rate is low, so catalytic amounts of copper (Cu(I) or 




reaction selectivity (Rostovtsev et al., 2002; Breinbauer and Köhn, 2003). This 
method has been previously used for the labelling of coronavirus RNA (a 
positive sense RNA virus) and hRSV RNA (a non-segmented negative-sense 
RNA virus) (Hagemeijer et al., 2012; Rincheval et al., 2017).  
 
Figure 73 Click chemistry reaction between alkyne-modified EU and 
azide-modified fluorophore.  
  Click chemistry reaction between alkyne-modified EU and azide-
conjugated fluorophore in the presence of copper for the labelling of 
nascent RNAs. Taken from Invitrogen, Thermo Fisher Scientific  
 
5.2.2.1 RNA FISH 
The visualisation of RNA molecules can be achieved through the use of RNA 
fluorescent in situ hybridisation (FISH). The system used here depends on the 
ability of custom designed DNA oligonucleotide probes complementary to the 
RNA molecule of interest, which in this case was the sense and anti-sense 
TULV S segment RNA sequences. Each probe set targets a specific RNA and 
comprises a minimum of 25 individually labelled oligonucleotides that 
hybridize at non-overlapping locations on the same RNA target, thus allowing 
molecule-specific detection with a high signal to noise ratio. Fixed cells are 
permeabilised before incubating with a probe set and probes can be visualised 





Figure 74 Labelling cells through RNA-FISH hybridisation.  
A) Cells are fixed and permeabilised with alcohol. B) Probes are mixed 
and added to cells. C) RNA-FISH probes hybridise to target RNAs within 
cell at complementary regions D) Cells are imaged using fluorescent 
microscopy. Taken from Stellaris®   
 
5.2.2.2 Identifying viral replication factories by RNA labelling  
The location of several viral replication factories have been identified through 
the use of RNA labelling techniques. Cytoplasmic inclusion bodies (IBs) were 
identified as replication sites for hRSV through the use of 5EU labelling via 
click-chemistry. These IBs were further characterised by RNA FISH and it was 
found they contained exclusively viral genomes, whereas viral mRNAs were 
concentrated instead within alternative granular structures located elsewhere 
in the cytoplasm (Rincheval et al., 2017). RNA-FISH was also used to show 
that rabies virus replication factories were located within Negri bodies (NBs), 
in which all viral transcripts as well as genomic RNAs were located. The NBs 
were also shown to be the sites of on-going RNA synthesis, identified through 
the metabolic incorporation of bromo-uridine triphosphate (Br-UTP), an 
alternative strategy for detection of incorporated nucleotides that relies on 
subsequent immunological detection (Lahaye et al., 2009). Labelling of LCMV 
genomes by RNA-FISH identified early endosomes as a scaffold for viral 
replication (King et al., 2017). Taken together, these reports provide 
precedence for both the use of FISH and the metabolic incorporation of 









5.2.3 Utilising click-IT chemistry for labelling nascent TULV RNA  
 
Figure 75 Labelling newly synthesised TULV RNA utilising 5EU in Vero 
E6 cells at 4 dpi.  
Nascent TULV RNA labelled using click-iT™ chemistry. White bar 
represents 30 µm. LSCM of TULV infected Vero E6 cells (MOI 0.1) at 4 
dpi using 40X magnification. Nuclei stained using DAPI (blue) and newly 
synthesised RNA labelled with azide-conjugated fluorophore (red).  
 
5.2.3.1 Nascent TULV RNA visualised using click-iT™ chemistry  
To identify orthohantavirus replication sites of in vitro, 5EU was incorporated 
during viral replication into nascent viral RNAs and these were detected using 
an azide-conjugated fluorophore. Sites of viral replication were detected using 
LSCM. Discrete puncta of fluorescence was detected in the perinuclear region 
of TULV infected Vero E6 cells (Figure 75, top panel). These puncta were 
around 0.5-1.5 µm in diameter. Actinomycin D untreated cells were used as a 
positive control to display effectiveness of the 5EU incorporation. As seen in 
Figure 75, bottom panel, nuclei were stained red showing labelling of host cell 
RNA during the DNA-dependant RNA polymerization of mRNA transcripts. 
Attempts were made to co-stain TULV infected cells with 5EU and NP anti-




5.2.4 Co-localisation of sense and anti-sense TULV S segment 
RNA with TULV NP  
5.2.4.1 TULV S segment RNA co-localises with TULV NP  
Metabolic labelling provided information on the location of newly produced 
viral RNAs however there was no discrimination between RNAs involved in 
replication or transcription. Therefore RNA-FISH probes were designed 
specifically to recognise either sense (transcription/replication) or anti-sense 
(replication) S segment RNA and provide greater resolution to the localisation 
of RNAs involved in replication and transcription. The localisation of sense or 
anti-sense TULV S segment RNA alongside the signal for TULV NP was 
examined using RNA-FISH and NP antisera by LSCM and WFDM. The TULV 
anti-sense RNAs generated during infection comprises exclusively genomic 
RNAs, thus the anti-sense signal corresponds to viral RNA replication. In 
contrast, TULV sense RNAs will include both anti-genomic replication 
products and also mRNA transcripts. However, previous work with other 
bunyaviruses shows the abundance of antigenomic replication products is 
likely several orders of magnitude less than mRNAs, (Barr et al., 2003) thus 
the vast majority of the sense RNA signal will represent mRNA transcription 
products. TULV NP is the major structural component of the RNP, which forms 
the template for both mRNA transcription and also RNA replication, thus 
detection of NP is predicted within regions where all forms of viral RNAs are 
being made. 
At 36 hpi the majority of sense and anti-sense TULV S segment RNA closely 
co-localised with TULV NP in strand-like structures, with the morphology of 
the stained areas of both RNA and NP being superimposable. These strands 
were 4.0-8.5 µm in length with a diameter of ~ 0.7 µm and were dispersed 
throughout the cytoplasm. Anti-sense RNA also co-localised with larger 
punctate NP structures in the cytoplasm with an average diameter of ~1.5 µm 
(Figure 76, Figure 79A), and as described above for the strand-like structures, 
the areas staining for both RNA and NP were essentially superimposable. Not 
all TULV NP co-localised with TULV RNA, which is in agreement with previous 
studies stating TULV NP possesses alternative roles in addition to its role as 




At 7 dpi, the distribution of TULV RNA was similar to that observed at 36 hpi, 
however, there was little evidence of NP-RNA structures dispersed throughout 
the cytoplasm. Instead, sense and anti-sense RNA co-localised with 
filamentous and tubular NP structures in the perinuclear region within either 
large accumulations of 5.0-10.0 µm diameter or in thinner arrangements of 
1.0-3.0 µm in diameter and up to 25 µm in length that appear to wrap around 
the nucleus. Some RNA also co-localised with NP within perinuclear puncta 
of around 1.0-2.0 µm diameter (Figure 77, Figure 79B). These punctate NP 
structures contained lower quantities of sense or antisense RNA compared to 
perinuclear compartments as seen in Figure 77. As above, for the most part, 
areas of both NP and RNA staining appeared to precisely coincide within the 
two-dimensional section, strongly suggesting these components occupy the 
same three-dimensional space. Also, in agreement with observations at 36 
hpi, not all TULV NP co-localised with TULV RNA, suggestive of additional 
roles for NP outside of RNP assembly. This is also shown through the co-
localisation threshold overlap score (TOS), where the overlap value of viral 
RNA and NP increases as the infection progresses, consistent with 
accumulation of viral RNA. However the TOS never reaches a score of 1 
which would indicate every NP signal colocalised with S segment RNA (Figure 
80).  
In persistently infected cells at 30 dpi, accumulation of sense and anti-sense 
S segment RNA was also observed in the macromolecular tubular filamentous 
NP structures. These tubular structures, similarly to 7 dpi, existed as either 
extensive bundles of filaments up to 25 µm in diameter or as a few individual 
thinner strands of ~0.7 µm in diameter (Figure 78, Figure 79). These structures 
either appear to be individual filamentous structures or tubes as seen in the 
3D projection of stacked optical sections (Figure 81). 
TULV RNA also co-localised with larger some punctate NP in the cytoplasm. 
The majority of these puncta occurring within the cytoplasm but close to the 
plasma membrane. Most TULV NP puncta containing TULV RNA were 1.0-
1.8 µm in diameter with some puncta as large as 2.0 µm in diameter (Figure 
78, Figure 79C). Additionally, the concentration of RNA in large punctate NP 
appears to be much higher and similar to the concentration found in 




by qRT-PCR analysis (Chapter 4, Figure 38), accumulation of both sense or 
anti-sense S segment RNAs increased with time up to 10 dpi, as did NP 
abundance. Through IF analysis, all signals corresponding to TULV RNAs 
closely co-localised with TULV NP at each time point examined (36 hpi, 7 dpi 
and 30 dpi). There was no apparent difference in the localisation of sense or 
anti-sense RNA as both localise to perinuclear NP structures and cytoplasmic 
NP puncta.  
In summary, both sense and anti-sense TULV RNA localized within two 
distinct morphological structures, namely punctate bodies and filamentous 
structures. Both these types of structures were present in all time points, and 
both closely colocalized with NP such that their signals were overlapping. 
However, a fraction of the punctate NP structures did not colocalize with RNA, 
thus suggesting TULV NP possesses one or more alternative roles other than 
RNP formation. The size of RNA and NP colocalizing structures increased 
throughout the time course, and at the 30 dpi time points, the RNA-NP 
assemblies occupied a significant proportion of the cell volume, approaching 








Figure 76 Co-localisation between TULV NP and TULV S segment RNA in 






Figure 76 Co-localisation between TULV NP and TULV S segment RNA in 
Vero E6 cells at 36 hpi.  
The spatial distribution of TULV NP (green) and S segment RNA (red) was 
observed at 36 hpi using LSCM at 40 X magnification. Vero E6 cells were 
infected at MOI 0.1. The white bar represents 30 µm and 10 µm (zoom). 
Fluorescent line scans taken using Fiji software. Nuclei are stained with 
DAPI (blue), TULV NP detected using NP antisera and S segment RNA 









Figure 77 Co-localisation between TULV NP and TULV S segment RNA in 






Figure 77 Co-localisation between TULV NP and TULV S segment RNA in 
Vero E6 cells at 7 dpi.  
The spatial distribution of TULV NP (green) and S segment RNA (red) was 
observed at 7 dpi using LSCM at 40 X magnification. Vero E6 cells were 
infected at MOI 0.1. The white bar represents 30 µm and 10 µm (zoom). 
Fluorescent line scans taken using Fiji software. Nuclei are stained with 
DAPI (blue), TULV NP detected using NP antisera and S segment RNA 







Figure 78 Co-localisation between TULV NP and TULV S segment RNA in 





Figure 78 Co-localisation between TULV NP and TULV S segment RNA 
in Vero E6 cells at 30 dpi.  
The spatial distribution of TULV NP (green) and S segment RNA (red) 
was observed at 30 dpi using LSCM at 40 X magnification. Vero E6 cells 
were infected at MOI 0.1. The white bar represents 30 µm and 10 µm 
(zoom). Fluorescent line scans taken using Fiji software. Nuclei are 
stained with DAPI (blue), TULV NP detected using NP antisera and S 







Figure 79 Co-localisation between TULV NP and TULV S segment RNA in 





Figure 79 Co-localisation between TULV NP and TULV S segment RNA in 
Vero E6 cells using WFDM.  
The spatial distribution of TULV NP (green) and S segment RNA (red) was 
observed during early, peak and persistent infection using WFDM at 100 X 
magnification. Vero E6 cells were infected at MOI 0.1. The white bar 
represents 30 µm (zoom). Nuclei are stained with DAPI (blue), TULV NP 
detected using NP antisera and S segment RNA detected using sense or 
anti-sense RNA FISH probes. A) Vero E6 cells at 36 hpi, B) Vero E6 cells 








Figure 80 Co-localisation analysis of TULV NP and S Segment RNA. 
Co-localisation of Figure 76, Figure 77 and Figure 78 were analysed using 
FIJI plugin EzColocalization. Scatter plots pictorially representing co-
localisation were produced and the threshold overlap score (TOS) 








Figure 81 Three-dimensional co-localisation of TULV NP and anti-sense S 
segment RNA in persistently infected cells.  
LSCM of TULV infected cells at 30 dpi using 40 X magnification. The white 
bar represents 30 µm. Nuclei are stained with DAPI (blue), TULV NP 
detected using NP antisera (green) and S segment RNA detected anti-
sense RNA FISH probes (red). Images were taken on 40 different focal 
planes and stacked. A) Represents one focal plane of the hyper-stack, 
section 9 of 40, B) Orthogonal view of hyper-stacked images using Fiji 
software C) 3D reconstruction of persistently infected cells using 3D viewer 








5.2.5 Disruption of multimeric NP has a negative effect on production 
of TULV RNA  
5.2.5.1 Okadaic acid treatment of TULV persistently infected Vero E6 cells 
reduces viral genome copies  
As previously shown in Chapter Four, section 4.3.2.5, treatment with okadaic 
acid (OA) resulted in the depolymerisation of vimentin filaments and disruption 
of the perinuclear tubular/filamentous NP structures. The accumulation of sense 
and anti-sense TULV S segment RNA with tubular NP structures suggests that 
viral replication and possibly storage of viral RNAs may occur within these 
regions. Consequently, disruption of these tubular NP structures would be 
predicted to cause a reduction in total cellular RNA genome copy number, either 
due to abrogated genome replication and/or release of viral RNA into the 
cytoplasm followed by its degradation. 
Vero E6 cells were infected with TULV and at either 3 dpi or 30 dpi were treated 
with 400 nM OA and incubated for 30, 60 and 90 minutes before harvesting. As 
a drug treatment control, the effect of 17 µM NOC on viral genome copy numbers 
was also assessed. As NOC did not appear to significantly affect the structure of 
tubular NP, it was expected this would not reduce viral copy numbers but would 
give a measure of control for drug-induced cytopathology. The number of TULV 
genome copies in the cytoplasm were assessed by qRT-PCR. As expected, 
treatment with OA at 30, 60 and 90 minutes reduced TULV genome copies/mL 
relative to NOC treatment which did not reduce TULV genome copies/mL when 
compared to mock-treated cells. This effect could be replicated at both 3 dpi and 
30 dpi (Figure 82). This suggests vimentin polymerisation is important for the 







Figure 82 Okadaic acid treatment of TULV infected Vero E6 cells decreases 
viral genome copies.  
TULV infected Vero E6 cells at 3 dpi (A) and 30 dpi (B) were treated with 
400 nM okadaic acid (OA) for 30, 60 or 90 minutes or 17 µM nocodazole 
(NOC) for 60 minutes. After harvesting, cell lysates were examined for 
TULV genome copies by qRT-PCR.  
 
5.2.6 Co-localisation of sense and anti-sense TULV S segment RNA 
with TULV NP, stress granule marker and Golgi network 
marker  
5.2.6.1 TULV S segment RNA co-localises with TULV NP and Golgi network 
marker  
The results of the previous section showed TULV NP and TULV S segment RNA 
(both sense and anti-sense) co-localised within both punctate and 
filamentous/sheet/tubular structures. Interestingly, morphologically-similar 
filamentous sheet tubular structures were previously identified as co-localizing 
sites for TULV NP and the Golgi apparatus (Chapter Four,  
Figure 55). Therefore, to confirm colocalization of all three components, TULV 
infected Vero E6 cells were stained using FISH for TULV S segment RNAs, as 
well as antisera specific for TULV NP, and the Golgi network. IF and fluorescent 
line-scan analysis revealed sense and anti-sense TULV S segment RNA 
displayed precise co-localisation with the Golgi marker as well as both 












5.2.6.2 TULV S segment RNA co-localises with TULV NP and stress 
granule marker TIA-1  
The results of section 4.3.4 showed TULV NP and the stress granule marker 
TIA-1 co-localised within punctate bodies. The size and distribution of these 
puncta were similar to many of the structures where TULV S segment RNA and 
NP localise (Chapter Four, Figure 60). Therefore, to confirm co-localization of all 
three components, the intracellular localisation of TULV S segment RNA was 
visualized by IF analysis and fluorescent line scan alongside that of TULV NP 
and TIA-1.  
Staining associated with TULV and anti-sense RNAs exhibited precise 
colocalization with both TIA-1 and NP in structures that were both punctate and 
filamentous in appearance (Figure 84). Sense RNAs also displayed high levels 
of co-localisation with punctate NP and TIA-1 (Figure 85). NP puncta displaying 
co-localisation with TIA-1 and S segment RNA were on average 1.7 µm in 
diameter (Figure 84, Figure 85). Sense RNA however, while co-localising with 
some areas of filamentous NP and TIA-1 co-localisation was completely absent 
from other areas of perinuclear NP and TIA-1 co-localisation. Additionally, some 
perinuclear areas of high levels of  TULV NP and sense RNA displayed low levels 
of TIA-1 staining (Figure 85), consistent with the TOS determined for TULV NP, 
sense S segment and TIA-1 being lower than the TOS for TULV NP, anti-sense 
S segment and TIA-1, being TOS=0.696 and TOS=0.775 respectively (Figure 
86). This suggests there may be difference in the perinuclear localisation of 
sense and anti-sense RNA. Areas in which sense RNAs are absent may be sites 
of viral assembly or transport to the plasma membrane as predominately for 
negative-sense RNA viruses only anti-sense RNA is required in the mature virus 
particle, with the exceptions of RVFV and UUKV (Simons et al., 1990; Ikegami 














Figure 83 Co-localisation between TULV NP, TULV S segment RNA and the Golgi 
network in Vero E6 cells during persistent infections.  
The spatial distribution of TULV NP (green), S segment RNA (red) and the Golgi 
(magenta) was observed during persistent infections using LSCM at 40 X 
magnification. Vero E6 cells were infected at MOI 0.1. The white bar represents 30 µm 
and 10 µm (zoom). Fluorescent line scans taken using Fiji software. Nuclei are stained 
with DAPI (blue), TULV NP detected using NP antisera, S segment RNA detected 











Figure 84 Co-localisation between TULV NP, TULV anti-sense S segment RNA and 
TIA-1 in Vero E6 cells during persistent infections.  
The spatial distribution of TULV NP (green), S segment RNA (red) and TIA-1 (magenta) 
was observed during persistent infections using LSCM at 40 X magnification. Vero E6 
cells were infected at MOI 0.1. The white bar represents 30 µm and 10 µm (zoom). 
Fluorescent line scans taken using Fiji software. Nuclei are stained with DAPI (blue), 
TULV NP detected using NP antisera, S segment RNA detected using sense or anti-











Figure 85 Co-localisation between TULV NP, TULV sense S segment 
RNA and TIA-1 in Vero E6 cells during persistent infections.  
The spatial distribution of TULV NP (green), S segment RNA (red) and 
TIA-1 (magenta) was observed during persistent infections using LSCM 
at 40 X magnification. Vero E6 cells were infected at MOI 0.1. The white 
bar represents 30 µm and 10 µm (zoom). Fluorescent line scans taken 
using Fiji software. Nuclei are stained with DAPI (blue), TULV NP 
detected using NP antisera, S segment RNA detected using sense or 








Figure 86 Co-localisation of TULV NP, S Segment RNA with the host 
protein TIA-1 or Golgi.  
Co-localisation of confocal images shown in Figure 83, Figure 84 and Figure 
85 were analysed using FIJI plugin EzColocalization. Scatter plots pictorially 
representing co-localisation were produced and the threshold overlap score 
(TOS) demonstrates level of co-localisation. The average TOS from three 









5.2.7 Section Summary   
This section describes the spatial localisation of TULV S segment RNA within 
TULV infected Vero E6 cells during early, peak and persistent infection. The 
localisation of TULV RNA and interaction with TULV NP and host cell 
components, Golgi and TIA-1, was assessed by IF analysis. TULV RNA co-
localised exclusively with TULV NP. At early stages of infection RNA co-
localised with strand-like TULV NP within the perinuclear region whereas in 
peak and persistent infections RNA co-localised with perinuclear tubular 
accumulations and large cytoplasmic puncta.  
A clear target for the replication site of TULV was the perinuclear region as 
TULV RNA localised here at early time points and nascent RNAs was 
detected in the perinuclear region. As previously described in Chapter Four, 
the disassembly of vimentin filaments by treatment with OA disrupted the 
perinuclear formations of TULV NP. If these perinuclear areas are required for 
virus replication and storage of RNAs as suspected, OA treatment should 
have a detrimental effect on the genome copy number of TULV. OA was 
shown to reduce the genome copy number TULV providing further evidence 
for location of the orthohantavirus replication site.  
To further the identification of this site, target components of the host cell 
which co-localise with TULV NP within this region was used for IF analysis. It 
was found that TULV NP, RNA and Golgi marker showed high levels of co-
localisation with early, peak and persistently infected cells suggesting that the 
Golgi may be the site of viral replication and transcription. Additionally, it was 
found that puncta NP containing sense or anti-sense RNAs co-localised with 
stress granule component TIA-1, but while perinuclear filaments containing 
anti-sense RNA displayed high levels of co-localisation with TIA-1 this was not 
reflected for sense RNA. With some areas of TULV NP and TIA-1 co-
localisation displaying no RNA signal. This indicates there may difference in 
the locations of sense and anti-sense RNA which may indicate a site of viral 






Chapter 6 : Discussion 
 
6.1 Expression and purification of recombinantly expressed 
orthohantavirus nucleocapsid protein  
The orthohantavirus nucleocapsid protein is multifunctional and is associated 
with roles in the encapsidation of viral RNA, viral transcription, viral translation 
and immune evasion. As the orthohantavirus NP is a relatively small (50 kDa) 
protein, an interesting research question is how the NP performs and 
regulates these multiple functions. High resolution structural studies are a 
powerful approach to answer this question, however, the orthohantavirus NP 
proven problematical to recombinantly express and purify in the full-length 
form. Several groups were able to, with difficulty, express and purify various 
truncated versions of the orthohantavirus NP; initial expressions of full-length 
SNV and ANDV NPs were unsuccessful due to solubility and stability, 
suggested to be due to the N- and C-terminal domains role in NP 
oligomerisation. Truncated NP constructs of E111-G399 were successfully 
expressed, purified and used to solve the structure of the NP core domain 
(Guo et al., 2016). Olal and Daumke 2016 were able to solve the structure of 
a similar truncated HTNV NP, containing the NP core region and the N-
terminal domain from residues 113-429. This construct was fused to maltose 
binding protein to aid solubility, but still had problems due to the intrinsic 
flexibility of NP and its tendency to oligomerise. These previous studies 
utilised bacterial expression for production of NP.  
In this current study, bacterial expression was utilised to produce SEOV NP. 
Like Guo et al., 2016 and Olal and Daumke 2016, full-length SEOV NP 
displayed poor expression and stability despite multiple attempts to optimise 
expression and purification conditions. A truncated SEOV NPcore was 
produced, based on conditions described by Guo et al., and low 
concentrations (0.5 mg/mL) of SEOV NPcore was produced at >85% purity 
while unsuitable for X-ray crystallography was acceptable for antibody 
generation. Recently, full length HTNV NP was purified utilising a baculovirus-
insect cell expression system (Arragain et al., 2019). This suggests that 




achieved through bacterial cell expression. As a high percentage of SEOV 
NPcore was found in inclusion bodies this suggests improper folding during 
expression which may be due to a lack of post-translational modification. It 
has also been suggested that solubility problems may arise due to slow proline 
isomerisation, improper reduction/oxidation of cysteine residues and the lack 
of essential component such as RNA or ribonucleases (Spiropoulou, 2001). 
Due to time constraints of the project, attempts to further purify SEOV NP were 
discontinued and focused instead on the molecular mechanisms of the 
orthohantavirus lifecycle. 
 
6.2 Development of molecular tools for the quantification of 
the orthohantavirus lifecycle  
Orthohantaviruses are traditionally titrated using the neutral red uptake plaque 
assays or by genomic counts using qRT-PCR. The neutral red uptake is a 
commonly used measurement of cytotoxicity and provides a measure of cell 
health. Healthy cells will incorporate and retain the neutral red dye within 
lysosomes whereas unhealthy cells will not (Borenfreund and Puerner, 1985; 
Repetto et al., 2008). This assay has been adapted to virus quantification by 
counting areas of viral infection where neutral red dye is not retained, forming 
“plaques”. This is an acceptable method for the quantification of non-cytolytic 
viruses, such as orthohantavirus, which do not cause cell lysis but instead 
establish latent infections that cause an overall reduction in host cell health. A 
major drawback of this method of orthohantavirus titration is the prohibitively 
long assay time, which includes  up to 7 days to establish the Vero E6 
monolayers followed by 7-14 days for viral infection and 1-5 days for viral 
plaque formation after addition of the neutral red dye (French et al., 1981; 
Schmaljohn et al., 1983; Hooper et al., 2001; McElroy et al., 2004). Together, 
these time requirements are prohibitive for many experimental systems, 
where high throughput readouts of virus multiplication are needed. 
Other methods to give a measure of viral amounts have been developed such 
as qRT-RT PCR, which is a much faster method for the quantification of 
orthohantaviruses and is the gold-standard for molecular diagnostics (Mackay 
et al., 2002; Jiang et al., 2013; Wigren Byström et al., 2018). However, PCR 




on virion viability or number of infectious virus particles. In addition, a standard 
curve must be used to give absolute genome copies, so quantified values will 
be relative to the accuracy of the standard curve used. 
Other methods of orthohantavirus detection have been developed. These 
include the focus reduction neutralisation assay (FRNT), tissue culture 
infective dose 50% (TCID50), plaque reduction neutralisation test (PRNT) in 
addition to various adaptations of focus-forming or infectious-virus centre 
assay which utilise antibody detection either in conjunction with 
chemiluminescent substrates or fluorescent antibodies. Orthohantavirus 
titration methods requiring a form of “plaque” formation require 5-18 days 
before a titre can be determined. Immunocytochemical or immunofluorescent 
assays tend to allow faster titration and can be completed in 1-5 days 
(Gavrilovskaya et al., 1998; Ramanathan et al., 2007; I.N. Gavrilovskaya et 
al., 2012). To provide a more rapid assay to measure infectious virus 
quantities, an immunofluorescent-based assay was developed for the titration 
of TULV orthohantavirus. This assay relies on orthohantavirus NP anti-sera 
generated in sheep against recombinantly expressed SEOV NPcore. This 
assay allows reliable and reproducible quantification of TULV titres within 72 
hours post viral adsorption.  
 
6.3 Tula orthohantavirus lifecycle kinetics and formation of 
multinuclear persistently infected cells  
TULV multiplication, infectious virus production and replication kinetics were 
examined over an extended time-course using the molecular tools developed 
in Chapter One. This revealed TULV replication consisted of a lag-phase (0-
30 hpi) where no increase in viral RNA or infectious virus was detected, 
followed by an exponential phase (30-42 hpi) where viral RNA production 
rapidly increased followed by a phase of slower viral RNA and infectious virus 
production, reaching an eventual plateau (6-10 dpi). Extension of the time 
course to 30 dpi revealed a slow decrease in viral RNA and infectious titres 
but remaining at least one log above initial infection values. Based on these 
observations distinct time points of 36 hpi, 7 dpi and 30 dpi were defined as 




Previous studies have shown a similar pattern of orthohantavirus replication 
kinetics, but few studies assess infective virus, viral RNA and viral protein 
loads simultaneously. Assessment of orthohantavirus titres (by plaque assay 
and TCID50) showed a gradual increase in infective virus particles (Shim et 
al., 2011). One study, described an increase in ANDV titre up to 5 dpi, but a 
decreases in HTNV and TULV titre from 3-5 dpi (I.N. Gavrilovskaya et al., 
2012). Orthohantavirus RNA analysis has previously been described with 
increasing viral titres up to at least 10 dpi (Witkowski et al., 2017). A more 
recent study showed lag phase of viral RNA replication up 24 hpi followed by 
a period of replication up to 2-8 dpi followed by a decrease in viral RNA 
concentration (Wigren Byström et al., 2018). These studies broadly agree with 
the lifecycle kinetics described here for TULV.  
IF analysis of TULV infected Vero E6 cells displayed distinct distribution of NP 
at early, peak and persistent time points. Early infection was characterised by 
small distinct puncta and strand-like TULV NP. Peak infection was 
characterised by large NP puncta with NP filament crescents in the 
perinuclear region. At 30 dpi, infected cells displayed large macromolecular 
complexes of NP in the perinuclear region in addition to dispersed NP puncta, 
with large puncta towards the outer edge of the cell membrane. TULV has 
previously been described to exhibit this NP phenotype of small puncta at 
early stages of infection and crescent shaped tubes in the later stages of 
infection (Vapalahti et al., 1996). Ramanathan et al., 2007 describes 
condensed tubular NP structures in the perinuclear region at 5 dpi.  
In addition to phenotypic localisation of TULV NP, persistent infections were 
characterised by the formation of multinuclear cells with upwards of two nuclei. 
These multinuclear cells were often found with normal nuclear morphology, 
but some cells displayed evidence of nuclear fragmentation. Orthohantavirus 
syncytia have been described previously and cell-fusion was thought to be 
mediated by the glycoproteins, which act as fusogens on the cell surface 
(Ogino et al., 2004). This cell-to-cell fusion may be induced by low pH 
conditions in multiple species of orthohantavirus including HTNV, PUUV and 
SEOV (Arikawa et al., 1985; McCaughey et al., 1999). The multinuclear 




were found to have giant, multinuclear cells in alveolar regions at 14 dpi 
(Sanada et al., 2011).  
 
6.4 Tula orthohantavirus NP requires vimentin filaments for 
maintenance of NP macromolecular complexes  
To examine the relationship between TULV NP and the host cell cytoskeleton, 
the spatial location of TULV NP and the cytoskeletal filaments; actin, tubulin 
and vimentin were examined by indirect immunofluorescence. The cellular 
localisation NP was also examined with drug-induced depolymerisation of 
cytoskeletal filaments. Previously, it has been shown that ANDV, BCCV, 
HTNV and SEOV NP co-localise with tubulin in infected Vero E6 cells. When 
infected Vero E6 cells were treated with NOC, NP displayed a cytoplasmic 
instead of perinuclear distribution. This redistribution of NP could repeated 
using a dynein-inhibitor, EHNA, suggesting NP was transported to the 
perinuclear region on microtubules via dynein motors (Ramanathan et al., 
2007; Ramanathan and Jonsson, 2008). Actin filament depolymerisation was 
not found to affect NP subcellular localisation despite previous studies 
suggesting actin was required for NP intracellular transport (Ravkov et al., 
1998; Ramanathan and Jonsson, 2008). However, it was found that intact 
actin and microtubule networks were required for efficient viral entry and 
potentially viral replication (Ramanathan and Jonsson, 2008). The study by 
Ramanathan et al., 2008 suggested that different orthohantavirus species 
may utilise different components of the cytoskeleton at different points 
throughout their lifecycles. In this study, TULV NP was not found to co-localise 
closely with actin but was found to co-localise with tubulin and vimentin in both 
infected and transfected cells. The depolymerisation of actin and tubulin were 
not found to drastically effect the sub-cellular localisation of TULV NP. 
Depolymerisation of vimentin by treatment with OA caused disruption of 
macromolecular NP structures. Removal of OA leading to recovery of vimentin 
polymerisation permitted the re-formation of macromolecular NP structures. 
This suggests that the vimentin cytoskeleton is involved in the maintenance 
and formation of TULV NP macromolecular structures, which was further 
supported by the observation that qRT-RT PCR measurements of OA-treated 




This suggests that the macromolecular NP complexes may be site of viral 
replication or viral RNA storage and the depolymerisation of vimentin may lead 
to viral RNA degradation due to its release or exposure into the cytoplasm. 
Vimentin has previously been shown to be important in the lifecycle of other 
viruses. For example, Dengue virus (DENV), requires an intact vimentin 
scaffold for the localisation and formation of viral replication complexes (Teo 
and Chu, 2014). The parvovirus, minute virus of mice (MVM), induces 
rearrangement of the vimentin network to form vimentin ‘cages’ in the 
perinuclear region and was important for MVM transport and replication (Fay 
and Panté, 2013). In African Swine Fever virus (ASFV) infections, the vimentin 
cage was found to have important roles in the formation of viral assembly sites 
and protection from cytoplasm (Stefanovic et al., 2005). The vimentin cage 
has also been identified during foot-and-mouth disease virus (FMDV) 
infections as being required for viral replication (Gladue et al., 2013). 
Ultrastructural analysis of Zika virus also revealed a requirement for 
remodelling of the cytoskeleton to form a cage around the replication complex 
(Cortese et al., 2017).  These studies show that vimentin has an important role 
during multiple virus life cycles, such as formation of replication factories and 
protection from the host cell. The vimentin cage formation has been identified 
through multiple different virus infections as important in formation of 
replication sites. This gives precedent to the importance of vimentin for 
orthohantavirus replication and maintenance of NP coated replication sites. 
Therefore, the perinuclear region of the cell may be the site of orthohantavirus 
replication within a vimentin cage.  
 
6.5 TULV orthohantavirus NP interacts with host proteins at 
different lifecycle stages  
Orthohantavirus NP is a multifunctional protein that has been suggested to 
interact with multiple host cell proteins at different stages of the virus lifecycle. 
After entry into the host cell viral components need to be trafficked through 
the cell to sites of uncoating, transcription and translation. PUUV and HTNV 
NPs co-localise with early endosomal marker EEA-1 (early endosomal 
antigen-1). It was also found that HTNV NP co-localises with lysosomal 




perinuclear region (Jin et al., 2002; Witkowski et al., 2017). These results 
suggest transport of virus particles through the endocytic pathway. In contrast, 
a separate study also found accumulation of HTNV NP in the perinuclear 
space but independent from EEA-1 and it was suggest that virus components 
were transported directly to the ERGIC via the microtubule network 
(Ramanathan et al., 2007).  
TULV was found to show a small-degree of co-localisation with Rab5 (early 
endosome), Rab7 (early to late endosome) and Rab11 (late and recycling 
endosome) markers, but not LAMP-1 at early time points indicating a role in 
the endocytic but not lysosomal network for TULV trafficking. ANDV has been 
shown to associate with Rab8 and Rab11 (recycling endosomal) markers 
suggested to be important for transport to plasma membrane from the Golgi 
network (Rowe et al., 2008). However, at 30 dpi no colocalization was 
observed for TULV NP with any endosomal markers examined. It was 
expected that TULV proteins and RNA or assembled virions would be being 
transported from site of synthesis to the plasma membrane at this time. 
Instead, more co-localisation at this time point can be seen with clathrin. 
Orthohantaviruses may use clathrin-mediated endocytosis as a method of 
entering cells (Vaheri, Strandin, et al., 2013). Clathrin co-localises with some 
TULV NP puncta in the cytoplasm at 36 hpi and 30 dpi. It was possible that 
this may be some mechanism of viral transport from the Golgi to the plasma 
membrane within a transport vesicle. Clathrin has been implicated in 
regulation of exocytosis of post-Golgi vesicles and has been implicated in the 
transport of cargo from the trans-Golgi network where uncoating occurs near 
the plasma membrane (Puertollano et al., 2003; Jaiswal et al., 2009) . This 
function of clathrin may be utilised for orthohantavirus transport from the Golgi 
to the plasma membrane.  
In addition to trafficking, orthohantavirus NPs have been associated with 
functions related to viral transcription and translation. NP has been described 
to localise to P bodies, sites of RNA degradation, where it binds to 5’ capped 
mRNAs and protects from degradation by cellular machinery it a process 
known as cap-snatching. These 5’ capped mRNAs are used as primers by the 
RdRp for viral RNA synthesis (Mir et al., 2008; Cheng and Mir, 2012). The co-




within the cell during early, peak and persistent infections. This suggests that 
if this mechanism of cap-snatching occurs, it is not a major function of the 
TULV NP but may assist with increasing efficiency of viral RNA transcription.  
 
6.6 TULV NP was cleaved in infected cells and may sequester 
activated caspase-3 during persistent infection to 
suppress apoptosis 
The relationship between TULV infection and apoptosis induction in Vero E6 
cells was examined through an extended time course. Previous studies have 
shown that TULV along with other hantaviruses were able to inhibit apoptosis 
(Li et al., 2002; Ontiveros et al., 2010; Gupta et al., 2013; Solà-Riera et al., 
2019). Firstly, it was observed that casp-3C was absent from TULV infected 
Vero E6 cells at early phases of infection but was abundant in non-infected 
bystander cells. Western blot analysis of TULV-infected Vero E6 cells reveals 
the slow accumulation of apoptotic marker casp-3C. This was in direct conflict 
with previous studies in which TULV-infection was associated with the fast 
and abundant detection of apoptotic markers by western blotting (Markotic et 
al., 2003; Li et al., 2004; Li et al., 2005). Discrepancies between studies may 
be due to technical differences in approaches used to detect the apoptotic 
marker. In addition to western blot analysis, fluorescent line-scans were 
carried out to examine the spatial distribution of TULV NP and casp-3C in 
individual cells. This revealed casp-3C was predominantly located in 
bystander cells rather than TULV infected cells at 36 hpi, consistent with a 
separate study demonstrating the “bystander effect” of SEOV, HTNV, and 
ANDV infected cells (Markotic et al., 2003) and may be the source of apoptotic 
markers observed in other previous studies (Markotic et al., 2003; Li et al., 
2004; Li et al., 2005). The “bystander effect” is an established phenomenon 
and has been described for HIV infections where the Env glycoprotein induces 
apoptosis in neighbouring cells (Garg et al., 2012) and has been utilised in 
cancer therapy by the use of “suicide genes”, which allow production of a toxic 
metabolite that acts deleteriously on neighbouring cells (Karjoo et al., 2016). 
The apoptotic casp-3C marker was not detected in infected cells at 36 hpi and 
but was detected in TULV infected cells at 7 dpi and 30 dpi. However, it was 




without significant cytopathic effect (CPE) or development of an apoptotic 
phenotype. Taken together, this suggest that TULV infection inhibits host cell 
apoptosis.  
Previously, it has been shown that orthohantavirus NPs, recombinantly 
expressed or purified from virions, can be cleaved by recombinant activated 
caspase-3 in cell-free assays. TULV NP was cleaved during infection with 
cleavage products produced having apparent masses consistent with 
expected products based on an identified caspase-3 cleavage site in ANDV 
NP, namely DLID (Gupta et al., 2013). This cleavage site was conserved in 
TULV NP. The role of TULV NP cleavage by casp-3C in infected cells has yet 
to be determined. TULV NP could act as a ‘decoy’ substrate in a similar 
fashion to Junín arenavirus (JUNV) where the NP acts as a ‘caspase sink’ and 
prevents the cleavage of downstream effector proteins (Wolff et al., 2013). 
However, the ability of TULV NP to interact with casp-3C in a robust manner 
shown by indirect immunofluorescence and immunoprecipitation suggests an 
alternative mechanism. Fluorescent line-scan analysis on the spatial 
distribution of TULV NP and casp-3C in persistently infected cells revealed 
TULV NP and casp-3C do not occupy precisely the same position, with TULV 
NP forming a distinct boundary around casp-3C indicating TULV NP may form 
a viral-induced compartment in which casp-3C was physically separated from 
the rest of the cell. It is possible that TULV NP compartmentalises casp-3C 
and physically-segregates it from downstream components of the apoptotic 
cascade. This was supported by the immunoprecipitation of casp-3C using 
NP antisera and suggests a stable casp-3C/NP interaction that differs from 
the canonical enzyme:substrate interaction. This apparently stable interaction 
suggests the casp-3C/NP interaction encompasses addition residues outside 
of the casp-3C active site.  
This mechanism of apoptotic protection has been previously demonstrated in 
a variety of other human diseases, and in cell homeostasis. In Alzheimer’s 
disease, amyloid-β (Aβ) fibrils sequester caspase-3 into compartments and 
protects the cell from apoptosis (Chang et al., 2016). During thermotolerance, 
heat shock protein 27 (Hsp27) sequesters procaspase-3 and cytochrome-c 
which prevents the formation of the apoptosome (Concannon et al., 2001). In 




established example of a protein that regulates apoptosis by sequestering the 
caspase-activating factor ced-4, an analogue of mammalian Apaf-1, to the 
mitochondria, preventing non-programmed apoptosis. When the interaction 
between ced-9 and ced-4 is disrupted, downstream caspase cleavage and its 
subsequent activation result in apoptosis (Hengartner et al., 1992; Yan et al., 
2005; Tan et al., 2007). These examples provide precedent for apoptotic 
protein sequestration acting to prevent apoptosis in both health and disease 
systems.  
The co-localisation and co-precipitation of TULV NP and casp-3C in addition 
to the presence of a casp-3C recognition site suggests that TULV NP 
interferes with the host cell apoptotic pathway. TULV NP may bind to and 
sequester casp-3C in NP-coated vesicles and physically separate casp-3C 
from downstream effectors.    
 
6.7 TULV RNA and NP co-localise with the Golgi and TIA-1 
within early, peak and persistently infected Vero E6 cells  
The location of the orthohantaviruses replication sites have not yet been 
identified. It has been suggested that like Bunyamwera virus (BUNV), 
replication may take place within the Golgi network (Fontana et al., 2008; 
Vaheri, Strandin, et al., 2013). To determine the replication site of 
orthohantaviruses in vitro, localisation of nascent and accumulated TULV 
RNA was examined by IF analysis. Firstly, the localisation of newly made 
TULV RNA was examined utilising Click-iT™ chemistry to fluorescently label 
newly transcribed viral RNA. Nascent TULV RNA localises to the perinuclear 
region of infected Vero E6 cells to a similar location to where filamentous 
structures of TULV NP were located during peak and persistent infection. To 
positively identify these fluorescent RNA puncta as replication sites, co-
localisation with NP antisera was attempted. Unfortunately, attempts to 
visualise both nascent TULV RNA and TULV NP proved unsuccessful. 
Therefore, an alternative approach using RNA-FISH was used, in which 
fluorescent probes were designed against the sense and antisense TULV S 
segment sequences and used to determine their location within TULV infected 
cells. Early, peak and persistently TULV infected cells were probed for the 




and markers for the host cell Golgi and TIA-1. Golgi and TIA-1 were previously 
identified as co-localising with TULV NP in the correct spatial location.  
TULV sense and anti-sense RNA co-localise predominately within filamentous 
strands of NP in the perinuclear region of infected cells at early times post 
infection. During peak and persistent infections, TULV NP and S segment 
RNA co-localise in perinuclear filamentous structures but also within large 
TULV NP puncta toward the outer edge of the cytoplasm. Similar cytoplasmic 
structures have been seen in other viral infections, such as hRSV, Ebola virus 
and rabies virus, where viral replication factories were found within 
cytoplasmic inclusion bodies (Lahaye et al., 2009; Hoenen et al., 2012; 
Rincheval et al., 2017). However, many Bunyaviruses have replication 
factories associated with the Golgi network, such as Bunyamwera virus 
(BUNV) (Salanueva et al., 2003; Fontana et al., 2008). TULV NP puncta and 
perinuclear filaments containing S segment RNA exhibit very close co-localise 
well with the Golgi. These filament structures no longer resemble 
characteristic granular Golgi and instead appear to be large filament bundles 
or aggregations. This suggests that TULV may reorganise the Golgi structure 
to form the viral replication factory. Similar formations have been described 
previously for BUNV with viral factories were found to be located within the 
tubular-rearrangements of the Golgi network  (Fontana et al., 2008; Shi et al., 
2010). RNA-FISH analysis of Rift Valley Fever virus (RVFV) demonstrated S, 
M and L viral segments were recruited to the Golgi complex early in viral 
infection mediated by interactions with RVFV NP with the Gn cytoplasmic tail 
(Wichgers Schreur and Kortekaas, 2016). Uukuniemi virus (UUKV) buds 
through the Golgi apparatus and progressively induces vacuolisation 
(Kuismanen et al., 1982; Kuismanen et al., 1984). A similar phenotype was 
induced during TULV infection. This phenotype may be due to the 
accumulation of viral RNA and proteins in the Golgi. Previously, 
orthohantavirus glycoproteins and NP have been described to accumulate on 
the Golgi network membranes (Spiropoulou, 2001), suggesting the Golgi may 
act as one site of virus maturation. Glycoproteins have also been found to 
accumulate on the plasma membrane suggesting assembly occurs here 
rather than at the Golgi (Ravkov et al., 1997). It was likely that different 




old world viruses may assemble at the Golgi and new world viruses assemble 
at the plasma membrane. Results here, showing accumulation of sense and 
anti-sense RNA within Golgi network, suggests TULV (like other old-world 
viruses) may assemble within the Golgi before budding off into transport 
vesicles and transported to the plasma membrane.  
TULV NP and TIA-1, stress-granule marker, were also shown to co-localise in 
Vero E6 infected cells. However, attempts to co-localise TULV NP and G3BP 
(Ras-GAP SH3 binding-domain protein) were unsuccessful suggesting either 
staining was unsuccessful, or stress granule formation had not occurred. TIA-
1 and G3BP were both found in stress granules and detection of both markers 
substantiates stress granule formation. The lack of one of these suggests an 
alternative to stress granule formation was occurring. Chikungunya virus 
(CHIKV) has also been described to interfere with stress granule formation by 
sequestering G3BP into cytoplasmic foci (Fros et al., 2012). West Nile virus 
(WNV) and DENV have been shown to interfere with the formation of stress 
granules and interact with TIA-1 to form pseudo-stress granules which may 
be the site of viral RNA synthesis (Emara and Brinton, 2007). Similarly, TULV 
NP, TIA-1 and viral RNAs were observed to co-localise with some sense viral 
RNAs displaying lower levels of co-localisation with TIA-1. Areas positive for 
anti-sense RNA signal but negative for sense RNA signal may represent sites 
of viral assembly as, generally speaking, only anti-sense genomes are 
packaged into virus particles. Other areas displaying signal for both viral 
RNAs, TIA-1 and NP are areas of viral replication and transcription. 
Cytoplasmic puncta displaying high levels of co-localisation of TIA-1, NP, 
Golgi and viral RNAs may cytoplasmic bodies independent from replication or 
transcription in a similar manner to coronaviruses which induce the formation 
of cytoplasmic granules containing TIA-1, TIAR, PTB and viral RNA. These 
granules may be sites of RNP formation or post-transcriptional modification of 
viral RNAs (Sola et al., 2011). However further exploration is necessary for 
any definitive conclusions to be made.  
These results suggest orthohantavirus replication occurs within the 
perinuclear region in a viral-induced compartment which may arise from a 
rearrangement of the Golgi network and may involve an interaction with TIA-




to the perinuclear region supports this. Viral transcription may take place 
within NP-Golgi compartments where sense RNA was localised. This site may 
be part of the ER-Golgi intermediate compartment (ERGIC) as suggested by 
Ramanathan et al., 2008 and Li et al., 2010.  
 
6.8 The TULV orthohantavirus lifecycle  
The findings described in this study have been added to previously described 
knowledge and used to suggest an updated model for the orthohantavirus 
lifecycle. Orthohantavirus particles attach to the host cell via interactions with 
host surface proteins such as β1/β3 integrins or pro-cadherin 1. Viruses are 
internalised via clathrin-dependent or clathrin-independent mechanisms and 
are trafficked through early- to late-endosomes or to lysosomes. 
Orthohantavirus attachment, internalisation into the host cell and subsequent 
trafficking are all likely to be through species specific mechanisms. In late-
endosomes and lysosomes, low pH induces a conformational change in viral 
glycoprotein structure which inserts into target membrane and causes a 
membrane fusion event releasing viral genomes and proteins into the 
cytoplasm. Virus components are trafficked to sites of replication and 
transcription which is likely to be in the perinuclear region of the cell. 
Alternatively, some orthohantavirus species virus particles are trafficked 
directly to the Golgi apparatus from the plasma membrane. Viral replication 
and transcription likely occur within the Golgi apparatus where viral NP are 
also located. Orthohantavirus NP also may interact with TIA-1 to generate 
replication factories and protect genomes from the host cell immune response. 
The formation of viral replication factories may require interaction with and the 
vimentin cage which maintains the viral factory. Viral RNA and protein 
accumulate within the reorganised Golgi compartment.   New World 
orthohantavirus replication products and proteins are transported to the 
plasma membrane where viral assembly occurs. Assembly of old world 
orthohantaviruses occurs at the Golgi before transport of virions to plasma 
membrane. Assembled virions may be trafficked to the plasma membrane 
through recycling endosomes or clathrin-coated transportation vesicles. 
Mature hantaviruses bud from the plasma membrane by exocytosis. 




apoptotic factor, casp-3C, in NP coated vesicles and thereby preventing its 
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